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Development of the diff erent muscle types
Muscles can be broadly divided into three types: heart, skeletal and smooth muscle. Th eir 
common features include contractility and the presence of sarcomeres, but they diff er 
signifi cantly in their developmental origin and functional characteristics. Th is thesis concerns 
a novel protein important for contractile function in all muscle cell types.
Development of the heart
Th e heart is the fi rst functional organ in the embryo1. In mammals and birds the cardiac 
crescent, the fi rst distinct cardiac structure, is formed from cardiac precursor cells that 
originate from the anterior lateral plate mesoderm2-4. Th e cells in the cardiac crescent are 
specifi ed by multiple inhibiting and inducing signals which result in a defi ned area of cardiac 
cells, known as the fi rst heart fi eld. Inhibitory canonical Wnt signals (Wnt3a and Wnt8) from 
the ectoderm and Noggin and Chordin (bone morphogenetic protein (BMP) antagonists) 
from the notochord prevent formation of cardiac mesoderm. On the other hand, cardiac 
mesoderm is induced by signals activated by BMP2, fi broblast growth factor 8 and sonic 
hedgehog homolog (Ssh) secreted from the pharyngeal endoderm1. Fusion of the cardiac 
crescent at the midline of the embryo (Figure 1) results in the formation of a linear heart 
tube that shows polarity at the outset, with anterior (ventricular) and posterior (atrial) 
specifi cation2, 3. In all vertebrates the linear heart undergoes rightward looping (Figure 1) 
and in higher vertebrates, the looped heart subsequently undergoes septation at the level of 
the atrium, ventricle and arterial pole. At embryonic day 8 (E8) in the mouse embryo and 
Hamburger-Hamilton (HH) stage 24 in the chick embryo, new myocardium is added to the 
outfl ow tract of the heart. Th ese cells are derived from the second heart fi eld (SHF), which is 
located in the pharyngeal mesoderm (Figure 1)2-5. Th e fi rst heart fi eld (FHF) gives rise to the 
linear heart tube, defi nitive left  ventricle and part of the infl ow region of the heart, whereas 
the second heart fi eld (SHF) gives rise to right ventricular and outfl ow tract myocardium and 
part of the infl ow region4, 5. 
Figure 1: Schematic overview of heart development. In the cardiac crescent stage two pools of cardiac progenitors can 
be identifi ed; the fi rst heart fi eld (FHF) and second heart fi eld (SHF). In the linear heart tube stage polarization of the 
heart can already be recognized. In third stage there is rightward cardiac looping and in the last stage there is chamber 
formation and septation. Ventricle (V), sinus venosus (SV), atrium (A), left  ventricle (LV), right ventricle (RV), outfl ow 
tract (OT), left  atrium (LA) and right atrium (RA).
Skeletal muscle development
In vertebrates, muscles are formed from the paraxial mesoderm, which segments into 
somites. Th e ventral part of the somite, the sclerotome, gives rise to the cartilage and bone 
of the vertebral column and ribs, whereas the dorsal part of the somite, the dermomyotome, 
give rise to skin and muscles of the trunk and the limbs. Th e dermomyotome can be divided 
into epaxial and hypaxial parts (Figure 2)6-8, which give rise to diff erent muscle groups and 
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diff er in the way myogenesis is induced. Th e epaxial part is located adjacent to the neural tube 
and notochord and will form the muscles of the back. Th e hypaxial part forms the muscles 
of the limbs, body wall and tongue. In the epithelium of the hypaxial dermomyotome, that 
is located opposite to the limb buds, muscle progenitor cells delaminate and migrate into 
the limb buds, forming the muscles of the limbs6, 8. Myogenesis is regulated largely by the 
MyoD family of basic helix-loop-helix factors6, 8. In the epaxial part, paired homeobox gene 
3 (Pax3), myogenic factor (Myf) 5 and 6 induce myogenic diff erentiation 1 (MyoD1). In 
the hypaxial part, on the other hand, Pax3 induces MyoD indirect, via activation of Myf5 
expression (see fi gure 2). Th ese signaling cascades are induced by Shh from the ventral 
neural tube and notochord and (non-)canonical Wnt signals from the neural tube (Figure 2). 
Two phases of myogenesis can be distinguished. Th e primary myotome is formed from the 
dermomyotome. Th e epithelium of the dermomyotome is formed as a central sheet that is 
surrounded by four lips. During the fi rst myogenic phase, cells of the four epithelial lips of the 
dermomyotome delaminate and locate between the dermomyotome and sclerotome to form 
the primary myotome7 (primary fi bers); this occurs between E11 and E14 in the mouse6. In 
the second myogenic phase the central part of the dermomyotome epithelializes, resulting in 
a second phase of muscle formation7 (secondary fi bers), which occurs between E14 and E16 
in the mouse6. Generally speaking, the primary fi bers tend to become slow fi bers, whereas 
the secondary fi bers become fast fi bers6. In the postnatal period the muscle mass increases by 
Figure 2: Schematic overview of myogenic induction in the mouse. In the epixial part myogenic diff erentiation 1 
(MyoD1) is induced by synergetic action of paired box gene 3 (Pax3), myogenic factor (Myf) 5 and 6, which are induced 
by Sonic hedgehog and Wnt1 from the notochord and neural tube , respectively. In the hypaxial part , on the other hand, 
Pax3 induces Myf5 and 6, which in turn induces MyoD1.
hypertrophy (growth of individual cells) of existing muscle fi bers8. 
Adult myogenesis is achieved by activation of quiescent satellite cells, which are marked by 
expression of Pax7, c-met proto-oncogene and M-cadherin. Aft er muscle injury, these cells 
commit to a muscle-progenitor fate and activate transcription factors such as Pax3 and Myf56, 
7, leading to diff erentiation of skeletal muscle cells. Th e satellite cells only have limited capacity 




Vascular smooth muscle cell di erentiation
Vascular smooth muscle cells (VSMCs) have diff erent embryonic origins which are refl ected 
in their distribution in diff erent tissues and organs. Th e walls of the great arteries (pulmonary 
artery, dorsal aorta, carotid and subclavian arteries) for example are derived from progenitor 
cells that migrate from the dorsal surface of the neural tube (neural crest) into the pharyngeal 
arch complex between E8.5 and 9.5 in the mouse. VSMCs of the coronary arteries arise 
from the epicardium, which forms during embryonic development from pro-epicardial 
cells (pro-epicardial organ) and grow over the surface of the myocardium to form a single 
layer of epicardial cells. Between E13.5 and E14.5 some of these cells undergo epithelial-to-
mesenchymal transition and form the VSMCs of the coronary arteries9, 10. A third source of 
VSMC progenitors is an Islet-1 positive cell population, which produces the VSMC in the 
walls of the pulmonary trunk, aortic root and the branching coronary arteries10.
Development of VSMCs from embryonic progenitors is regulated in three phases. During 
the fi rst phase, vasculogenesis occurs and angioblasts diff erentiate into endothelial cells that 
assemble in a capillary vascular network. In the second phase (E10.5 in the mouse), increased 
cardiac output demands a more active vascular network, which leads to the production of 
chemo-attractants by the endothelial cells, this in turn attracts progenitors of VSMCs, the 
mesenchymal cells, to surround the vessel wall. Close contact between mesenchymal cells and 
endothelial cells, mediated by platelet derived growth factor, initiates SMC diff erentiation. In 
the last phase the cells further mature and form the vascular extracellular matrix10.
Diff erentiated VSMCs are defi ned by expression of a specifi c subset of cytoskeletal and 
contractile proteins, such as α-smooth muscle actin (ASMA), smooth muscle calponin and 
smooth myosin heavy chain (MHC), SM22-α, desmin and smoothelin10, 11. Th e function 
of mature diff erentiated VSMCs is contraction, regulation of vascular tone, important for 
the regulation of blood pressure and blood fl ow distribution. Adult VSMCs proliferate very 
slowly, have a very low synthetic activity  (low production of extracellular matrix) and are 
non-migratory11. However, unlike cardiac and skeletal muscle cells, adult SMCs can undergo 
reversible changes in phenotype between a contractile and synthetic state in response to 
changes in the local environment9-11. For example, aft er vascular injury contractile SMCs are 
capable of undergoing a transient modifi cation of their contractile phenotype to a synthetic 
phenotype and in this way play an essential role in the repair of the vascular injury by 
producing extracellular matrix 11.
Sarcomeres: contracting units of striated      
muscle and function in cardiac disease
In adult animals these three types of muscle cells can be recognized: heart, skeletal muscle 
and smooth muscle. In heart and skeletal muscle cells are ‘striated’, a striped pattern visible 
microscopically made up of sarcomeres. In these muscles sarcomeres form the basis for 
contraction. Th e function of sarcomeres in healthy and diseased muscle is discussed in the 
following section. 
Structure of sarcomeres
Sarcomeres are multi-protein complexes responsible for the contraction of striated muscle. 
Contraction is regulated by two fi lament systems, the thin actin and the thick myosin fi laments, 
that slide over each other. Th e sarcomere is a highly organized structure which can be divided 
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General introduction
into several subcompartments. Th e Z-discs form the boundary of each sarcomere, the I-band 
(for isotropic) surrounds the Z-disc and is composed of only actin fi laments, the A-band (for 
anisotropic) is composed of actin and myosin fi laments and the M-band (middle) forms the 
centre of each sarcomere (Figure 3)12, 13. 
Protein composition of the sarcomere is determined by the specifi c muscle type. In the heart 
the giant protein titin is the structural backbone of the sarcomere and two of these molecules 
run from Z-disc to Z-disc. Titin determines the stiff ness of the sarcomere and keeps the 
A-band in the middle of the sarcomere during contraction. Via T-cap, titin is connected to 
α-actinin14, 15, the major component of the Z-disc. Th ere are four α-actinin isoforms (1-4), of 
which α-actinin-2 and -3 are the only isoforms expressed in striated muscle. In cardiac tissue 
only α-actinin-2 is expressed. In the Z-disc, α-actinin-2 is organized as homodimers in an 
antiparallel manner and in this way cross-links actin16. Furthermore, α-actinin-2 functions in 
binding several proteins that are involved in stretch-sensor function of the Z-disc12. Th is will 
be discussed in more detail later in this chapter. 
Actin is a ubiquitously expressed protein important in many fundamental processes, such as 
cell cycle regulation, cell motility and muscle contraction. In striated muscle, two actin forms 
are present, cardiac actin and skeletal actin. In adult cardiomyocytes cardiac actin is the major 
isoform present 16. Via CapZ, a protein composed of α and β subunit, actin fi laments are 
connected to α-actinin-2, linking the thin fi laments to the Z-disc12, 16. Mutations in sarcomeric 
proteins can lead to the development of cardiomyopathy.
Figure 3: Schematic overview of a sarcomere. Th e Z-disc forms the boundary of the sarcomere and is composed of 
α-actinin homodimers that bind several signaling molecules (see text). Th e I-band is composed of only actin fi laments 
and the A-band is composed of actin and myosin fi laments. Th e M-band forms the middle of the sarcomere. Adapted 
from13. 
Mutations in sarcomeric proteins result in cardiomyopathy
Cardiomyopathy is a group of disorders of the heart that result in inadequate pumping of 
blood around the body. Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy 
(DCM) are mainly caused by mutations in sarcomeric proteins. HCM is characterized 
by left  ventricular hypertrophy (resulting from increased cell size or volume), increased 
systolic function and decreased diastolic function. At the histological level, hypertrophy and 
disarray of cardiomyocytes and interstitial fi brosis is observed17, 18. DCM, on the other hand, 
is characterized by ventricular dilation and contractile dysfunction of the left  and/or right 
ventricles. Depending on the location of the mutation, HCM or DCM is induced; in HCM 
regions of sarcomeric proteins are mutated that are directly involved in force generation, 
Disease model Gene Mutation  Species Approach Reference 
HCM α-MHC R403Q/+ Mouse Knock-in  19-21, 25 
β-MHC R403Q Rabbit Transgenic 26 
MyBP-C truncation Mouse Knock-in 19, 27-29 
cTnT R92Q Mouse Transgenic 22, 30-33 
DCM cTnT ΔK210 Mouse Knock-in 34 




whereas the regions that are mutated in DCM are involved in force transmission from the 
sarcomere to the extrasarcomeric cytoskeleton17.
Several mouse models for HCM and DMC have been generated, which refl ect the pathology 
of the human disease. For example in a mutant mouse with a truncation in myosin binding 
protein C (MyBP-C), a mild HCM phenotype was observed 19, while a mutation (R403Q) 
in α-MHC resulted in a more severe HCM phenotype 19-21. Mouse models with mutations 
in cardiac troponin T (cTnT) at diff erent domains, R92Q (transgenic) 22and ΔK210 (knock-
out)23, resulted in HCM and DCM, respectively.
Several mouse models for HCM and DCM have been reviewed in Beqqali et al and are 
summarized in table 124.
Table 1: Overview of animal models of hypertrophic and dilated cardiomyopathy. Adapted from24. 
 e Z-disc as stretch-sensor
α-actinin-2 anchors several proteins to the Z-disc, which act as stretch sensor. Several Z-disc 
proteins have been associated with cardiomyopathies, for example interacting proteins of 
α-actinin-2 such as calcineurin, muscle-specifi c LIM protein (MLP), T-cap, calcarcin-1, 
cypher and Enigma homologue protein (ENH) 12.  MLP has been found to be an essential 
component of the T-cap and titin complex, stabilizing the interaction between these proteins, 
which then can sense increase in stretch and activate downstream signals for hypertrophy 36. 
Th e phospatase calcineurin, a heterotrimer consisting of a catalytic subunit A (CnA), 
calcineurin B and calmodulin, is a key regulator of hypertrophy. In the calcineurin pathway 
hypertrophic stimuli lead to an elevation in the intracellular Ca2+ levels and subsequent 
activation of calcineurin. Activated calcineurin dephosphorylates nuclear factor of activated 
T-cells (NFAT), which then translocates to the nucleus to activate genes that are associated 
with stress, such as atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP), 
and genes that encode fetal isoforms of contractile proteins such as β-myosin heavy chain 
(β-MHC) 37. Molketin et al. generated transgenic (Tg) mice that express a constitutively active 
form of the catalytic subunit of calcineurin in the heart, by using of the α-MHC promoter to 
drive the calcineurin construct38. Hearts of calcineurin Tg mice show massive hypertrophy, 
disorganized cardiomyocytes, fi brosis and enlarged nuclei. Furthermore, with ageing 
calcineurin Tg mice show dilatation of the ventricles and are highly susceptible to sudden 
cardiac death38. NFATc2 39 and NFATc340, are essential mediators of the calcineurin induced 
hypertrophy, which is reduced in NFATc2-/- or NFATc3-/- mice. However, NFATc4-/- mice do 
not exhibit reduced calcineurin induced hypertrophy, suggesting that NFATc4 does not play 
an important role in the calcineurin-dependent hypertrophy pathway 40. 
Calsarcin, a novel target for calcineurin, binds to both calcineurin and α-actinin 41. 
Overexpression of Calsarcin-1, both in vitro and in vivo, has protective eff ects on hypertrophy 
by interfering with calcineurin-NFAT signaling 42, while lack of calsarcin-1 enhances this 
signaling pathway43. 
In addition to the interaction with calsarcin and calcineurin, α-actinin has also been shown to 




Regulation of cardiac development and disease via actin signaling pathway
Th e actin cytoskeleton is important in regulation cell shape changes and gene expression 
during development and disease. Polymerization of monomeric globular actin (G-actin) in 
fi lamentous actin (F-actin) is regulated by several actin binding proteins53. 
Rho GTPases (RhoA, Rac and Cdc42) induce actin polymerization via the Rho-associated 
kinase (ROCK)-LIM kinase-cofi lin pathway53-56. RhoA can be induced by phosphorylation 
of ezrin/radixin/moesin (ERM), proteins that function in linking the membrane to the actin 
cytoskeleton57. RhoA is highly expressed in embryonic hearts, downregulated in adults and 
re-expressed during cardiac hypertrophy58. Heart-specifi c overexpression of RhoA leads to 
the development of a DCM-phenotype59, whereas inhibiting ROCK protects the heart aft er 
aorta constriction60. 
Serum response factor (SRF) is a member of the MADS (MCM1, Agamous, Defi ciens, SRF) 
family of transcription factors, which share a conserved motif of 57 amino acids mediating 
homodimerization, association with other factors and DNA-binding activity61. SRF is expressed 
in many cell types and functions in many biological processes, including gastrulation, 
development and function of the cardiovascular system, T-cell and B-cell activities in the 
immune system and neuronal functions of the developing and adult brain. Homodimeric 
SRF binds to a palindromic DNA sequence (CC(A/T)6GG), which is called the CArG box
53. 
Several SRF-mouse models have shown that SRF is essential for cardiac development, as well 
as maintaining adult cardiomyocytes. SRF is responsible for maintaining the sarcomeric 
integrity in cardiomyocytes62-64 and disruption of its expression results in DCM in mice65, 66. 
Th erefore, it is not surprising to fi nd several sarcomeric genes, such as skeletal and cardiac 
actin, α-MHC and β-MHC, myosin light chain (MLC)2a and 2v, myomesin, troponin C, and 
titin, to be targets of SRF62. 
Myocardin and myocardin related transcription factors (MRTFs) function as co-activators of 
SRF resulting co-activator specifi c gene transcription determining skeletal and smooth muscle 
skeletal muscle during mouse and zebrafi sh development44-46, and interacts with α-actinin-244 
and calsarcin47. Deletion of cypher in mice and zebrafi sh results in disruption of the Z-disc 
structure and leads to the development of DCM46-48. However, in mice only deletion of the 
long isoform of cypher leads to development of late-onset DCM, whereas deletion of the 
short isoform has no eff ect49. More interestingly, mutations in cypher have been identifi ed 
in humans that cause DCM50. Th ese results indicate cypher as an essential component of the 
α-actinin-calcineurin-calsarcin complex to maintain cardiac structure and function. 
ENH is another PDZ-LIM protein which interacts with α-actinin-2 51, calsarcin and cypher. 
In ENH-/- mice expression of the short cypher isoform and calsarcin is lost, which leads to 
disruption of the Z-disc and development of DCM52.
Th ese data show an essential role for the Z-disc in the development of cardiomyopathies 
and targeting these components could reveal strategies for possible new therapies for the 
treatment of these diseases. Th erefore, it will be necessary ultimately to identify all Z-disc 
components and in this way, increase understanding of Z-disc function in the development 




diff erentiation. Furthermore, these factors also have distinct functions in pathophysiological 
remodeling of the heart61. 
Myocardin, MRTF-A and -B share a conserved so-called RPEL domain, which in MRTFs 
functions as G-actin binding domain. In myocardin, the RPEL domain does not bind G-actin, 
therefore myocardin is localized exclusively in the nucleus61. Myocardin is essential for 
smooth muscle diff erentiation and activates expression of smooth muscle genes in promoters 
with two adjacent CArG boxes by binding these as homodimers67.  Tracing studies show that 
myocardin specifi cally marks cardiac, smooth and skeletal muscle lineages during embryonic 
development. In skeletal muscle precursors, myocardin expression leads to inhibition 
of diff erentiation, whereas in smooth muscle cell precursors it induces diff erentiation68. 
Myocardin-/- mice die around E10.5 and these mutant embryos show vascular abnormalities 
which result from impaired smooth muscle cell diff erentiation69, 70. Cardiac specifi c deletion 
(α-MHC-Cre) of myocardin leads to decreased expression of sarcomeric genes (α-cardiac 
actin, MLC2v, and tropomyosin) and connexin 43 and desmin, which results in disruption of 
the structural organization of the sarcomere and intercalated discs, respectively. Furthermore, 
the hearts of α-MHC-Cre-myocardinf/f showed left  atrial enlargement, hypertrophy, interstitial 
fi brosis and a decreased cardiac function (decreased ejection fraction)71. Myocardin also has 
an essential function during pathophysiological events in the heart; it is upregulated in several 
in vivo and in vitro models of hypertrophy, as well as in human patient hearts with idiopathic 
DCM. Th e hypertrophic marker ANF is a direct target of myocardin and over-expression 
of myocardin in cardiomyocytes in vitro leads to a hypertrophic response, which can be 
abolished by expression of a dominant negative isoform lacking the transcriptional activation 
domain72.
MRTF-A-/- mice are viable and show no cardiac defects.  Female MRTF-A-/- mice are unable to 
nurse their off spring eff ectively, due to a failure in myoepithelial cell diff erentiation. Th ese are 
cells that posses characteristics of both epithelial and SMC and surround the milk producing 
cells giving structural and contractile support73. Deletion of MRTF-A in the heart has a 
protective eff ect on the heart and shows that MRTF-A has a role in controlling the expression 
of a fi brotic gene program and smooth muscle cell diff erentiation. Scar formation and fi brosis 
are decreased in MRTF-A-/- mice aft er myocardial infarction or Angiotensin II treatment74.  
MRTF-B is expressed in derivatives of the neural crest. Th erefore, MRTF-B knockout mice show 
cardiovascular abnormalities, resulting from impaired smooth muscle cell diff erentiation75, 76. 
Myocyte Enhancer Factor-2 (MEF2) is another MADS-box transcription factor. Four 
isoforms of MEF2 exist (A-D), of which isoforms A, C and D have distinct functions in the 
heart. Knockout studies show that MEF2A is essential for energy metabolism and sarcomeric 
organization in adult hearts77, MEF2C is involved in cardiac morphogenesis78, and MEF2D 
is a mediator of stress-dependent pathological remodeling of the adult heart79. On the other 
hand, overexpression of these factors induce (dilated) cardiomyopathy in mice80, 81.
Transcriptional activity of SRF is regulated by Striated Muscle Activator of Rho Signaling 
(STARS). STARS binds to actin and activates RhoA in this way promoting actin polymerization 
and depletion of the G-actin pool. Subsequently, MRTFs translocate to the nucleus and 
activate gene expression by acting as co-factor for SRF. SRF induces actin genes, in this way 
providing a negative feed back loop 82, 83. STARS is a direct target of MEF2, STARS expression 
is induced by MEF2 in several models of hypertrophy84. Th us, the formation of actin bundles 
is not only necessary for cell movement and polarization, but also leads to the induction of 
signal-transduction pathways important for cardiac development and hypertrophy. Th e actin 
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signaling pathway is summarized in fi gure 4. 
Figure 4: Th e actin signaling pathway. Rho is activated by Striated Muscle Activator of Rho (STARS) which leads to po-
lymerization of G-actin into F-actin and subsequent deletion of the G-actin pool. Myocardin Related Transcription Fac-
tors (MRTFs), normally inhibited by G-actin, translocate to the nucleus to act as transcriptional co-activator of Serum 
Response Factor (SRF). Actin is a target of SRF, in this way providing a negative feedback loop mechanism. 
 e synaptopodin gene family: role in actin polymerization
Proteins belonging to the synaptopodin gene family are involved in actin signaling. 
Synaptopodin is the founding member of the synaptopodin gene family. Th ree isoforms (of 
one gene) of synaptopodin exist: Synpo-short (685 aa) expressed in the brain, Synpo-long 
(903 aa) and Synpo-T (181 aa) which are both expressed in kidney podocytes. Both Synpo-
long and Synpo-short interact with α-actinin-2 and -4 resulting in elongation and bundling 
of actin fi laments85, which is regulated by preventing proteasomal degradation of RhoA86. 
Synaptopodin-/- mice lack ‘spine apparatus’, an organelle present in dendritic spines, which 
leads to defects in behavior. Th e structure and function of kidney podocytes is not aff ected 
by decreased synaptopodin expression87. Th is can be explained by the fact that in the brain of 
Synaptopodin-/- mice α-actinin-2 is downregulated, resulting in a reduction in actin fi lament 
formation. In contrast, kidney podocytes of Synaptopodin-/- mice upregulate Synpo-T and 
therefore have normal levels of α-actinin-4, resulting in rescue of actin fi lament formation85. 
Myopodin is the second member of the synaptopodin gene family, and has actin binding 
activity as well88. It is expressed in adult heart, skeletal muscle and smooth muscle cells. 
Myopodin localizes at the Z-disc of skeletal muscle cells and cardiomyocytes and can 
translocate to the nucleus 88, 89. Myopodin forms a protein complex with α-actinin, calcineurin, 
protein kinase A (PKA) and calmodulin-dependent kinase II (CaMKII). Activation of PKA 
and CaMKII or inhibition of calcineurin results in phosphorylation of myopodin and its 
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subsequent translocation to the nucleus90. 
CHAP is a new member of the synaptopodin gene family
Micro-array analysis of gene expression technique is a powerful tool to discover new genes 
associated with specifi c biological processes. Using an assay in which human embryonic stem 
cells (hESC) were diff erentiated to cardiomyocytes, we discovered a new cardiac enriched 
gene, which was homologous to synaptopodin and myopodin. Th is new gene was annotated 
as Synpatopodin-2-like (SYNPO2L)91 and we renamed it later Cytoskeletal Heart-enriched 
Actin-associated Protein (CHAP). Mouse CHAP is located on chromosome 14 and exists 
as two isoforms: a long isoform CHAPa (978 aa) and a shorter isoform CHAPb (749 aa), 
produced by an alternative ATG site at the beginning of exon 4. Th e CHAPa and b isoforms 
are almost identical, with a nuclear localization signal (NLS) and actin binding sites. However, 
the N-terminal of CHAPa is longer and contains a PDZ domain.
During development, ChapB is fi rst expressed at the cardiac crescent stage (E7.75), later in 
the linear heart tube and in the looped heart. Furthermore, from E10 onward expression is 
also detected in the somites. Expression of ChapB is downregulated in adult hearts, whereas 
ChapA is expressed adult heart and skeletal muscle (Figure 5)92. 
In cardiomyocytes, CHAP is detected in the Z-disc and co-stains with α-actinin-2, whereas 
Figure 5: Whole mount in situ hybridization (A-D) showing expression of Chap during mouse development. Chap is 
fi rst expressed in the cardiac crescent (cc) at E7.75 (A). In later stages Chap expression is observed throughout the whole 
heart at E8.5 (B) and E9.5 (C).  At E10 (D), besides expression of Chap in the heart, Chap expression observed in the 
somites. E: Section of an E8.5 mouse embryo showing Chap expression in cardiomyocytes of the heart. F: Section of an 
E10.5 mouse embryo showing Chap is expressed in the myotome part of the somites. G: RT-PCR analysis of showing 
expression of ChapA in adult heart and skeletal muscle, and expression of ChapB in the heart during embryonic de-
velopment. H: western blot analysis of CHAPa and b expression during embryonic development and in adult heart and 
skeletal muscle. Adapted from92.
17
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no co-staining is seen with the M-band marker myomesin. Furthermore, CHAP can interact 
directly with α-actinin-2. CHAP can also translocate to the nucleus, suggesting a function in 
transcription as a co-factor.
Morpholino mediated knockdown of chap in zebrafi sh resulted in defects in heart looping, 
cardiac edema and disturbed skeletal muscle development92. 
Th ese initial data showed an essential function of CHAP in cardiac and skeletal muscle 
development. Given the homology between CHAP, synaptopodin and myopodin it is likely 
that CHAP also functions as an actin bundling protein and/or in the calcineurin pathway. 
Furthermore, the location of CHAP in the Z-disc and the binding to α-actinin-2 suggests a 
role for CHAP in the development of cardiomyopathy. To elucidate this, we investigated the 
role of CHAP during development and disease in this thesis.
Aim and outline
In this thesis the function of CHAP during embryonic development and in adult tissues and 
disease was analyzed by making use of transgenic mouse models, expression analysis and in 
vitro experiments. We show that CHAP expression during development is conserved between 
species, which implies an important role during cardiac and skeletal muscle development. 
Furthermore, we show in vivo and in vitro that CHAPa and CHAPb have distinct functions in 
muscle development and function. 
Chapter 2 describes the sequence and expression analysis of the chick (Gallus gallus) homolog 
of human and mouse CHAPa. Furthermore, detailed expression analysis of mouse CHAP in 
embryonic and adult skeletal and smooth muscle is given. To investigate the function of CHAP 
during muscle development and disease in more detail, we attempted to generate a CHAP 
knockout mouse. As a fi rst step, chapter 3 gives a detailed description of generation of CHAP 
targeted mouse embryonic stem cells. Th ese cells were used to investigate the consequences 
of CHAP knockdown on cardiac diff erentiation in vitro. Th eir use to generate chimeric 
mice is pending. In addition, we investigated te eff ect of morpholino mediated knockdown 
of CHAP in chick embyro’s. In chapter 4 we analyzed the role of both CHAP isoforms in 
the adult heart by generation of CHAPa- and b heart-specifi c transgenic mice. Whereas, in 
CHAPa Tg mice no phenotype is observed, CHAPb Tg mice develop cardiomyopathy with 
diastolic dysfunction. In addition, the CHAPb Tg mice show formation of actin stress fi bers 
and upregulation actin signaling. To study the eff ect of CHAP overexpression more directly, 
we generated adenoviruses and in chapter 5 used these to study the function of CHAP by in 
vitro overexpression of CHAPa- and b in a model of skeletal muscle development (C2C12 
cells) and E17.5 mouse cardiomyocytes. We show that, as in the Tg mice, an actin bundling 
function in vitro for CHAPb and also show a function for CHAPa in the integrity of the 
Z-disc. However, unlike in vivo overexpression of CHAPb, the actin signaling pathway is not 
aff ected to the same extent by in vitro overexpression. In chapter 6 a more detailed expression 
analysis of CHAP is given. In this chapter expression of CHAP in small intestine, kidney and 
brain is shown. CHAPb expression in these organs is related to the expression of F-actin and 
show again a function for this protein in actin bundling.
Th e results of this thesis are summarized and discussed in chapter 7 and suggestions for 
future research are given.
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Chapter 2
CHAP is expressed in striated and smooth muscle cells in chick 
and mouse during embryonic and adult stages
Willemijn van Eldik, Abdelaziz Beqqali, Jantine Monshouwer-Kloots, 
Christine Mummery, Robert Passier




We recently identifi ed a new Z-disc protein, CHAP (Cytoskeletal Heart-enriched Actin-
associated Protein), which is expressed in striated muscle and plays an important role during 
embryonic muscle development in mouse and zebrafi sh. Here, we confi rm and further extend 
these fi ndings by (i) the identifi cation and characterization of the CHAP orthologue in chick 
and (ii) providing a detailed analysis of CHAP expression in mouse during embryonic 
and adult stages. Chick CHAP contains a PDZ domain and a nuclear localization signal, 
resembling the human and mouse CHAPa. CHAP is expressed in the developing heart and 
somites, as well as muscle precursors of the limb buds in mouse and chick embryos. CHAP 
expression in heart and skeletal muscle is maintained in adult mice, both in slow and fast 
muscle fi bers. Moreover, besides expression in striated muscle, we demonstrate that CHAP is 
expressed in smooth muscle cells of aorta, carotid and coronary arteries in adult mice, but not 
during embryonic development.
25
Expression of CHAP in mouse and chick
Introduction
Th e Z-disc delineates the borders of the sarcomere, the contractile unit of striated muscle 
and represents an anchoring plane for various proteins. In addition to their role in force 
transmission, Z-disc proteins may also be involved in signal transduction1. Recently, we 
indentifi ed a novel Z-disc protein, which we named CHAP (Cytoskeletal Heart-enriched 
Actin-associated Protein) 2, 3. We have shown that CHAP has two isoforms, CHAPa and 
CHAPb, in both humans and mice. CHAPa, the longest isoform (978 amino acids (aa)) 
contains an N-terminal PDZ domain, as well as a nuclear localization signal (NLS). Th e 
shorter CHAPb isoform (749 aa) lacks the PDZ domain, but still contains the NLS. CHAP 
interacts with α-actinin-2, another Z-disc protein, and is able to translocate to the nucleus 3. 
Previously, we have shown that ChapA is predominantly expressed in adult heart and muscle 
tissues, whereas ChapB is expressed at higher levels in striated muscles during embryonic 
development. ChapB expression in mouse is evident from the cardiac crescent stage (E7.5) 
onwards. During later embryonic stages ChapB expression is maintained in the developing 
heart, but is also expressed in the somites (giving rise to skeletal muscle). In addition, we 
have identifi ed the zebrafi sh chap orthologue and demonstrated by morpholino antisense 
oligonucleotide-mediated knockdown that chap is essential for zebrafi sh heart and muscle 
development. Knockdown of chap in the zebrafi sh resulted in aberrant muscle development, 
indicated by defects in cardiac looping, formation of pericardial oedema and disorganized 
sarcomeres 3.
Here, we identifi ed the chick (Gallus gallus) orthologue of CHAP. We show that CHAP 
gene and protein resembles the human and mouse CHAPa isoform, with the predicted 
PDZ and NLS domains. A detailed analysis of CHAP mRNA and protein expression during 
development in chick and mouse embryos and in adult tissues is shown. Furthermore, we 
demonstrate that CHAP is not only expressed in cardiomyocytes, and slow and fast skeletal 





Swiss mice were intercrossed and females were sacrifi ced for collection of embryos at 
diff erent time points (E12.5, 13.5 and 17.5). Fertilized eggs of White Leghorn chicken were 
incubated at 37 oC and 80% humidity. Chick embryos were staged according to the criteria 
of Hamburger and Hamilton (HH)4. Mouse (E12.5 and E13.5) and chick embryos (HH8-
HH30) were collected and fi xed in 4% paraformaldehyde (PFA; w/v) in phosphate buff ered 
saline (PBS) overnight at 4 oC. Embryos were further processed for whole-mount or section in 
situ hybridization, or immunohistochemistry. Processing of mouse embryos for cryosections 
was adapted from 5. In brief, E17.5 embryos were fi xed in 0.2% PFA solution containing 4% 
sucrose, 0.12mM CaCl2.2H2O, 0.2M Na2HPO4.2H2O, 0.2M NaH2PO4.H2O over night at 4 
oC. 
Next, embryos were washed in the same solution without PFA during the day at 4 oC, followed 
by 0.24M phosphate buff er and 30% sucrose over night at 4 oC. Th e next day embryos were 
embedded in Tissue-Tek (Sakura Finetek) on dry ice and stored at -20 oC until sectioning. 
Organs of adult Swiss mice were isolated, rinsed in PBS and processed for RNA isolation and 
cryosectioning. 
RNA isolation and cDNA synthesis
Total RNA from chick hearts of stage 19, 21 and 27 was isolated using Trizol reagent 
(Invitrogen), followed by chloroform extraction and ethanol precipitation. Subsequently 
mRNA was reverse transcribed into cDNA using Superscript II (Invitrogen) and random 
primers according to the suppliers’ protocol. 
For qPCR analysis, total RNA was isolated from gastrocnemius and soleus muscles of adult Swiss 
mice using Trizol reagent as describe above, followed by DNase-treatment (DNA-free, Ambion) 
and conversion to cDNA using iScript cDNA synthesis kit according to the suppliers’ protocol 
(Bio-Rad). qPCR was performed using the CFX96 Real-Time PCR detection system (Bio-Rad). 
Th e following primers were used: ChapA (sense: 5’-GAGGAGGTGCAGGTCACATT-3’; 
antisense: 5’-CTGAAGAGCCTGGGAAACAG-3’), ChapB (sense: 
5’-CCGCCGCTTCTTAAACATAA-3 antisense: 5’-GGCTTTAAAGGGCCTTGG-3’) 
and as reference gene Gapdh (sense: 5’-GTTTGTGATGGGTGTGAACCAC-3’, antisense: 
5’-CTGGTCCTCAGTGTAGCCCAA-3’). Data were analyzed with Bio-Rad CFX Manager.
Cloning of full-length chick CHAP
Using the mouse and human CHAP coding sequences, a chick CHAP orthologue (XM_421618) 
was identifi ed aft er BLAST search. Full-length cDNA of chick CHAP was amplifi ed by PCR 
(multiple clones) from chicken HH19-27 hearts and subsequently cloned into the pCRII-
TOPO vector (Invitrogen). Th e full-length coding sequence of chick CHAP was confi rmed 
by sequencing.
Whole- mount and section in situ hybridization
RNA probes were generated from PCR products cloned into pCRII-TOPO using T7 or SP6 
primers. For generation of a chick CHAP probe template, the following primers were used: sense 
5’- GGTCTCCCCTTTCTCACCTC-3’ and antisense 5’-CACCACAAACTTGTCCATGC-3’ 
(PCR product: 810 bp). Probes for detection of mouse Chap were generated as described 
previously 3.  Probes were digoxigenin-labeled according to the suppliers’ protocol (Roche 
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Applied Science). For in situ hybridization 10 µm sections of chick or mouse embryos were 
mounted on superfrost slides (Menzel). In situ hybridization was performed as previously 
described 6. Whole-mount in situ hybridization was performed as previously described 7. 
Immuno uorescence
Mouse embryos and adult tissues were sectioned (5 μM) and mounted on starfrost slides 
(Knittel). Antibody staining on cryo-sections was performed as previously described 8. 
Primary antibodies were as follows: anti-CHAP (rabbit, 1:50, custom made by Eurogentec), 
anti-myosin (mouse, 1:1000, NOQ7.5.4D, Sigma-Aldrich Chemie) and anti-α-smooth muscle 
actin (mouse, 1:500, 1A4, Sigma-Aldrich Chemie). Secondary antibodies were as follows: 
Cy-3 conjugated anti-mouse (1:250, Jackson Immunoresearch Laboratories) and Alexa488 
conjugated anti-rabbit (1:200, Invitrogen). Cell nuclei were stained with DAPI (Molecular 
Probes)
Immunohistochemistry
Mouse embryos (E12.5) were sectioned (5 μM) and mounted on starfrost slides (Knittel). 
Antigen retrieval was performed by microwave heating of tissue sections in citrate buff er 
(pH 6). Endogenous peroxidase was blocked by incubating the slides in 0.3% H2O2 in PBS. 
Sections were incubated overnight with CHAP antibody (1:2000) at room temperature. 
Biotin-conjugated goat anti-rabbit (BA-1000, Vector Labs) was used as secondary antibody. 
Subsequently, the sections were incubated with Vectastain ABC staining kit (PK-6100, Vector 
Labs) for 45 min. Slides were rinsed in PBS and Tris/Maleate (pH 7.6). 3-3 diaminobenzidine 
tetrahydrochloride (D5637, Sigma-Aldrich) was used as chromogen and Mayer’s hematoxylin 




Aft er BLAST search using full-length sequences of the previously identifi ed CHAP 
orthologues (zebrafi sh, mouse, and human) 3, we identifi ed the chick (Gallus gallus, Gg) 
orthologue of CHAP (GenBank accession no. XM_421618). For amplifi cation, cloning and 
sequencing of chick CHAP we amplifi ed the predicted full-length open reading frame (ORF) 
from hearts of chick embryos (HH19, 23 and 27), which resulted in a 3243 bp PCR product. 
Aft er sequencing we found that the 1081 aa predicted chick CHAP protein (Fig. 1C) had a 
 48% and 47% homology with human (Hs) and mouse (Mm) CHAPa, respectively (Fig. 1A). 
Furthermore, there was a 43% and 40% homology with zebrafi sh Chap-1 (DrChap-1) and 
Chap-2 (DrChap-2), respectively (Fig. 1A). Th e NLS and PDZ domain are conserved between 
the diff erent species. Th e chick PDZ domain of CHAP showed 63% and 61% homology with the 
PDZ domains of human and mouse, respectively. Th e CHAP gene is mapped on chromosome 
6 and consists of four exons (Fig. 1B). Similar to zebrafi sh chap, no chick CHAPb (lacking the 
PDZ-domain) was identifi ed. In addition to homology of sequence between diff erent species, 
we also observed conserved syntenic organization. For instance, myozenin-1, another z-disc 
protein, is located immediately downstream of the mouse Chap gene 3. A similar genomic 
organization was found in the chick genome.
Figure 1: Sequence and genomic organization of chick CHAP. A) Alignment and amino acid comparison of Homo 
sapiens (Hs), Mus musculus (Mm) CHAPa, Gallus gallus (Gg) and Danio rerio (Dr) CHAP. Identical amino acids are 
shown in black, similar amino acids are gray and gaps are represented by a dash. PDZ and NLS (*) domains are indicated. 
B) Genomic organization of chick CHAP gene. ATG represents start codon, TGA represents stop codon and exons (black 
boxes) are numbered. C) Schematic representation of chick (Gg) CHAP protein showing the location of the PDZ and 
NLS domains.
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Expression of CHAP during development in chick and mouse embryos
To investigate the expression pattern of chick CHAP during development we performed 
whole-mount in situ hybridization. Expression of CHAP could fi rst be detected at stage HH8 
in the cardiac crescent (Fig. 2A). At HH10 and HH11 CHAP was expressed in the linear and 
looping heart tube (Fig. 2B and C). CHAP could be detected in the ventricle and outfl ow tract 
(OFT), but not in the sinus venosus. At stage HH13, CHAP was strongly expressed in the 
looping heart (Fig. 2D). From HH15 onward CHAP was expressed in the heart and somites 
(Fig. 2E), with higher expression in the anterior somites, which are more mature than the 
posterior somites. At HH17 (Fig. 2F) CHAP was also expressed in the more posterior somites, 
suggesting that the expression increases as the somites mature. At stage HH17 (Fig. 2F) and 
stage HH21 (Fig. 2G and H) CHAP expression was maintained in the heart and somites. 
At stage HH25 CHAP was expressed in the muscle precursors of the limb buds, heart and 
somites (Fig. 2I and J). Th e expression of CHAP in muscle precursors of the limb buds of the 
developing legs and wings was more pronounced in embryos in stages HH28-30 (Fig. 2K, 
N and O). Hearts of HH30 showed a high expression of CHAP in both atria and ventricles, 
but not in the OFT (Fig. 2L and M). Comparison of expression pattern of CHAP during 
early embryonic development with that of mouse and zebrafi sh, demonstrate that the CHAP 
expression pattern is conserved between these species 3.
Figure 2: Whole mount in situ hybridization of chick CHAP during development. A-O) Whole mount in situ hybridiza-
tion with digoxigenin-UTP labeled chick CHAP riboprobe on diff erent developmental stages of chick embryos: HH8 (A), 
HH10 (B), HH11 (C), HH13 (D), HH15 (E), HH17 (F), HH21 (G-H), HH25 (I-J), HH28 (K), HH30 heart (L-M), HH30 leg 
(N) and HH30 wing (O). Cardiac crescent (cc), ventricle (v), atrium (a) and outfl ow tract (oft ), sinus venosus (sv), heart 
(h), somites (s), muscle precursors (arrow head) of the limb buds (lb) , left  ventricle (lv), right ventricle (rv), left  atrium 
(la), right atrium (ra).
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To study CHAP expression during chick development in more detail, we performed section 
in situ hybridization at diff erent stages. At stage HH18 and HH26 CHAP was expressed in 
heart muscle cells and the myotome part of the somites (Fig. 3A-C), confi rming the results of 
whole-mount in situ hybridization. Occasionally, higher levels of CHAP could be identifi ed 
at the border with the dermatome, suggesting that CHAP is expressed in more mature cells of 
the somites, which is also in agreement with the higher expression of CHAP in more anterior 
somites. At stage HH30 expression of CHAP was localized in ventricles and atria, whereas 
endocardial cushions are negative for CHAP (Fig. 3D and G). Furthermore, trunk muscle 
masses (Fig. 3E and H), muscle groups from the limb buds of the developing wings (Fig. 3F), 
tongue, eyes and jaws show CHAP expression (Fig. 3I). 
Figure 3: In situ hybridization of CHAP chick on sections. A-I: In situ hybridization with digoxigenin-UTP labeled CHAP 
riboprobe was performed on sections of chick embryos on stages HH18 (A), HH26 (B-C) and HH30 (D-I). Somites (s), 
myotome (m), limb buds (lb), eye muscles (em), jaw muscles (jm) and tongue muscles (tm), sinus venosus (sv), left  ven-
tricle (lv), ventricle (v), left  atrium (la), right atrium (ra), atrium (a), neural tube (nt). Scale bars: 250 µm.
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To compare CHAP expression in chick and mouse embryos, we performed in situ hybridization 
on sagittal sections of E13.5 mouse embryos, using a probe that recognizes both ChapA and 
ChapB isoforms. As expected, expression of Chap was pronounced in the ventricles and atria 
of the heart (Fig. 4A and B). Furthermore Chap was also expressed in the developing muscles 
of the tongue, jaw, limb buds and tail (Fig. 4A). Detection of Chap was considered to be 
expression of ChapB, since we have previously demonstrated that ChapB is the predominant 
isoform in embryonic and fetal stages 3. In order to determine whether Chap mRNA expression 
was comparable with protein expression, we performed immunohistochemistry with an 
antibody that specifi cally recognizes CHAP (both a and b isoforms). In E12.5 embryos, CHAP 
protein was detected in heart, trunk muscle masses and muscles of the tongue, eyes and jaws, 
which was comparable to Chap mRNA expression (Fig. 4C and D). Furthermore, a striated 
expression pattern for CHAP, as expected for Z-disc proteins, was observed in muscle cells 
(Fig. 4E), confi rming the specifi city of the antibody staining. 
Figure 4: Expression and localization of CHAP in mouse embryos. A-B) Section in situ hybridization with digoxigenin-
UTP labeled mouse Chap riboprobe was performed on sagittal sections of E13.5 mouse embryos. A higher magnifi cation 
of Chap expression in the heart (box in A) is shown in (B). C-E: Immunostaining for CHAP on sagittal sections of E12.5 
mouse embryos (C). Magnifi cation of C (box) is shown in (D). A higher magnifi cation (E) of heart shown in (D) displays 
a sarcomeric pattern for CHAP. Heart (h), jaw muscle (jm), tongue muscle (tm), ventricle (v), atrium (a), cardinal vein 
(cv), and outfl ow tract (oft ). Scale bars in A/C 500 µm, in B/D 250 µm and in E 10 µm.
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Expression of CHAP in adult skeletal muscle
We have previously shown that both CHAPa and CHAPb are expressed in adult mouse heart 
and skeletal muscle 3. Here, we investigated the expression of CHAP in adult skeletal muscles 
in more detail. Skeletal muscle can be divided into slow (type I) and fast (type II) twitch 
fi bers. To determine the expression levels of both Chap isoforms, we isolated slow (soleus) 
and fast (gastrocnemius) muscles of adult mice. qPCR analysis of these tissues showed that 
both ChapA (Fig. 5, black bars) and ChapB (Fig. 5, white bars) were expressed higher in 
soleus than in gastrocnemius. Expression of ChapA was approximately 10-fold higher than 
Figure 5:  ChapA and ChapB expression in adult skeletal mus-
cle. Quantitative real-time PCR expression of ChapA and ChapB 
mRNA in soleus (slow) and gastrocnemius (fast) muscles. 
Gapdh used as internal control.
ChapB expression in both soleus and gastrocnemius. To confi rm expression at the protein 
level, we performed CHAP antibody staining in combination with myosin, a slow muscle 
fi ber marker, on sections of mouse soleus and gastrocnemius. Indeed, CHAP protein was 
expressed in both soleus and gastrocnemius muscle cells (Fig. 6), confi rming the results of 
the qPCR. Although Chap mRNA levels were approximately 3-fold higher in soleus muscle, 
immunofl uorescence did not show obvious diff erences for CHAP protein expression between 
soleus and gastrocnemius muscles. However, more quantitative proteins assays would be 
necessary to confi rm this.
Figure 6: Expression and localization of CHAP in adult fast and slow muscle. Immunostaining on cross-sections of 
mouse soleus (slow, upper panel) and gastrocnemius (fast, lower panel) using anti-CHAP (green) and anti-myosin 
(red) antibodies. Myosin staining (red) was used as a marker for slow muscle fi bers, and DAPI was used to stain nuclei 
(blue). Scale bars: 50 µm.
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Figure 7: Co-localization of CHAP with α-smooth muscle actin (ASMA) in cardiomyocytes of the vena cava. 
Immunostaining for CHAP (green) and α-smooth muscle actin (red) on cross-sections of E17.5 mouse embryos (A-C). 
DAPI was used to stain nuclei (blue). Vena cava (vc), brachiocephalic artery (bc), left  carotid artery (lca), subclavian 
artery (sc) trachea (t), and oesophagus (o). Scale bars: in A 250 µm, B 50 µm and C 20 µm.
CHAP is expressed in smooth muscle cells
We have previously observed CHAP expression at the Z-disc in cardiomyocytes of adult 
mice. More detailed examination indicated CHAP expression in smooth muscle cells. To 
confi rm this observation we performed immunostainings for CHAP and α-smooth muscle 
actin (ASMA), a smooth muscle marker (but also expressed in cardiomyocytes during early 
cardiac development), on sections of embryonic (E17.5), adult mouse heart, carotid arteries 
and aorta. We observed that besides expression in cardiomyocytes in E17.5 mouse embryos 
CHAP was also expressed in the vena cava, but not in the aorta (data not shown), carotid 
arteries (Fig. 7A) and subclavian artery (Fig. 7B and C). A higher magnifi cation (Fig. 7B and 
C) showed that CHAP is expressed in a striated pattern and co-localized with ASMA-positive 
cells, suggesting that CHAP is expressed in cardiomyocytes from the vena cava. It has been 
demonstrated previously that cardiomyocytes are present in the tunica media of the vena 
cava during embryonic development 9, 10. However, in adult tissues CHAP expression was 
also observed in smooth muscle cells of aorta, carotid arteries and coronary arteries (Fig. 8). 
Although CHAP and ASMA are expressed in the same cells, the subcellular localization of 
both proteins is clearly diff erent. 
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Figure 8: Expression and localization of CHAP in adult smooth muscle cells. Immunostaining for CHAP (green) and 
α-smooth muscle actin (ASMA; red) on cross-sections of adult mouse aorta, left  carotid artery and coronary artery. 
DAPI was used to stain nuclei (blue). Scale bars: 20 µm.
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Conclusion
In the present study we identifi ed and characterized chick CHAP which has signifi cant 
homology to the human and mouse CHAPa isoform and zebrafi sh Chap-1 and -2, and contains 
highly conserved motifs such as the N-terminal PDZ domain and the NLS.  Expression of both 
chick CHAP and mouse Chap mRNA and protein were detected in heart and skeletal muscle 
(such as limbs, jaw, eye and tongue) throughout embryonic development. Furthermore, we 
demonstrate in the present study that CHAP is also expressed in cardiomyocytes from the 
vena cava during mouse embryonic development and in smooth muscle cells of aorta, and 
coronary and carotid arteries of adult mice. It has been shown previously that multipotent 
cardiovascular progenitor cells, marked by transcription factors Isl-1 and Nkx2.5, have 
the capacity to diff erentiate to vascular smooth muscle cells and cardiomyocytes. 11, 12. 
Since cardiomyocytes and smooth muscle cells are derived from diff erent origins during 
development, this suggests that CHAP is expressed in diff erent cardiovascular progenitor 
cells. 
Conserved predicted motifs, syntenic organization and developmental expression patterns, 
suggest that CHAP may play an important role during muscle development. Indeed, 
knockdown of chap by antisense oligonucleotides in zebrafi sh had shown previously decreased 
cardiac contractility, defects in cardiac looping and myofi brillar disarray in muscle cells during 
embryonic development 3. CHAP displays homology to synaptopodin and myopodin, which 
have both been shown to function in actin/α-actinin binding and /or signaling 13-15. Whereas 
synaptopodin is expressed in kidney and brain in an isoform specifi c manner 15, expression 
of myopodin can be found in smooth, skeletal and heart muscle cells, which is comparable to 
that of CHAP. Like CHAP, myopodin is localized at the Z-disc of striated muscles and is able 
to translocate to the nucleus 16, 17. It has been shown for myopodin that traffi  cking between the 
Z-disc and the nucleus is dependent on PKA and CamKII kinase and calcineurin phosphatase 
activities 18. Future studies will elucidate whether similar pathways control CHAP traffi  cking 
in muscle cells. Furthermore, it would be of interest to study the function and mechanism 
of action of CHAP in physiological and healthy and pathophysiological situations related 
to striated and smooth muscle cells. In humans, hypertrophic cardiomyopathy (HCM) and 
dilated cardiomyopathy (DCM) have been associated with mutations in cytoskeletal and 
sarcomeric proteins 19, 20. In addition, it has been shown in diff erent mouse models that 
mutations in sarcomeric proteins such as α-myosin heavy chain 21, 22, myosin binding protein 
C 23, 24 and cardiac troponin T 25 can cause HCM-like phenotypes. Th e sarcomeric protein 
CHAP may represent a novel candidate gene for screening mutations in DCM and HCM 
patients.
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Th e role of CHAP during heart development: in vivo and in 
vitro knockdown in mouse and chick
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We have previously shown that Cytoskeletal Heart-enriched Actin-associated Protein 
(CHAP) plays an important role during skeletal and heart muscle development in zebrafi sh 
by a gene knockdown approach. In order to study the role of CHAP more specifi cally during 
muscle development and disease we targeted the CHAP genomic locus in mouse embryonic 
stem cells (mESC) for creating both straight and conditional knockout mice for CHAP. High 
percentage chimeric mice were obtained for both approaches and were further bred for 
germline transmission. At the present time, no germ knockout lines were generated for both 
targeted constructs. Besides the opportunity to study the loss of CHAP during development 
and disease at specifi c times and organs, another advantage is to study the role of CHAP 
during cardiomyocyte diff erentiation in these targeted ESC lines.
To investigate the cardiac diff erentiation potential of the heterozygous CHAP LacZ mESC 
in vitro, we diff erentiated these cells to cardiomyocytes by formation of embryoid bodies 
(EBs). qPCR analysis showed that ChapB was signifi cantly downregulated in these EBs in 
comparison to wild type cells. Although, expression levels of ChapA were not signifi cantly 
diff erent, a trend towards reduced mRNA levels in the heterozygous cells could be observed. 
Despite decreased levels of CHAPb, both sarcomeric organization and beating frequency 
were not aff ected in CHAP heterozygous mESC lines, indicating that mutation of one single 
copy of CHAP does not lead to haploinsuffi  ciency based on cellular and functional in vitro 
readouts. 
Since CHAP is also expressed during muscle development in chick, which only has one 
isoform of CHAP and does not contain a duplicated genome (as in the zebrafi sh), we 
knocked down CHAP expression in chick during embryonic development. With increasing 
concentrations of CHAP morpholino’s a higher percentage of embryo’s with an aberrant 
cardiac looping phenotype was observed, although this was not statistically signifi cant. Th ese 
results from both mouse and chicken experiments show that reduced levels of CHAP are 
suffi  cient to maintain cardiomyocyte integrity and functionality with minimal eff ects on 
cardiac development. 
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Cytoskeletal Heart-enriched Actin-associated Protein (CHAP) is highly conserved in diff erent 
species such as human, mouse, zebrafi sh and chicken. Whereas two isoforms of CHAP exist 
in human and mouse, only one isoform is present in zebrafi sh and chicken. In previous 
experiments in mice we identifi ed that the shorter isoform CHAPb is expressed during 
embryonic development, whereas the longer isoform CHAPa is expressed in adult heart and 
skeletal muscle. Th e longer isoform consists of a PDZ domain, important for protein-protein 
interactions and a nuclear localization signal (NLS), whereas the shorter isoform lacks the 
PDZ domain. In both zebrafi sh and chick only one isoform can be identifi ed with highest 
homology to the longer isoform CHAPa. We have previously shown by antisense morpholino 
knockdown of CHAP in zebrafi sh resulted in cardiac defects and impaired muscle formation, 
suggesting an important role for CHAP during development1. 
To elucidate the function of CHAP in specifi c organs and at specifi c times during mouse 
development and disease we developed diff erent strategies for generating CHAP knockout 
lines in mouse embryonic stem cells (mESC). First, a CHAP LacZ knockin (CHAP LacZ+/-) 
mouse embryonic stem cell line was generated, which replaces the complete CHAP gene for a 
LacZ gene. Th is line was used to study the eff ect of CHAP knockdown on the diff erentiation 
of mESC-derived cardiomyocytes in vitro. Second, a conditional knockout mESC line was 
generated in which the CHAP exon 5 was fl anked by loxP sites. Both lines can be used to 
generate CHAP knockout (CHAPf/+) lines, which can be used to study the eff ect of CHAP 
knockdown in mouse in vivo.
In addition, we investigated the eff ects of CHAP knockdown on heart development in 
chick embryos. In contrast to human and mice, the chick genome contains only one CHAP 
isoform (see chapter 2) and in contrast to the zebrafi sh, there is no duplication of the genome. 
Furthermore, the four-chambered chick heart represents a convenient model for studying 
human heart development2, 3. Comparable to the zebrafi sh it is possible to achieve knockdown 
of the gene of interest. Following an antisense morpholino-mediated knockdown in chick 






Wild type (IB10) and   targeted CHAP LacZ+/- and CHAPf/+ mESC were grown on feeders 
in complete medium (CM: 1x GMEM (Invitrogen), 2 mM L-glutamin (Invitrogen), 1 mM 
Sodium Pyruvate (Invitrogen), non-essential amino acids (1:100, Invitrogen)), 8.8% fetal calf 
serum (FCS; Sigma-Aldrich Chemie). To keep the cells undiff erentiated β-mercaptoethanol 
(1000x) and leukemia inhibitory factor (106 units/ml LIF, ESGRO, Millipore) were added to 
the CM (CM++). For long-term feeder free growth of mESCs, cells were plated on gelatine 
coated dishes and grown in 60% BRL medium with β-mercaptoethanol and LIF added. 100% 
BRL medium was made by conditioning CM on Buff alo Rat Liver (BRL) cells. 60% BRL 
medium was made by mixing 100% BRL and CM to a 60/40 ratio. 
Generation of CHAP lacZ knockin and CHAP conditional mESC lines
For generating CHAP LacZ+/- mESC the pNeo-LacZ-TK2 targeting vector (kindly provided 
by Dr. E. Olson) was used. A 5.3 kb long arm (primers: 5’- GTCGACTCAGTTTTTT-
GAGACTGGAT-3’ and 5’- GTCGACCGCACAGCTTAGCCTGTGG-3’) was designed, 
amplifi ed by PCR from a BAC-clone, subcloned into pGEM-T easy (Promega) and 
sequencing. Th e long arm was designed as such that the ATG starting codon of the CHAP 
gene was replaced by the coding sequence of LacZ gene (starting with ATG). A 2.5 kb short 
arm (primers: 5’-GGTACCCTCCTCAGCTCTCTGCTGGT-3’ and 5’- ATGGTTGC-
AGGTCAACACAA-3’) was amplifi ed and subcloned in a similar way as described for the 
long arm and was positioned at the 5’ end of LacZ (see fi gure 1A). 
For generating CHAP conditional knockout (CHAPf/+) mESC line the pl451 targeting 
vector (kindly provided by J. van Es) was used. Th e following products were amplifi ed and 
subcloned in pGEM-T easy vector and verifi ed by sequence analysis: CHAP exon 5 (primers: 
5’-CGGGATCCGCCAGCCTGGTCTACATAGC-3’ and 5’-CGGGATCCAGCCTTG-
TTCCTGGCTTTTG-3’), a 5.8 kb long arm (primers: 5’-CCATCGATCTTTCAAT-
GACCGTGGCAAA-3’ and 5’-CCATCGATGTCGGCCTTGAACTCACAGA-3’) and a 2.5 
kb short arm (same primers were used as for the CHAP LacZ+/-). Th e products were subcloned 
into the pl451 targeting vector: the CHAP exon 5 product was fl anked by loxP sites and the 
long arm and short arm were upstream and downstream of exon 5, respectively. Following 
correct targeting by homologous recombination exon 5 of CHAP will be fl anked by LoxP sites 
(see fi gure 2A). Both targeting vectors contained a neomycin cassette for positive selection 
and a thymidine kinase (TK) cassette for negative selection.
Th e targeting constructs were linearized, purifi ed and dissolved in sterile PBS (Invitrogen). 
75-100 ug DNA was electroporated in mESC (IB10) with a 129Sv background. Cells were 
plated on gelatin-coated dishes and put overnight in the incubator. Aft er 1 day medium was 
replaced by medium containing G418 and gancyclovir for positive and negative selection, 
respectively. Th e medium was replaced every other day. Aft er approximately one week 
colonies were picked and transferred to 96 well plates on feeders. Th ese plates were split into 
three other 96 well plates (two with feeders, one feeder-free). Th e two plates on feeders were 
frozen by dissolving cells in freezing medium (44.3% CM++, 44.3% FCS and 11.4% DMSO) 
and stored at -80 oC. Th e feeder-free plate was used to isolate DNA to screen resistant colonies 
for correct homologous recombination by Southern blot (see below). Correct recombined 
colonies were thawed, scaled-up and frozen again in multiple aliquots in liquid nitrogen.
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Southern blot
Genomic DNA of resistant ES cell colonies was extracted by adding lysisbuff er (10 mM Tris 
pH 7.5, 10 mM EDTA, 10mM NaCl, 0.5% sarkosyl and 2 mg/ml protK) at 60 oC overnight. 
DNA was precipitated and digested by BamHI (5’targeting of CHAPf/+), NcoI (5’targeting of 
CHAP LacZ+/-) or KpnI (3’targeting of CHAPf/+and CHAP LacZ+/-) overnight and run on a 
1% v/w agarose gel. Th ree probes were generated using the following primers: BamHI (329 
bp) 5’-GGAGAGCCAGATGCTTTTTG-3’ and 5’- CCACTCTTCTGCCCAGCTAC-3’, 
NcoI (1 kb) 5’-GTCCTTCCAAACGCTAAACG-3’ and 5’-CTACCGTAGGGAC-
GCAAATC-3’, KpnI (416 bp) 5’-CCACTATCTGCTCCCTCTCG-3’ and 5’-CTCAGAA-
GAGTGGGCTCCAG-3. Th e PCR products were cloned into pCRII (Invitrogen) and 
products were excised. Th e products were then radioactively labelled using α-[p32]dATP 
(PerkinElmer) by random priming (RadPrime, Invitrogen). DNA blots (Hybond-N+, GE 
Healthcare) were hybridized with the radioactive probe in ExpressHyb Hybridization buff er 
(Clontech) and visualized by using phosphor-imager (location of probes are indicated in 
schematic drawings of fi gure 1A and 2A). 
Generation of chimeric mice
Recombinant ESC clones were injected in blastocysts obtained from C57BL6 (conditional 
knockout) or CD1 females (LacZ knockin). Chimeric male mice were crossed with C57BL6 
or CD1 females to derive germline F1 progeny.
Di erentiation assays
Wild type (IB10) and CHAP LacZ+/- mESC were diff erentiated using the hanging drop 
method. Before the procedure, cells were plated on gelatine-coated dishes for feeder depletion 
and grown in CM medium with β-mercaptoethanol and LIF. Cells were then washed with 
PBS, trypsinised and counted. 20 µl drops containing 1500 cells in diff erentiation medium 
(Iscove’s Modifi ed Dulbecco’s Medium, Invitrogen), 15% FCS (Greiner), 5% Protein free 
Hybridoma medium (PFHMII, Invitrogen), 2 mM L-glutamine (Invitrogen), 50 µg/ml 
asorbic acid, 0.3% α-MTG and 0.5% Pen/Strep (Invitrogen)) w ere put on the lids of bacterial 
dishes with PBS and left  for 7 days. Th en embryoid bodies (EBs) were plated on gelatine-
coated dishes in diff erentiation medium. Aft er 7 days cells we either fi xed EBs for 30 minutes 
in 2% paraformaldehyde (PFA) or dissolved them in Trizol (Invitrogen) and stored at -80 oC. 
RNA isolation and quantitative PCR
EBs were dissolved in Trizol (Invitrogen) and RNA was isolated. RNA was treated with 
DNase (DNA-free, Ambion) and cDNA was made with the iScript kit (BioRad). qPCR 
was performed using the CFX96 Real-Time PCR detection system (Bio-Rad). Th e 
following primers were used ChapA (sense: 5’-GAGGAGGTGCAGGTCACATT-3’; 
antisense: 5’-CTGAAGAGCCTGGGAAACAG-3’), ChapB (sense: 
5’-CCGCCGCTTCTTAAACATAA-3 antisense: 5’-GGCTTTAAAGGGCCTTGG-3’) 
and as reference gene Gapdh (sense: 5’-GTTTGTGATGGGTGTGAACCAC-3’, antisense: 
5’-CTGGTCCTCAGTGTAGCCCAA-3). Data were analyzed with Bio-Rad CFX Manager.
Immuno uorescence
EBs were grown on gelatine-coated coverslips and fi xed in 2% PFA for 30 minutes. Cells were 
permeabilized in 0.1% Triton-x-100 in PBS for 8 minutes. Subsequently, cells were incubated 
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with primary antibodies (CHAP 1:50 (rabbit, custommade by Eurogentec), myomesin 
(mouse, kindly provided by E. Ehler) 1:50 and α-actinin (mouse, Sigma) 1:800) in 4% normal 
goat serum overnight at 4 oC. Secondary antibodies used were goat-anti-mouse cy3 (1:250, 
Jackson Immuno research) and goat-anti-rabbit Alexa Fluor 488 (1:200, Invitrogen) for 1 
hour at room temperature. Cells were counterstained by DAPI. Stainings were analysed with 
SP5 confocal microscope (Leica). 
Morpholino knockdown of CHAP in chick embryos 
Morpholino knockdown of CHAP was done as described by Cing et al2. In brief White 
Leghorn eggs were incubated at 38 oC. At Hamburger and Hamilton stage 11 a window 
was created and the extra-embryonic membranes overlying the heart were removed. 
Embryos were treated with control morpholino’s (mutated human β-globin; sequence: 
5’-CCTCTTACCTCAGTTACAATTTATA-3’), two concentrations of CHAP-specifi c 
morpholino’s (sequence: 5’-TGAGCATTTCTTCTTCGGCTCCCAT-3’) or left  untreated 
(wild type). Aft er 29 hours (stage 20) embryos were harvested, washed in PBS and fi xated in 
4% paraformaldehyde. Embryos were dehydrated by ethanol and xylene series and embedded 
in paraffi  n. Embryos (E12.5) were sectioned (5 μM) and mounted on starfrost slides (Knittel). 
Antigen retrieval was performed by microwave heating of tissue sections in citrate buff er 
(pH 6). Endogenous peroxidase was blocked by incubating the slides in 0.3% H2O2 in PBS. 
Sections were incubated overnight with Troponin I antibody (1:400; TnI; Santa Cruz) at 
room temperature. Biotin-conjugated goat anti-rabbit (BA-1000, Vector Labs) was used as 
secondary antibody. Subsequently, the sections were incubated with Vectastain ABC staining 
kit (PK-6100, Vector Labs) for 45 min. Slides were rinsed in PBS and Tris/Maleate (pH 7.6). 
3-3diaminobenzidine tetrahydrochloride (D5637, Sigma-Aldrich) was used as chromogen 
and Mayer’s hematoxylin as counterstaining. Finally, all slides were dehydrated and mounted 
with Entellan (Merck). 
Reconstructions were made as follows: a picture was taken of every TnI positive stained slide, 
which were adapted in Photoshop (Adobe) and the program Amira 5.3 was used to make the 
reconstructions. 
In situ hybridization
CHAP in situ hybridization were performed as described before (van Eldik et al.; Chapter 2) 
and was performed on CHAP morpholino treated, control morpholino treated and wild type 
embryo’s.
Statistical analysis
Data were analysed with GraphPad Prism. All data are expressed as mean + the standard error 
of the mean (SEM). Statistical analysis was performed using students unpaired t-test. P < 0.05 
was considered to be statistically diff erent.
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Results
Generation of CHAP knockout mouse ESC lines
To investigate the consequences of CHAP knockdown in vivo, we knocked out CHAP in mESC. 
We used two approaches for this, a straight knockdown (CHAP LacZ+/-), and a conditional 
knockdown (CHAPf/+). In fi gure 1A a schematic overview for the CHAP LacZ+/- targeting 
is shown. Th e targeting construct was linearized and electroporated in mESC (IB10) with a 
129Sv background. Screening of 200 colonies yielded two correctly recombined lines (Figure 
1B). Th ese lines were used to generate chimeric mice, by injecting mESC in blastocysts with 
CD1 background. Chimeric mice were obtained (Figure 1C) and high-percentage chimeric 
mice were crossed with CD1 mice in order to achieve germline transmission. CD1 mice have a 
white coat colour, whereas mice with a 129Sv background have an agouti coat colour. Germline 
transmission is achieved when the agouti coat colour of the 129Sv background is observed 
in progeny. Unfortunately, aft er several rounds of off spring, no germline transmission was 
achieved. 
Figure 1: Targeting strategy for CHAP LacZ mouse embryonic stem cells. A) Schematic overview of CHAP LacZ target-
ing. First panel shows the targeting construct. Th e construct replaces the wild type CHAP gene (second panel) for a LacZ 
gene starting at the ATG site of the CHAPa gene (third panel). Neomycine and thymidine kinase cassettes can be used for 
positve and negative selection respectively. Probes which can be used for testing for recombination are shown (lines in 
second and third panel). For 5’ targeting NcoI gives a 8.3 kB band (wild type) and 7 kB band (targeted). For 3’ targeting 
KpnI gives a 5.5 kB band (wild type) and 3.9 kB band (targeted). B) Southern blot showing the results of the targeting. 
Two positive clones were obtained which showed recombination of both 5’ and ‘3 arm. C) Chimeric mice obtained aft er 
blastocyst injections.
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In fi gure 2A a schematic overview for the CHAPf/+ is shown. In order to avoid interference 
of the neomycine-casette with endogenous expression of CHAP, the  CHAPf/+ line can be 
crossed with a mouse line expressing FLPe, leading to excision of this cassette (Figure 2A 
panel 3). Th e construct was linearized and electroporated in mESC (IB10) with a 129Sv 
background. Screening of 100 colonies yielded 7 correctly recombined lines (fi gure 2B). Two 
lines were used to generate chimeric mice, by injecting mESC in blastocysts with C57BL6 
background. Male chimeric mice were crossed back to mice with a C57BL6 background. We 
obtained progeny with the agouti coat colour of the 129Sv background from one chimeric 
mouse, however aft er PCR and southern blot analysis (data not shown) these were found to 
be all wild type.  
Figure 2: Targeting strategy for CHAPf/+ mouse embryonic stem cells. A) Schematic overview of CHAPf/+ targeting. First 
panel shows the targeting construct. Th e construct replaces the wild type CHAP gene (second panel) for a CHAP gene 
with a LoxP fl anked exon 5 (third panel). Neomycine and thymidine kinase cassettes can be used for positve and nega-
tive selection respectively. Probes which can be used for testing for recombination are shown (lines in second and third 
panel). For 5’ targeting BamHI gives a 15 kB band (wild type) and 11.7 kB band (targeted). For 3’ targeting KpnI gives a 
5.5 kB band (wild type) and 3.9 kB band (targeted). Th e neomycine cassette is fl anked by FRT sites and can be removed 
by crossing CHAPf/+ mouse with a mouse that expresses FLPe (fourth panel). A heart specifi c CHAP knockout mouse can 
be obtained by crossing this mouse with a mouse that expresses Cre B) Southern blot showing the results of the target-
ing. Seven positive clones were obtained which showed recombination of both 5’ and ‘3 arm.
Cardiac di erentiation of wild type and CHAP LacZ+/- mESC
To investigate the eff ect of CHAP knockdown in mESC in vitro, we diff erentiated wild type 
IB10 and CHAP LacZ+/- mESC to cardiomyocytes by using the hanging drop method. First, 
we investigated the expression of ChapA and ChapB in diff erentiated EBs. As expected qPCR 
analysis showed that expression of ChapA and ChapB in CHAP LacZ+/- EBs was approximately 
half of expression of wild type EBs, although this was not statistically signifi cant for ChapA in 
three independent experiments (Figure 3). 
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Figure 3: qPCR analysis of expression of ChapA and ChapB in wild type (white bars) and CHAP LacZ+/- (black bars) 
embryoid bodies.
Next, we investigated the functional properties of wild type and CHAP LacZ+/- EBs . For this 
we investigated if the number of beating EBs and the beating frequency (beats per minute) 
was diff erent for wild type and CHAP LacZ+/- EBs.  We did not observe a diff erence in the 
cardiac diff erentiation potential indicated by a similar percentage of beating EBs (Figure 
4A), although we cannot exclude that the percentage of cardiomyocytes per EB is diff erent 
between groups. Similarly,  beating frequency also did not diff er between groups (Figure 4B). 
In order to determine whether structural properties of wild type and CHAP LacZ+/- EBs were 
aff ected, we performed immunofl uorescent analysis. Wild type and CHAP LacZ+/- EBs were 
co-stained for CHAP and α-actinin (Figure 5A), a Z-disc marker, and CHAP and myomesin 
(Figure 5B), an m-band marker. Staining of wild type and CHAP LacZ+/- EBs showed that 
there was no diff erence in sarcomeric organization and subcellular localization for α-actinin 
and myomesin between wild type and CHAP LacZ+/- EBs. 
Figure 4: Diff erentiation potential of wild type and CHAP LacZ+/- mouse embryonic stem cells (mESCs). A) Percentage 
beating areas obtained aft er diff erentiation of wild type (white bars) and CHAP LacZ+/- (black bars) mESCs. B) Beating 
frequency of wild type (white bars) and CHAP LacZ+/- (black bars).
Knockdown of CHAP in developing chick embryos
In addition to analysing the function of CHAP by knockdown in mice, we also investigated the 
function of CHAP during chick heart development. In chapter 2 we showed that in chick only 
one CHAP isoform (homologous to human and mouse CHAPa) is expressed and that this 
isoform is expressed from the cardiac crescent stage onwards, and in later stages in somites 
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Figure 5: sarcomeric organization of wild type and CHAP LacZ+/- embryoid bodies. A) Wild type and CHAP LacZ+/- EBs 
stained for CHAP (green) and α-actinin (red). Merge images are shown. B) Wild type and CHAP LacZ+/- EBs stained for 
CHAP (green) and myomesin (red). Merge images are shown. Scale bars: 20 μM.
and developing muscles as well. To knockdown chick CHAP during development we treated 
embryos of stage 11 with two concentrations CHAP morpholinos, control morpholinos or 
untreated (wild type). Embryos were harvested at stage 20. Although cardiac defects, such as 
a cardiac looping defect, could occasionally be observed in the CHAP morpholino group, no 
consistent signifi cant cardiac malformations were evident (Figure 6). Next, we investigated the 
expression of CHAP by in situ hybridisation. No diff erence was detected between the diff erent 
groups (data not shown). Th is is not unexpected since morpholino antisense oligonucleotides 
block translation of RNA to protein. In addition, we also used our custommade antibody 
Chapter 3
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Figure 6: CHAP morpholino knockdown in chick embryos. Examples of wild type and CHAP-morpholino treated chick 
embryos of stage HH19 are shown. Th e CHAP morpholino treated embryo shows a looping defect.
against mouse CHAP, but unfortunately did not reveal specifi c staining.
To study changes in cardiac development in detail we decided to perform immunohistochemical 
stainings for TnI, which marks cardiomyocytes, for cardiac reconstructions. Because we found 
impaired looping in zebrafi sh embryos aft er chap morpholino treatment1, we investigated the 
cardiac looping in these embryos as well. Cardiac looping varied among all embryos in the 
diff erent groups, including in the control groups and therefore we cannot conclude at the 
present time that chick CHAP aff ects cardiac looping (Figure 7). To reach a possible statistical 
signifi cant fi nding, these experiments should be extended (see discussion).
Figure 7: Summary of cardiac looping (classifi ed as not looped -, not completely looped +/- and looped +) of wild type 




Here, we generated CHAP LacZ+/- and CHAPf/+ mESC lines. Control experiments show 
successful targeting leading to high-percentage chimeric mice. However, several attempts 
(more than 6 off spring litters for each chimeric mouse) did not yield germline transmission 
at the present time. In addition, we used the CHAP LacZ+/- mESC to study the eff ect of CHAP 
knockdown on cardiac diff erentiation in vitro. Although we found downregulation of ChapA 
and ChapB, no eff ect on diff erentiation was found. We found no diff erence in the number 
of beating areas, beating frequency and sarcomeric organization. From this we conclude 
that mutation of one allele of CHAP does not lead to haploinsuffi  ciency. Alternatively, in 
vitro experiments using CHAP siRNA in hESC-derived cardiomyocytes could be used to 
investigate the eff ect on sarcomere structure and cardiomyocyte function. Preliminary data 
show that siRNA knockdown of CHAP results in disruption of the sarcomeric structure. 
However, we were not able to investigate down regulation of CHAP protein expression. 
Additional future experiments using proper controls (control siRNA) and investigating the 
eff ect on RNA and protein expression will give more information about the function of CHAP 
in human cardiomyocytes.
New techniques for effi  cient generation of knockout mice have been developed. Chimeric 
mice with more than 90% ES cell contribution can still be ineffi  cient germ line transmitters. 
Th erefore, a new technique in generating chimeric mice was developed. In this approach 8 
cell embryos are laser injected with mESCs. Where in the conventional blastocyst injection 
method the injected ESC compete with host to create the inner cell mass (ICM), which results 
in F0 chimeric mice, in the 8 cell stage injected ESC seem to have an advantage over the 
host cells, which results in an ICM that consist completely of injected cells and thus fully ES 
cell derived F0 mice4. Using this technique it would be possible to obtain CHAP LacZ+/- and 
CHAPf/+ mice. 
Morpholino mediated knockdown of chap in zebrafi sh has shown that CHAP is essential for 
cardiac looping1. In vertebrates defects in cardiac looping result in cardiac malformations 
like double-outlet right ventricle, double-inlet left  ventricle and transpositions of the great 
arteries5. If replacement of CHAP by a LacZ gene leads to embryonic lethality, a conditional 
knockdown approach may be used to overcome this problem. For example, crossing the 
CHAPf/f with a mouse that expresses Cre in the cardiac (α-MHC or Nkx2.5) lineage or skeletal 
muscle (MyoD) will elucidate more about the specifi c function of CHAP in these cells. 
Furthermore, using a tamoxifen inducible Cre approach, CHAP can be knocked down at a 
specifi c moment in adult mice. 
In addition to investigating the role of CHAP during development, the knockout models can 
be used to investigate the role of CHAP in disease. For example, we have shown in vitro 
that CHAP mediates calcineurin signalling. Crossing a mouse with a constitutively active 
calcineurin in the heart6 with CHAP knockout mice will give more evidence about the role of 
CHAP in calcineurin signalling in vivo. 
In addition to using mouse as a model organism for heart development, chick embryos 
can also be used as model organism. Th e chick has the advantage to manipulate embryos 
in ovo by morpholino treatment2, 3, 7 or RNAi electroporation8-11. In this experiment we 
chose to knockdown chick CHAP by morpholino treatment. Unfortunately, lack of CHAP-
specifi c chick antibody prevented us to study CHAP protein expression in these embryos. 
We investigated the cardiac looping in these embryos, but found no consistent abnormality 
Discussion and future directions
Knockdown of CHAP in mouse and chick
in CHAP morpholino treated embryos compared to controls. Th ese experiments need to be 
repeated in order to make solid conclusions on whether CHAP aff ects cardiac development 
in chick. In summary, future experiments including knockdown of CHAP in diff erent species 
(mouse, chick and human) in vivo (mouse and chick) or in vitro (human, mouse, chick) will 
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Abstract
Cytoskeletal Heart-enriched Actin-associated Protein (CHAP) is a recently discovered Z-disc 
protein, which we found to be important for cardiac development. Here we studied the 
function of its two isoforms, resulting from alternative splicing of the Chap gene, in adult 
mouse hearts. 
To determine the function of the “adult” CHAPa and “fetal” CHAPb isoforms through 
transgenic (Tg) overexpression specifi cally in mouse heart.
Two CHAPa and three CHAPb Tg founder lines were generated in which CHAP was driven by 
the myosin heavy chain (MHC) promoter. CHAPa Tg mice displayed normal cardiac function 
and phenotype, whereas CHAPb Tg mice showed mild cardiac hypertrophy, interstitial 
fi brosis and enlargement of the left  atrium at 3 months of age, which was more pronounced 
by 6 months. Morphological cardiac hypertrophy and fi brosis were confi rmed by evidence of 
activation of the hypertrophic gene program (Nppa, Nppb, Myh7) and increased expression 
of several collagens, respectively. Connexin40 and 43 were also downregulated in the left  
atrium, which was associated with delayed atrial conduction. CHAPb Tg hearts displayed 
both systolic and diastolic dysfunction partly caused by impaired sarcomere function evident 
from a reduced force generating capacity of single cardiomyocytes. Impaired cardiac function 
of CHAPb Tg mice coincided with activation of the actin-signaling pathway leading to the 
formation of stress fi bers. 
Th is study demonstrated that the fetal isoform CHAPb can initiate progression towards cardiac 
hypertrophy, which is accompanied by delayed atrial conduction and diastolic dysfunction. 
CHAP may thus be a novel candidate gene for familial cardiomyopathy.
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Introduction
Cardiac hypertrophy is an important determinant of cardiac disease. In pathological cardiac 
hypertrophy the increase in heart size is initially a compensatory mechanism, which eventually 
leads to impaired cardiac function and progression to heart failure1-3. Cardiac hypertrophy has 
various causes, which include responses to local environmental changes, such as myocardial 
infarction, pressure or volume overload and valvular defects, or by an intrinsic genetic defect 
that aff ects the cardiomyocyte directly and is referred to as familial hypertrophic and dilated 
cardiomyopathy (HCM and DCM, respectively). Besides cardiac hypertrophy, familial 
cardiomyopathy is also characterized by systolic and/or diastolic dysfunction, myofi brillar 
disarray and interstitial fi brosis. Several mutations in a relatively small group of genes have 
been associated with HCM and DCM. Whereas in HCM mutations predominantly interfere 
with proteins that are crucial for force generation, in DCM mutations aff ect proteins that play 
a role in force transmission from the sarcomere to the cytoskeleton4. Despite the increase 
in genetic associations with familial cardiomyopathies, our understanding of molecular 
regulation and signal pathways involved in familial cardiomyopathy (FCM) is still limited. 
Recently, we discovered a novel protein that we called Cytoskeletal Heart-enriched Actin-
associated Protein (CHAP)5, 6, which is predominantly expressed in mouse striated muscle and 
localized at the Z-disc of sarcomeres. CHAP interacts with other Z-disc proteins, including 
α-actinin-2, the major component of the Z-disc6. Two CHAP isoforms have been identifi ed 
as a result of alternative splicing:  CHAPa, expressed in adult mouse striated muscles, is the 
longer isoform, containing an N-terminal PDZ and a nuclear localization signal (NLS), whilst 
CHAPb is shorter and lacks the PDZ domain. CHAPb is predominantly expressed during 
early cardiac and skeletal muscle development and is downregulated in adult mouse tissues. 
Interestingly, we observed a perinatal switch in splice variant expression from the fetal CHAPb 
to the adult CHAPa isoform6. Zebrafi sh and chick orthologues of CHAP, both of which only 
express the CHAPa isoform, are present in the heart during embryonic development from 
the cardiac crescent stage onwards, but at later stages can be detected in somites and smooth 
muscle cells7. Morpholino-mediated knockdown of chap in the zebrafi sh resulted in impaired 
heart looping, cardiac oedema, decreased cardiac contractility and impaired skeletal muscle 
formation, demonstrating the importance of chap during muscle development 6, 7. 
CHAP displays highest homology to myopodin and synaptopodin. Whilst synaptopodin is 
expressed in the brain and kidney, myopodin, like CHAP, is expressed in skeletal muscle, 
smooth muscle and heart8, 9. Both synaptopodin and myopodin bind to α-actinin and are 
involved in actin signalling. Synaptopodin induces fi lamentous actin (F-actin) formation via 
α-actinin in an isoform dependent manner in neurons and kidney podocytes9. In podocytes, 
stress fi ber formation by synaptopodin is regulated by preventing proteasomal breakdown of 
RhoA10. Myopodin on the other hand, is localized at the Z-disc through binding to α-actinin; 
its phosphorylation leads to detachment from the Z-disc and subsequent translocation to 
the nucleus11, suggesting a role in molecular regulation by converting signaling pathways to 
downstream nuclear events.   
Here, we demonstrate that CHAP initiates hypertrophic cardiomyopathy in transgenic mice 
if, specifi cally over-expressed in the heart. Th is was specifi c for CHAPb since the hearts of 
CHAPa Tg mice appeared normal up to one year of age. CHAPb Tg mice developed cardiac 
hypertrophy, fi brosis, left  atrial enlargement as well as delayed atrial conduction, cardiac 
diastolic dysfunction and impaired calcium handling. Furthermore, activation of actin 
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signaling in these transgenic mice led to the formation of stress fi bers. Together the results 
indicate that the fetal isoform CHAPb may be a novel candidate gene for cardiac hypertrophy 
and familial cardiomyopathies.
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Material and methods
Generation of CHAP Tg mice
Full length cDNA of mouse CHAPa or b cDNA, preceded by a N-terminal Flag and Kozak 
consensus sequence, was fused to the heart-specifi c murine α-myosin heavy chain (α-MHC) 
promoter. At the 3’end of CHAP a poly-A-signal of the human growth hormone (hGH) was 
included. Plasmid DNA was linearized by digestion with NotI, gel purifi ed and dialyzed against 
Tris-EDTA (TE) buff er. DNA was injected into pronuclei from mice with a C57BL/6-CBA 
background. Transgenic (Tg) founder mice were crossed back (5 generations) to C57BL/6 
mice to obtain a pure background. For genotyping genomic DNA was isolated from mice tail 
biopsies and analysed by PCR with a forward primer recognizing the C-terminus of CHAP 
(5’-TGGTGAAACCCCGTCTCTAC-3’) and a reverse primer recognizing the hGH polyA 
signal (5’-CAGATTTTCCACTCCTGCAC-3’). All animal experiments were performed 
according to the regulations of the Leiden University Medical Center.
Protein isolation and western blot analysis 
CHAP Tg mice and wild type littermates were sacrifi ced by cervical dislocation. Hearts were 
harvested, rinsed in PBS, snap frozen in liquid nitrogen and stored at -80oC until further 
use. Hearts were homogenized using an ultra-turrax tissue separator (IKA, Germany) in 
T-PER tissue protein extraction reagent (Pierce) with extra added protein inhibitors (protease 
inhibitor cocktail tablets (10 µg/ml; Roche, Germany), 0.1 mmol/L dithiothreitol (DTT; 
Invitrogen) and 1 mmol/L phenylmethanesulfonylfl uoride (PMSF; Sigma Aldrich), 5 mmol/L 
NaF and 1 mmol/L Na3VO4). Samples were incubated on ice for 15 minutes and centrifuged 
at 10.000 RPM at 4oC for 10 minutes and supernatants were transferred to new tubes. Protein 
concentration was determined by the Bradford assay (BioRad) using bovine serum albumin 
as a standard. Proteins (50µg/lane) were separated by SDS-page gel electrophoresis and 
subsequently blotted using Hybond-P membranes (GE Healthcare) 3 hours at RT. Incubation 
with the following antibodies was performed overnight at 4oC in 5% milk/TBS-Tween 
(unless stated else): CHAP (1:200, custom made by Eurogentec MW CHAPa=140 kDa, MW 
CHAPb=110 kDa), actin (1:1000; Millipore BV, MW=43 kDa), RhoA (1:200, 26C4, Santa 
Cruz, MW=24 kDa), alpha-actinin (1:800, EA-53, Sigma-Aldrich Chemie, MW=100 kDa), 
Ezrin/Moesin/Radixin (1:1000 in 5% BSA/TBS-Tween, Cell Signaling Technology MW 
moesin=75 kDa, MW Ezrin and Radixin=80 kDa), Cofi lin (1:1000 in 5% BSA/TBS-Tween, 
Cell Signaling Technology, MW=19 kDa), SRF (1:200, G20, Santa Cruz, MW=40-67 kDa), 
Myocyte Enhancer Factor 2 (MEF2, 1:200, C21, Santa Cruz, MW=40-65 kDa) and GAPDH 
(1:10000, 6C5, Millipore, MW=38 kDa). Peroxidase-conjugated antibodies used were anti-
mouse IgG HRP linked antibody (1:1000, Cell Signaling Technology) and anti-rabbit HRP 
linked antibody (1:2000, Cell Signaling Technology). For the detection of protein bands 
SuperSignal West Pico Chemiluminescent Substrate (Pierce) was (the substrate) used.
Southern blot analysis
Genomic DNA of wild-type and CHAPb Tg mouse tails was extracted by adding 0.5 ml tail 
lysisbuff er (50 mM Tris pH 8.0, 100 mM EDTA pH 8.0, 100mM NaCl, 1% SDS and 10 mg/ml 
prot K) at 55 oC overnight. DNA was precipitated by phenol-chloroform extraction and 10 µg 
DNA was digested by adding BamHI (Promega) or XmnI (New England Biolabs) overnight 
and run on a 1% v/w agarose gel. Probes were generated using the following primers: 5’- 
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AGGGGTCCAGCTCTTTGAAC-3’ and 5’-AGGCTTAAAGCGTCCTCCTC-3’. Th e PCR 
products were then radioactively labelled using α-[p32]dATP (PerkinElmer) by random 
priming (RadPrime, Invitrogen). DNA blots (Hybond-N+, GE Healthcare) were hybridized 
with the radioactive probe in ExpressHyb Hybridization buff er (Clontech) and visualized by 
using a Phosphorimager.
RNA isolation and quantitative PCR
Transgenic and wild-type hearts were homogenized in TRIzol (Invitrogen) using an ultra-
turrax tissue separator (IKA, Germany) and RNA was isolated according to the supplier’s 
protocol. RNA was treated with DNase (DNA-free, Ambion) and cDNA was made with the 
iScript kit (BioRad). qPCR was performed using the CFX96 Real-Time PCR detection system 
(Bio-Rad). Primers used are listed in supplemental table 1. Data were analyzed with Bio-Rad 
CFX Manager.
Table 1: list of qPCR primers usesd
Gene name Sequence Melting 
temp. (oC) 
Remarks 
ChapA 5’-GAGGAGGTGCAGGTCACATT-3’ 58  
5’-CTGAAGAGCCTGGGAAACAG-3’ 
ChapB 5’-CCGCCGCTTCTTAAACATAA-3 58 endogenous 
5’-GGCTTTAAAGGGCCTTGG-3’ 
ChapB  5’- CCAAGCCAGCTGTGACAAA -3’ 58 Endogenous 
+ transgenic 5’- CCGCCGCTTCTTAAACATAA -3’ 
Connexin40 5’- CTGGCTCACTGTCCTGTTCA -3’ 60  
5’- GCAACCAGGCTGAATGGTAT -3’ 
Connexin43 5’- TGGACAAGGTCCAAGCCTAC -3’ 60  
5’- ACAGCGAAAGGCAGACTGTT -3’ 
Connexin45 5’- AAGAGCAGAGCCAACCAAAA -3’ 60  
5’- CCCACCTCAAACACAGTCCT -3’ 
CollagenI 5’- GAGCGGAGAGTACTGGATCG -3’ 60  
5’- GTTCGGGCTGATGTACCAGT -3’ 
CollagenIII 5’- ACCAAAAGGTGATGCTGGAC-3’ 60  
5’- GACCTCGTGCTCCAGTTAGC -3’ 
Nppa 5’- GGGGGTAGGATTGACAGGAT -3’ 60  
5’- CAGAATCGACTGCCTTTTCC -3’ 
Nppb 5’- ACAAGATAGACCGGATCGGA -3’ 60  
5’- ACCCAGGCAGAGTCAGAAAC -3’ 
Myh7 5’- GAGCCTTGGATTCTCAAACG -3’ 60  
5’- CTTGCTACCCTCAGGTGGCT -3’ 
Serca2 5’- TACTGACCCTGTCCCTGACC -3’ 60  
5’- CACCACCACTCCCATAGCTT -3’ 
GAPDH 5’-GTTTGTGATGGGTGTGAACCAC-3’ 58 Reference 
gene 5’- CTGGTCCTCAGTGTAGCCCAA -3’ 
H2A 5’-GTCGTGGCAAGCAAGGAG-3’ 60 Reference 
gene 5’- GATCTCGGCCGTTAGGTACTC -3’ 
PGK 5’-TGAGAAAGGAAGTGAGCTGTAAA-3’ 52 Reference 
gene 5’-AGATTGCCATGCTGAGTC -3’ 
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Transmission Electron Microscopy (TEM)
Hearts of CHAPb Tg mice and wild type littermates were collected and left  ventricles were 
used for TEM. Tissues were cut into smaller pieces (1 mm3). For electron microscopy samples 
were fi xed in glutaraldehyde (2.5%) in 0.1 mol/L phosphate buff er for 24 hours, post fi xed 
in 1% Os04 in 0.1 mol/L cacodylate buff er for 1 hour at 4°C, dehydrated in a graded ethanol 
series and embedded in an epoxy resin. Ultrathin sections were post stained with uranyl 
acetate and lead citrate and viewed and imaged with a FEI Tecnai 12 transmission electron 
microscope, operated at 120 kV and equipped with an Eagle 4kx4k camera (FEI, Eindhoven, 
Th e Netherlands)
Immunohistochemistry
For histological and immunohistochemical analysis hearts were obtained at diff erent time 
points (1, 3 and 6 months). Mice were sedated by injection of a mixture of 100 µl ketamine, 50 
µl rompun and 10 µl atropine in 1ml 0.9% NaCl. 
For paraffi  n sections mice were perfused with 0.9% NaCl and subsequently with 4% 
paraformaldehyde (PFA). Hearts and other organs (lungs, kidney and liver) were dissected, 
fi xed over night in 4% PFA, dehydrated by ethanol-xylene series and embedded in paraffi  n. 
Serial heart sections (5 µm) were made, mounted on starfrost slides (Knittel) and followed 
by heamatoxilin-eosin (HE) staining, Sirius red staining, and immunohistochemistry as 
indicated. For all antibody stainings, except Myosin Light Chain 2a (MLC2a), microwave 
antigen retrieval in citrate buff er (pH 6) was applied. Endogenous peroxidase was blocked 
by incubating the slides in 0.3% H2O2 in PBS. Sections were incubated overnight at room 
temperature with Connexin40 antibody (1:100; Santa Cruz), Connexin43 (1:500; Zymed), 
MLC2a (1:4000 gift  from S. Kubalak) and Troponin I (TnI, 1:800; Santa Cruz). Secondary 
antibody used was biotin-labeled goat anti-rabbit (Vector Labs) or biotin-labeled horse 
anti-goat (Vector Labs). Subsequently, the sections were incubated with Vectastain ABC 
staining kit (Vector Labs) for 45 min. Slides were rinsed in PBS and Tris/Maleate (pH 7.6). 
3-3’-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich Chemie) was used as 
chromogen and Mayer’s heamatoxylin as counterstaining. Finally, slides were dehydrated and 
mounted with Entellan (Merck).
For cryosections mice were perfused with 0.9% NaCl only, then hearts were isolated. Processing 
of hearts for cryosections was adapted from Bajanca et al.12. In brief hearts were fi xed in 0.2% 
PFA solution containing 4% sucrose, 0.12 mmol/L CaCl2.2H2O, 0.2 mol/L Na2HPO4.2H2O, 
0.2 mol/L NaH2PO4.H2O over night at 4
oC. Th ereaft er, hearts were washed in the same 
solution without PFA during the day at 4oC followed by a solution containing 0.24 mol/L 
phosphate buff er and 30% sucrose over night at 4oC. Th e next day hearts were embedded in 
Tissue-Tek (Sakura) on dry ice and stored at -20oC until sectioning. Serial sections (5 µm) 
were made and mounted on starfrost slides (Knittel) and antibody staining was performed 
as previously described13. Antibodies used were CHAP (1:50), myomesin (1:50 E. Elher), 
α-actinin (Sigma Aldrich), RhoA (1:100, 26C4, Santa Cruz) and pERM (1:50, Cell Signaling 
Technology). Secondary antibodies used are Cy-3 conjugated anti-mouse (1:250, Jackson 
Immunoresearch Laboratories) and Alexa488 conjugated anti-rabbit (1:200, Invitrogen). Cell 





Th e volume of the atria and ventricle was estimated by the Cavalieri principle. For this serial 
sections were stained for an atrial marker, MLC2a, or TnI to identify the ventricle. Th en a grid 
was used to estimate the surface of the stained section and the distance between the sections 
was used to estimate the volume.
Magnetic Resonance Imaging (MRI)
For MRI measurements 4 wild type and 5 CHAPb transgenic mice of 6 months of age were 
used. Animals were sedated by 4% isofl uran and MRI images were produced as described 
below.
Hardware
All experiments were performed on a vertical 9.4T magnet (Bruker, Ettlingen, Germany) 
supplied with an actively shielded Micro2.5 gradient system of 1T/m and a 30 mm transmit/
receive birdcage RF coil, using Para vision 4.0 soft ware.
MRI protocols
In vivo:
At the start of each examination, several 2D FLASH scout images were recorded in the 
transverse and axial plane of the heart to determine the orientation of the heart 
A modifi ed FLASH sequence with a navigator echo (IntraAngio) was used for retrospective 
CINE MRI with the following parameters:
Short-axis (oriented roughly perpendicular to the septum) and long-axis (oriented through 
the apex and aortic valve) cardiac cine MRI images with the navigator positioned through 
the aortic arch were acquired with the following parameters: hermite-shaped RF pulse 1 ms; 
FA 10°; 200 avarages, TR 68.1 ms; TE 1.86 ms; reconstruction of 18 cardiac frames; FOV 
2.56*2.56 cm2; matrix 192*192; in-plane resolution 133 µm, slice thickness 1.0 mm; total 
acquisition time approximately 30 min. 
Heart function was assessed using MASS for Mice 5.1 soft ware package (Leiden, Th e 
Netherlands) by manual delineation of LV and RV borders. 
Based on these segmented areas, LV and RV area, end-diastolic volume (EDV), end-systolic 
volume (ESV), LV stroke volume (SV), and LV ejection fraction were computed automatically.
Electrocardiogram (ECG) measurements
ECG measurements on wild type and CHAPb Tg mice of 6 months of age were performed 
as described in Henkens et al.14. In brief animals were sedated by 4% isofl uran and ECG 
measurements were recorded for at least one minute. Th e data were analysed with the program 
LEADS and heart rate, PR duration and P duration were calculated. 
Sarcomere measurements
Hearts of CHAPb Tg mice and wild type litter mates were isolated at diff erent time points 
(1 month and 3 months) and snap frozen in liquid nitrogen. Single cardiomyocytes were 
obtained by grinding hearts in liquid nitrogen. Cardiomyocytes were defrosted in relaxing 
solution (pH 7.0; 1 mmol/L free Mg2+ 1, 145 mmol/L KCl, 2 mmol/L EGTA, 4 mmol/L ATP, 10 
mmol/L imidazole).  Th en cardiomyocytes were treated with relaxing solution containing 1% 
Triton-x-100 for 5 minutes, to remove the membranes. Cardiomyocytes were washed twice in 
relaxing solution to remove Triton-X-100. Single cardiomyocytes were placed between a force 
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tranducer and piezoelectric motor. Isometric force measurements were performed at 15oC 
and a sarcomere length, measured in relaxing solution, of 2.2 μm. Th e calcium concentrations 
of relaxing and activation solution (pH 7.1) were 10-3 and 30 μmol/L, respectively. Solutions 
with intermediate free [Ca2+] were obtained mixing relaxing and activation solution. Th e fi rst 
control activation was performed at maximum [Ca2+] and thereaft er, the r esting sarcomere 
length was set to 2.2 μm again. Th e second control measurement was performed to calculate the 
maximum isometric tension (force divided by cross-sectional area). Th e next measurements 
(4-5) were performed in submaximal [Ca2+], followed by a control measurement. Force values 
obtained from submaximal [Ca2+] were normalized to control values. 
Protein phosphorylation
Protein phosphorylation of sarcomeric proteins was measured in hearts of CHAPb Tg and 
wild type litter mates at 3 months of age. A detailed description of the procedure can be found 
in R. Zaremba et al.15. Briefl y, samples were separated by SDS-page gels. Subsequently, gels 
were stained by SYPRO Ruby stain or Pro-Q Diamond Phosphoprotein Stain.
Statistical analysis
Data were analysed with GraphPad Prism. All data are expressed as mean + the standard error 
of the mean (SEM). Statistical analysis was performed using Student’s unpaired t-test. P < 0.05 
was considered to be statistically diff erent.
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Ectopic CHAP expression in transgenic mice 
Many genes expressed during heart development, but not in the adult, are re-expressed in 
cardiac pathology. We previously identifi ed CHAP as such a developmentally regulated and 
functional cardiac gene and here investigated whether it also has a role in the adult heart. 
For this purpose we generated transgenic mice that expressed either the CHAPa or CHAPb 
isoform in the heart using a construct under control of the cardiac-specifi c α-myosin heavy 
chain (MHC) promoter and proceeded by an N-terminal FLAG-tag (Figure 1A). DNA vector 
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Figure 1: Expression analysis of CHAPa- and b Tg founders. A) Schematic overview showing the construct used to gener-
ate transgenic mice. FLAG-CHAPa- or b cDNA is downstream of the α-MHC promoter and upstream a human Growth 
Hormone polyA signal. B) qPCR analysis of ChapA and ChapB in wt (white bars, n=6), CHAPa Tg (gray bars, n=4) and 
CHAPb Tg hearts (black bars, n=3). GAPDH was used as internal control. C) Western blot showing CHAP and fl ag ex-
pression in two wt and CHAPa Tg and two wt and CHAPb Tg hearts. GAPDH was used as loading control.
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constructs were linearized and injected into C57BL/6-CBA zygotes. Th is resulted in two 
CHAPa transgenic (Tg) founders among 29 animals and three CHAPb Tg founders among 
30 animals. First, we analysed the mRNA expression of ChapA and ChapB in the hearts of the 
off spring of the diff erent transgenic lines. Th e two CHAPa Tg lines had comparable expression 
of ChapA. Analysis of ChapA mRNA in hearts of CHAPa Tg hearts by qPCR showed an 
expected upregulation (40-fold) compared to wild type (wt) mice (Figure 1B). Next, we 
analyzed the expression of CHAPa protein using an antibody that recognizes both CHAP 
isoforms. In wild type hearts, faint expression of CHAPa (140 kDa) was detected, whereas 
in CHAPa Tg mice strong expression of CHAPa could be detected. However, surprisingly, 
when using the anti-FLAG antibody no expression was observed. Th is could indicate that 
CHAPa was partially degraded or folded incorrectly at the site of the FLAG-epitope (Figure 
1C). Histological analysis of CHAPa Tg hearts did not show any abnormalities at one and 
three months of age. Similarly, at one year of age no diff erences between wild type hearts and 
CHAPa Tg hearts was detected.
Th e three CHAPb Tg lines showed diff erent copy number levels as determined by Southern blot 
(supplemental fi gure 1A). Analysis of hearts of the CHAPb Tg mouse line with intermediate 
copy numbers by qPCR demonstrated upregulation of ChapB compared to wt mice (Figure 
1B). Western blot analysis of CHAPb Tg hearts showed a clear increase in CHAPb protein 
levels (110 kDa), when compared to wt hearts. Th is was confi rmed by the presence of anti-
FLAG immunoreactivity in the Tg hearts only (Figure 1C). 
Analysis of CHAPb Tg founder phenotype
Southern blot analysis of founders showed high CHAPb copy number in transgenic line 29 
and intermediate CHAPb copy number in line 14 compared to endogenous genomic levels of 
CHAP (supplemental fi gure 1A). CHAPb Tg founders died from around 6 months of age and 
onwards. Th e highest CHAPb expressing founder (CHAPb Tg line 29) died aft er 7 months, 
without progeny. Histological analysis of the heart of this founder is shown in supplemental 
fi gure 1B-D, left  panels. Progeny of the CHAPb Tg line 14 died spontaneously at the earliest 
time point of approximately 6 months (supplemental fi gure 1B-D, right panels). Hearts of 
both transgenic lines (14 and 29) displayed comparable phenotypes with enlargement of left  
and right atrium (supplemental fi gure 1B,C). Histological analysis revealed that the left  atrium 
was fi lled with a chronic and organized thrombus. Furthermore, thickness of the septum, left  
and right ventricle wall was increased, suggesting cardiac hypertrophy (supplemental fi gure 
1B). Th is was confi rmed by enlargement and apparent hypertrophy of cardiomyocytes on 
histological sections at higher magnifi cations (supplemental fi gure 1D).  
Overexpression of fetal isoform CHAPb in adult hearts leads to cardiac hypertrophy
We analyzed CHAPb Tg mice at one, three and six months of age. At one month, heart of 
wt and CHAPb Tg mice were indistinguishable (supplemental fi gure 2A-C). At 3 months 
of age the left  atrium of CHAPb Tg hearts was enlarged but without any signs of thrombus 
formation (fi gure 2A). Tg hearts showed obvious cardiomyocyte hypertrophy with enlarged 
nuclei (fi gure 2B) and interstitial fi brosis, as indicated by Sirius Red staining (fi gure 2C). To 
determine the extent of cardiac hypertrophy, we measured atrial and ventricular volume at 
one and three months of age. Myosin Light Chain 2a (MLC2a) and Troponin I (TnI) staining 
were used to identify the atria and ventricle, respectively. As expected, the myocardial volume 
of the left  and right atrium at one month of age was similar in wt and CHAPb Tg mice 
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(supplemental fi gure 2D and E) but at 3 months, the left  atrial volume of CHAPb Tg mice 
was signifi cantly greater than in wt (wt 2.046 ± 0.1346 n=4 mm3, CHAPb Tg 4.598 mm3 ± 
0.3853 n=4, p< 0.01; fi gure 2E) although the volumes of the right atria were similar (wt 2.041 
mm3 ± 0.2431 n=4, CHAPb Tg 2.114 mm3 ± 0.03001 n=4, p=NS). Furthermore, despite the 
hypertrophy evident in individual cardiomyocytes of the left  ventricle, the overall ventricular 
wall volume was not diff erent in CHAPb Tg mice (wt 57.81 mm3 ± 6.352 n=4, CHAPb Tg 
51.31 mm3 ± 2.705 n=4, p=NS). 
By 6 months of age, left  atrial enlargement was consistently more pronounced in Tg mice 
and was associated with cardiomyocyte hypertrophy and interstitial fi brosis (Figure 2B, C). 
Occasionally, intraventricular thrombi were identifi ed (Figure 2D). In general, changes in 
CHAPb Tg hearts were more pronounced at 6 months of age, displaying features that resemble 
cardiomyopathy, including sudden death.  
Figure 2: HE and Sirius red staining of CHAP Tg hearts. Wt (left  panels) and CHAPb Tg (right panels) at 3 and 6 months 
of age (A-C). A) HE stained overview section. Th e left  atrium in CHAPb Tg hearts is enlarged (indicated by *) compared 
to wt litter mates. B) Higher magnifi cation of left  ventricle. In the left  ventricle of CHAPb Tg hearts the cardiomyocytes 
are hypertrophic. C) Sirius red staining of the left  ventricle showing increase in interstitial fi brosis in CHAPb Tg. D) 
CHAPb Tg heart with severe phenotype showing pronounced atrial enlargement, fi lled by a thrombus and thickening of 
the ventricles. E) Myocardial volume of the left  atrium (left  panels) and right atrium (right panels) in wt (white bars) and 
CHAPb Tg (black bars) hearts at 3 months of age. Scale bars 1 mm in A and D, 50 µm in B, C.
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Activation of hypertrophic gene program and collagens in CHAPb Tg hearts
A hallmark of hypertrophy is re-expression of fetal cardiac genes, such as atrial natriuretic 
factor (ANF, Nppa), brain natriuretic peptide (BNP, Nppb) and β-MHC (Myh7). To investigate 
if the hypertrophy induced by CHAPb in Tg mice was also accompanied with upregulation 
of these genes, we isolated RNA from left  ventricles of 6 month old wt (n=3) and CHAPb Tg 
(n=3) mice. qPCR analysis showed signifi cant upregulation of Nppa (17.2x, p<0.01, Figure 
3A), Nppb (3.6x, p<0.01, Figure 3B) and Myh7 (28.3x, p= 0.0634, Figure 3C) in Tg hearts. 
Activation of the same genes was also evident in the right ventricle (data not shown). Th ese 
fi ndings corroborate the hypertrophic response observed morphologically.
Fibrosis is characterized by increased collagen production. To confi rm Sirius red evidence, we 
analyzed the expression of Collagen I and III, the major fi brin forming collagen types, in the 
left  ventricles of wt and CHAPb Tg mice. Increased expression of Collagen I (3.2x, p=0.0506, 
Figure 3D) and III (3.7x, p=0.0404, Figure 3E) was indeed observed in CHAPb Tg animals, 
as expected. Moreover, mRNA expression of Serca2, which encodes a protein involved in 
Ca2+ cycling16 and is generally downregulated in cardiac hypertrophy, was also decreased 
in CHAPb Tg hearts (Figure 3F). Expression of hypertrophic genes and collagens was also 
increased in the right ventricle (data not shown).
Finally, we examined endogenous Chap isoforms in CHAPb Tg mice. ChapA mRNA 
expression was the same in wt and CHAPb Tg hearts (Figure 3G) and although endogenous 
ChapB appeared slightly increased, this was not statistically signifi cant (Figure 3I). Exogenous 
ChapB (Figure 3H) was, as expected, strongly upregulated in CHAPb Tg hearts compared to 
wt. 
Figure 3: Expression of hypertrophy markers and collagens in left  ventricle. qPCR analysis showing mRNA expression of 
Nppa (A), Nppb (B), Myh7 (C), CollagenI (D) CollagenIII (E), Serca2 (F), ChapA (G), ChapB (H) and endogenous ChapB 
(I) in the left  ventricle of wt (white bars) and CHAPb Tg (black bars) mice. GAPDH, PGK and H2A were used as internal 
controls.
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Expression of CHAPb in adult heart leads to loss of Connexin expression in the le  atria and 
conduction disturbances 
Since cardiomyopathies are associated with disturbed electrical conductance and cardiac 
arrhythmia, we investigated the most predominant Connexin (Cx) isoforms in atria and 
ventricles. Cx40 is the main isoform expressed in atria. Cx43 is expressed at higher levels 
in ventricles, although Cx43 it is also expressed at low levels in the atria17. At one month 
of age, there was no diff erence in Cx40 and Cx43 expression between wt and CHAPb Tg 
(supplemental fi gure 3A and B). At three months, however, enlargement of the left  atrium 
was accompanied by loss of expression of Cx’s: both Cx40- and Cx43 immunoreactivity was 
reduced in the left  atrium, although in the right atrium (supplemental fi gure 3C and D) and 
ventricles they were unchanged. Th is decrease in Cx40 and Cx43 levels in the left  atrium was 
more pronounced at 6 months (fi gure 4A). Th ese fi ndings were confi rmed by qPCR, which 
indeed showed that Cx40 (-23x, p<0.01, fi gure 4B) and 43 (-6.9x, p<0.01, supplemental fi gure 
3E) were both downregulated in the left  atrium. Similar to the protein data, mRNA expression 
of Cx40 and Cx43 in the right atrium was unchanged (Figure 4C and supplemental fi gure 
3F). Expression of Cx45, which is specifi cally expressed in the sinoatrial- and atrioventricular 
nodes and is co-expressed with other isoforms in the rest of the conduction system17, was 
unchanged in the left  atrium. 
Figure 4: Decreased Connexin 40 expression in CHAPb Tg left  atrium at 6 months of age. Immunohistochemical staining 
showing Connexin 40 (A) expression in wt (left  panels) and CHAPb Tg (right panels) left  (upper panels) and right (lower 
panels) atria. qPCR analysis of Connexin 40 (B and C) expression in the left  (B) and right (C) atrium. Scale bars 50 µm.
To investigate whether the loss of expression of Cx40 and 43 was correlated with conduction 
disturbances, we performed ECG measurements of wt and CHAPb Tg mice. Th ese 
measurements showed that the PR interval was increased in CHAPb Tg mice (wt 40,89 ms ± 
1,150 n=3, CHAPb Tg 49,83 ± 1,784 n=8, p<0.05; Figure 5A) indicating a conduction delay 
from atria to ventricles. No signs of atrial fi brillation were observed, as the duration of the 




CHAPb Tg mice show decreased cardiac performance
To determine whether the phenotypic changes in CHAPb Tg hearts aff ected cardiac 
performance, we performed MRI measurements on 5 male wt and 5 male CHAPb Tg mice 
at 6 months of age. Enlargement of the left  atrium was clearly visible in the scans.  We then 
calculated the functional parameters of the left  and right ventricle. Th e results of the left  
ventricle are shown in fi gure 6. Representative scans for wt and CHAPb Tg are shown in 
fi gure 6A. Both the end diastolic volume (wt 45.81 µl ± 2.297 n=4, CHAPb Tg 29.08 µl ± 
1.176 n=5, p<0.01; Figure 6B) and end systolic volume (wt 15.72 µl ± 2.570 n=4, CHAPb Tg 
7.474 µl ± 1.702 n=5, p<0.05; Figure 6C) were signifi cantly decreased in the left  ventricle, 
which resulted in the ejection fraction being similar in wt and CHAPb Tg mice (wt 66.26 % 
± 3.972 n=4, CHAPb Tg 74.35 % ± 5.376 n=5, p=ns; Figure 6D). However, the cardiac output 
was signifi cantly decreased in CHAPb Tg mice compared to wt (wt 1559 µl/min ± 32.20 n=4, 
CHAPb Tg 1083 µl/min ± 117.6 n=5, p<0.01; Figure 6E). Both the left  ventricular mass of 
end diastole (wt 77.79 mg ± 2.572 n=4, CHAPb Tg 58.11 mg ± 5.399 n=5, p<0.05; Figure 
6F) and end systole (wt 93.97 ± 1.784 n=4, CHAPb Tg 71.39 ± 5.127 n=5, p<0.01; Figure 
6G) were decreased in CHAPb Tg mice. Similar data were obtained for the right ventricle 
(supplemental fi gure 4). Overall, these data show that CHAPb expression impairs diastolic 
and systolic function in both the left  and right ventricle compared to wt mice.
CHAPb Tg mice display decreased force generating capacity of cardiac sarcomeres
To investigate the functional properties of cardiac sarcomeres, we measured force development 
at diff erent calcium concentration in membrane-permeabilzed single cardiomyocytes 
(Figure 6H) from wt and CHAPb Tg sarcomeres at 1 month of age. At the highest calcium 
concentration (30 μmol/L) force development was decreased in CHAPb Tg cardiomyocytes 
(wt 50.40 kN/m2 ± 4.911 n=12, CHAPb Tg 30.23 kN/m2 ± 4.346 n=11, p= 0,006; fi gure 6I). 
Furthermore, sarcomere Ca2+-sensitivity (pCa50, the calcium concentration at which half of 
the maximum force was generated) was also decreased in CHAPb Tg sarcomeres compared 
to wt (wt 5.53 ± 0.02 n=12, CHAPb Tg 5.45 ± 0.02 n=11, p= 0,0046; fi gure 6J). Th e reduction 
in both maximal force and pCa50 shows that the CHAPb sarcomeres have less force generating 
capacity compared to wt sarcomeres. Th e phosphorylation status of the sarcomeric proteins 
troponin I and T, myosin binding protein C and myosin light chain 2, remained unchanged 
Figure 5: Conduction disturbances in CHAPb Tg mice at 6 months of age. ECG analysis of wt and CHAPb Tg mice show-
ing PR interval (A) and P duration (B).
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(data not shown). Th ese results correlated with the lower cardiac output observed in CHAPb 
Tg mice compared to wt mice, where we found decreased diastolic function, indicating a 
stiff er heart. 
Figure 6: Functional analysis of CHAPb Tg hearts. A) Example images of wt and CHAPb Tg longitudinal sec-
tions. Enlarged LA in CHAPb Tg is indicated with *. B-G) MRI measurements of the left  ventricle of wt (white 
bars) and CHAPb Tg (black bars) animals at 6 months of age. ED volume (B), ES volume (C), ejection frac-
tion (D), cardiac output (E), LV mass ED (F) and LV mass ES (G). H) Experimental setup for single membrane-
permeabilized cardiomyocyte measurements to determine sarcomere function. Sarcomere force measurements 
at one month of age showed reductions in maximum force (I; Fmax) and Ca2+-sensitivity (J; pCa50) in CHAPb 
Tg (black bars) compared to wt (white bars) . ED (end diastolic), ES (end systolic) and LV (left  ventricular).
Sarcomeric organization is disturbed in CHAPb Tg hearts
Next we investigated the sarcomeric organization in cryosections of wt and CHAPb Tg 
hearts. Immunohistochemical staining for CHAP, α-actinin (Z-disc protein) and myomesin 
(M-band protein) showed that both CHAP and α-actinin were co-localized at the Z-disc of 
cardiomyocytes in wt hearts (Figure 7A), whereas CHAP did not overlap with myomesin 
(supplemental fi gure 5). In CHAPb Tg h earts, CHAP was also localized at the Z-disc 
with α-actinin (Figure 7A) and did not overlap with myomesin (supplemental fi gure 5). 
However, in the CHAPb Tg hearts, CHAP was also localized in fi bers, which appeared to be 
perpendicular to the sarcomeres and resembled the formation of stress fi bers. Th ese fi bers 
stained with α-actinin (Figure 7A), but not myomesin (supplemental fi gure 5). Th e formation 
of these stress fi bers was already visible at 1 month. To study this in more detail we performed 
Transmission Electron Microscopy on 6 months old wt and Tg hearts. In wt hearts the 
organization of the sarcomeres was regular with well-formed Z-discs and intercalated discs. In 
CHAPb Tg hearts the sarcomeres were clearly irregular and both Z-disc and intercalated discs 
were disorganized (Figure 7B). Th ese data indicate that in CHAPb Tg hearts the organization 
of the Z-discs and intercalated discs are disturbed.
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Figure 7: Sarcomeric organization is disturbed in CHAPb Tg hearts. Hearts stained for CHAP (green) / α-actinin (red; 
A), merge images are shown. CHAP is localized in the Z-disc of cardiomyocytes of wt (upper panels) hearts. In cardio-
myocytes of CHAPb Tg (lower panels) CHAP also stains stress fi bers (arrows), which co-stain for α-actinin. B) Electron 
microscopy analysis of wt and CHAPb Tg hearts at 6 months of age. In CHAPb Tg the sarcomeres were irregular and 
Z-discs and intercalated discs (arrow heads) are disorganized. Scale bars 20 µm in A, 5 μm in left  panels and right panels 
1 μm of B. 
Activation of the actin signalling pathway in CHAPb Tg hearts
Since synaptopodin, a CHAP family member, has been associated with actin signalling in 
other tissues such as brain and kidney and since the actin signalling pathway is also involved 
in cardiac hypertrophy, we investigated whether components of the actin signalling pathway 
were activated in CHAPb Tg hearts. Staining of GTPase RhoA, a key component of the actin 
signalling pathway, in hearts at 6 months of age showed sarcomeric expression pattern in wt 
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hearts, while in CHAPb Tg hearts RhoA expression was increased and, interestingly, was 
displaced from its sarcomeric localization in cardiomyocytes (Figure 8A). To further confi rm 
the CHAPb dependent activation of actin signalling, we examined downstream eff ectors. 
Indeed, phosphorylation of Ezrin/radixin/moesin (ERM), a family of proteins involved in 
Rho-dependent signalling and linking the actin cytoskeleton to the plasma membrane19, 20, 
was increased in CHAPb Tg hearts and co-localized with CHAP (supplemental fi gure 6) 
and RhoA. Increased protein expression levels of RhoA, actin, α-actinin, ERM, cofi lin, and 
downstream actin-dependent transcription factors serum response factor (SRF) and myocyte 
enhancer factor-2 (MEF2) in hearts of CHAPb Tg compared to wt (fi gure 8B) confi rmed 
these fi ndings. Th ese results suggested CHAPb dependent activation of the actin-signalling 
pathway, from membrane to the nucleus, which may contribute to the molecular, phenotypic 
and functional alterations observed in the transgenic mice.
Figure 8: Increased actin signaling in CHAPb Tg hearts. A) Wt (upper panels) and CHAPb Tg (lower panels) hearts at 
6 months of age stained for RhoA (red). In wt mice RhoA is localized at the membrane of cardiomyocytes and shows a 
sarcomeric expression pattern. In CHAPb Tg hearts sarcomeric expression of RhoA is decreased and membrane expres-
sion is increased. B) Western blot analysis of 2 wt and 3 CHAPb Tg hearts at 6 months of age for RhoA, α-actinin, actin, 
Ezrin(80 kDa)/moesin(80 kDa)/radixin (75 kDa; ERM), cofi lin, SRF (40 – 67kDa) and MEF2. GAPDH is used as loading 
control. C) Summarizing model: in wt mice CHAPa is localized at the Z-disc with α-actinin and there is no expression of 
CHAPb, leading to high G-actin expression resulting in low expression of SRF target genes. In CHAPb Tg mice CHAPb 
expression results in activation of RhoA, leading to a shift  from G-actin to F-actin, binding of co-factors to SRF and acti-
vation of SRF target genes, such as ANF, BNP and β-MHC. In addition signaling of CHAPb to SRF might also be directly 




Here we show for the fi rst time that the Z-disc protein CHAP can initiate cardiac disease. CHAP 
was initially identifi ed as a gene upregulated during the diff erentiation of  human embryonic 
stem cell-derived to cardiomyocytes 5. In mice and human two CHAP splice variants were 
identifi ed which diff er in their temporal expression patterns: the shorter isoform CHAPb is 
expressed during embryonic development in the heart, somites and muscle precursors, whilst 
CHAPa is expressed in the adult heart and skeletal muscle. Morpholino knockdown of Chap 
in zebrafi sh showed that it is essential for heart development. Furthermore, overexpression 
of “embryonic” CHAPb, but not “adult” CHAPa, in rat cardiomyocytes led to dissociation of 
α-actinin-2 from the Z-disc6. In agreement with these fi ndings, we found that overexpression 
of CHAPa in the adult mouse heart had no eff ect on cardiac morphology or function, whilst 
CHAPb Tg mice displayed features which are comparable to cardiomyopathy, such as cardiac 
hypertrophy, interstitial fi brosis, diastolic dysfunction, and disturbed electrical conductance, 
which led to higher mortality.
CHAPb induces cardiac hypertrophy, le  atrial enlargement and  brosis
CHAPb overexpression in transgenic hearts was apparent both in qPCR and Western blot 
analysis. Th is had no eff ect at one month of age but by 3 months, molecular and cellular 
hypertrophy without ventricular wall thickening, left  atrial enlargement and interstitial 
fi brosis were clearly evident. Th is was more pronounced at 6 months of age and by then was 
occasionally accompanied by wall thickening of the left  and right ventricles and septum. In 
agreement with increasing severity of the phenotype, CHAPb Tg mice died spontaneously 
from 6 months of age and onwards. Occasionally thrombi were found in the left  atria, 
which may have disturbed blood fl ow in the left  atrium and impaired ventricular fi lling. 
Reduced ventricular fi lling may eventually contribute to pulmonary venous congestion 
and development of pulmonary oedema. Although we did not observe pulmonary oedema 
overall (indicated by preserved lung weights) in CHAPb Tg mice, we cannot exclude that this 
occurred in individual mice.  Indeed, occasionally MRI, revealed white/grey areas in lungs of 
CHAPb Tg mice, suggesting fl uid retention.
Impaired structural and electrical organization at intercalated discs in CHAPb Tg hearts
In addition to the morphological and histological changes in CHAPb Tg heart, we also 
observed changes at the intercalated discs of cardiomyocytes. In particular, gap junction 
proteins Cx40 and Cx43 were clearly downregulated in the left  atrium of CHAPb Tg hearts, 
which was already visible at 3 months of age but more pronounced at 6 months. Since gap 
junctions are crucial for fast spreading of action potentials between cardiomyocytes, impaired 
expression of gap junctions would be expected to aff ect electrical guidance. Indeed, decreased 
connexins expression in the left  atrium correlated with conduction disturbances, evidenced 
by increased PR interval, the time required for conduction between atria and ventricles. Loss 
of expression of Cx40 and 43 has been associated previously with conduction disturbances in 
mice. In Cx40-/- mutant mice, various conduction disturbances have been reported, including 
increased PR interval21, 22. In Cx43+/- mice ventricular conduction was delayed23, although 
no change in atrial conduction was observed24. In other hypertrophy mouse models, down-
regulation of Cx’s in the atria also correlated with conduction disturbances25-27. 
Although decreased expression of connexins and impaired electrical guidance in CHAP 
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Tg mice was limited to the atria, detailed analysis of individual cardiomyocytes by 
electronmicroscopy showed that there was disorganization of Z-discs and intercalated discs 
throughout the whole heart. Sarcomeric disorganization would suggest impaired contractility 
and/or relaxation of cardiac muscle, aff ecting cardiac function.
CHAPb Tg mice display cardiac diastolic dysfunction
MRI measurements indicated that CHAPb Tg mice had normal left  ventricular ejection 
fraction. Similarly, in patients with heart failure, almost half (47%) still have a normal 
ejection fraction28. Ejection fraction is determined by diff erences in both end diastolic and 
end systolic volumes and if both parameters are changed, as occurs in CHAPb Tg mice, 
ejection fraction may be unaff ected. Th e decreased diastolic volumes observed in CHAPb Tg 
mice may suggest impaired relaxation during diastole (diastolic dysfunction), which relates 
to impaired Ca2+ cycling in cardiomyocytes. Contraction of cardiomyocytes is achieved by 
entry of Ca2+ through L-type channels, which causes Ca2+ release into the cytosol, immediately 
followed by Ca2+ release from the sarcoplasmic reticulum (SR). Subsequently, Ca2+ binds to 
sarcomeric protein troponin C to initiate contraction. On the other hand, relaxation occurs 
through uptake of the Ca2+ into the SR via SERCA2. In CHAPb Tg cardiomyocytes, re-
uptake of Ca2+ might be aff ected, due to reduced levels of SERCA216, 29. Indeed, we found that 
SERCA2 mRNA expression is reduced in the hearts of CHAPb Tg. In addition, measurements 
in membrane-permeabilized cardiomyocytes revealed reduced force generating capacity of 
CHAPb Tg sarcomeres, which may in part underlie the signifi cant reduction in cardiac output 
observed in CHAPb Tg compared to wt mice. In primary cardiomyopathy, alterations in Ca2+-
sensitivity have been reported, which may depend on the location of the mutation in aff ected 
genes. Perturbations in Ca2+-sensitivity of the sarcomeres  may result in development of HCM 
or DCM30.  As overexpression of CHAPb reduced Ca2+-sensitivity, it would be interesting to 
investigate the role of CHAP in primary cardiomyopathy cases.
Activated actin signalling in CHAPb Tg hearts
We found that expression of RhoA is increased in CHAPb Tg hearts. RhoA belongs to the family 
of the small GTPases. Its eff ects on the actin cytoskeleton are mediated through stimulation 
of Rho Kinase (ROCK)31. RhoA is expressed in the heart during embryonic development, 
is downregulated aft er birth and re-expressed in cardiac hypertrophy32. Furthermore, RhoA 
transgenic mice develop a phenotype that resembles dilated cardiomyopathy (DCM), 
which is accompanied with conduction disturbances33. Alternatively, inhibition of ROCK 
reduces pressure overload-induced hypertrophy in rats34. It has been previously shown that 
synaptopodin, which has signifi cant homology to CHAP, is involved in actin stress fi ber 
formation by preventing proteasomal degradation of RhoA10. Like synaptopodin, CHAPb 
might be involved in the stabilization of RhoA, which may lead to actin stress fi ber formation 
and induction of hypertrophy via the Rho-ROCK pathway.
CHAP is involved in the SRF/MEF-2 actin signalling pathway
We observed increased expression of transcription factors SRF and MEF-2 in CHAPb Tg 
hearts. Previously, it has been demonstrated that Striated muscle activator of Rho signaling 
(STARS), an actin-bundling protein that is localized at the Z-disc, is associated with both 
SRF and MEF-2 signalling. STARS is induced by MEF-2, which in turn regulates the 
formation of F-actin fi bers via RhoA, leading to depletion of the monomeric globular 
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actin (G-actin) pool. Consequently, a reduction of G-actin may lead to activation of SRF 
mediated transcription35-37. Previous studies in mice have indicated the relevance of SRF in 
the development of cardiomyopathy38, 39. In addition, the importance of SRF in cardiomyocyte 
function, maintenance and regulation was shown in experiments in which it was knocked-
down: expression of cytoskeletal genes, such as α- and β-MHC, cardiac α-actin and smooth 
muscle actin were decreased and also, interestingly, CHAP 40, 41. With respect to the MEF2 
transcription factor family (MEF-2a,c and d), Tg mice overexpressing these genes in the 
heart also showed cardiac hypertrophy and stress-dependent cardiac remodelling42-44. 
Th e phenotypes of the diff erent Tg models do not overlap completely with the phenotype 
observed here, suggesting that additional pathways may be involved in the CHAPb induced 
hypertrophy.  In summary, our study suggests a model in which increased levels of CHAPb 
may activate actin signalling leading to subsequent activation of cardiac transcription factors 
MEF2 and SRF, initiating a hypertrophic response and structural and functional changes in 
cardiomyocytes (fi gure 8C).
Conclusion
We show that overexpression of the “embryonic” isoform of CHAP, CHAPb, in mice causes 
cardiomyopathy with diastolic cardiac dysfunction and conduction disturbances, which 
is associated with sarcomere dysfunction and activation of actin signalling and of the 
downstream transcription factors MEF-2 and SRF. In contrast, overexpression of “adult” 
isoform CHAPb did not lead to cardiac phenotypical and fucntional changes. Recently, 
Kong45 et al demonstrated that apart from alterations in gene expression, changes in mRNA 
splicing of sarcomeric genes particularly are associated with heart failure. Th ese fi ndings and 
our study demonstrate the importance of correctly spliced sarcomeric genes and substantiates 
further investigation in developmentally (dys-) regulated alternative splicing of other cardiac 
genes.
Taken together our results identify CHAPb as a novel component in the pathology of 
cardiomyopathy and a potential new candidate gene for screening mutations in familial 
cardiomyopathies.
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Supplemental fi gure 1: Hearts of CHAPb Tg founders that died spontaneously. A) Southern blot analysis of genomic wild 
type and CHAPb Tg DNA showing intermediate copy number in line 14 and high copy number in line 29, compared to 
wild type copy numbers. Hearts of CHAPb founder line 29 (left  panels) and line 14 (right panels). B) Hearts showing en-
larged atria and malformed ventricles. C) HE stained overview section showing enlarged atria and thickened ventricles. 
D). Higher magnifi cation of the left  ventricle. Scale bars in B 1 mm, in C 50 µm.
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Supplemental fi gure 2: HE and Sirius red staining of CHAPb Tg hearts at one month of age. Wt (left  panels) and CHAPb 
Tg (right panels) at 1 month of age (A-C). A) HE stained overview section. B) Higher magnifi cation of left  ventricle. C) 
Sirius red staining of the left  ventricle. D and E) Volume of the left  atrium (D) and right atrium (E) in wt (white bars) and 
CHAPb Tg (black bars) hearts. Scale bars 1 mm in A, 50 µm in B, C.
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Supplemental fi gure 3: Expression of Connexin 40 and 43 at 1, 3 and 6 months. Immunohistochemical staining showing 
Connexin 40 (A and C) and 43 (B and D) expression in wt (left  panels) and CHAPb Tg (right panels) left  atria (A, B and 
upper panels of C and D) and right atria (lower panels of C and D) at one month (A and B) and 3 months of age (C and 
D) of age. qPCR analysis of Connexin 43 (E and F) expression in the left  (E) and right (F) atrium at 6 months of age. Scale 
bars 50 µm.
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Supplemental fi gure 4: Functional analysis of CHAPb Tg hearts. MRI measurements of the right ventricle of wt (white 
bars) and CHAPb Tg (black bars) animals at 6 months of age (A-F). ED volume (A), ES volume (B), ejection fraction (C) 
and cardiac output (D). ED (end diastolic), ES (end systolic) and LV (left  ventricular).
Supplemental Figure 5: Expression of m-band marker myomesin is not aff ected in CHAPb Tg hearts. Hearts stained for 
CHAP (green) / myomesin (red), merge images are shown. CHAP is localized in the z-disc of cardiomyocytes of wt (up-
per panels) hearts. In cardiomyocytes of CHAPb Tg (lower panels) CHAP also stained stress fi bers (arrows), which did 
not stain for myomesin. Scale bars: 20 µm.
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Supplemental fi gure 6: Ectopic pERM expression in CHAPb Tg hearts. Wt (upper panels) and CHAPb Tg (lower panels) 
hearts at 6 months of age stained for pERM (green) and alpha-actinin (red). Nuclei are stained blue, merge images are 
shown. Scale bars: 20 µm.
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Chapter 5
Abstract
In the previous chapter we have described that CHAPb transgenic mice displayed features 
of cardiomyopathy and cardiac dysfunction, whereas CHAPa transgenic mice did not 
display any abnormalities. In order to determine direct eff ects of both CHAP isoforms, we 
infected mouse cardiomyocytes (E17.5) and skeletal muscle cells myoblast cells (C2C12) with 
adenoviral constructs for CHAPa and CHAPb. 
In vitro overexpression of CHAPa resulted in Z-disc disruption, as shown by α-actinin-2 
staining in both C2C12 cells and cardiomyocytes. CHAPb overexpression in C2C12 and 
cardiomyocytes resulted in stress fi ber formation, which stained for F-actin. Although 
RhoA and phosphorylated Ezrin/Moesin/Radixin, proteins involved in linking the actin 
cytoskeleton to the plasma membrane, were ectopically expressed in cardiomyocytes, no 
activation of the actin signaling pathway was observed. Surprisingly, in both CHAPa and 
CHAPb infected cells downregulation of hypertrophy markers Nppa, Nppb and Myh7 was 
observed, whereas Myh6 was upregulated. In agreement with these fi ndings we observed that 
a key player in muscle hypertrophy and development, the transcription factor Nuclear Factor 
of Activated T-cells-c2 (NFATc2), was translocated from the nucleus to the cytoplasm. Th ese 
results show that CHAPa and CHAPb have an important role in maintaining the integrity of 
muscle cells. Furthermore, interestingly our fi ndings suggest that CHAPa and b isoforms may 
directly aff ect transcriptional regulation regarding maturation and/or blocking hypertrophy 
of cardiomyocytes.
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Introduction
Cardiac hypertrophy is a compensatory mechanism of the heart to increased workload as 
a result of loss of cardiomyocytes that occurs in pathophysiological events (for example 
myocardial infarction). During a hypertrophic response cardiomyocytes increase their cell 
volume to compensate for the loss of cardiomyocytes. Cardiomyocytes respond to stress by 
expressing a specifi c subset of fetal genes, such as Atrial Natriuretic Factor (ANF), Brain 
Natriuretic Peptide (BNP) and β-Myosin Heavy Chain (β-MHC), leading to the described 
hypertrophic response1-3. Th e basic contractile unit of cardiomyocytes is the sarcomere, which 
is delineated by the Z-disc4, which consists of a protein complex, including α-actinin-2 and 
CHAP. Z-disc proteins may sense stress signals, and activate signaling pathways leading to 
activation of the fetal gene program5, 6.In the previous chapters we have seen that CHAP is 
expressed in skeletal and heart muscle cells during embryonic development and in adulthood. 
Two isoforms of CHAP exists: CHAPa is the longest isoform and contains a PDZ domain 
and nuclear localization signal (NLS), whereas the shorter isoform CHAPb lacks the PDZ 
domain. Whereas CHAPa is predominantly expressed in adult tissues, CHAPb is expressed 
at higher levels in the developing heart and muscles7. CHAP is homologous to synaptopodin 
and myopodin, which have both been implicated in actin signaling. Myopodin is expressed 
in the Z-disc of cardiac and skeletal muscle and interacts with α-actinin-28. Synaptopodin 
interacts with α-actinin-2 and -411, and is  involved in actin signaling in kidney podocytes by 
the formation of actin stress fi bers via RhoA12. 
Besides localization at the Z-disc, Myopodin is also able to translocate to the nucleus, which 
is mediated by 14-3-39.It has been shown that interaction between 14-3-3 and Myopodin can 
be regulated by various kinases and phosphatases, such as Protein Kinase A (PKA), Ca2+/
calmodulin-dependent kinase II (CaMKII) and the phosphotase calcineurin, a key player in 
cardiac hypertrophy10. 
In the previous chapter, we described the phenotypes of heart-specifi c CHAPa- and b 
transgenic (Tg) mice. CHAPa Tg mice did not show a phenotype aft er one year of age or 
aft er myocardial infarction (Chapter 4 and data not shown), although misfolding or partially 
degradation could not be excluded. CHAPb Tg mice, on the other hand developed features 
of cardiomyopathy, including cardiac hypertrophy and diastolic dysfunction. Furthermore, 
stress fi bers were apparent in CHAPb Tg hearts which was associated with activation of the 
actin signaling pathway.
To study the direct eff ects of CHAP we induced expression for both isoforms by adenoviral 
transduction in skeletal muscle cells (C2C12) and embryonic 17.5 (E17.5) mouse 
cardiomyocytes. We found that CHAPa- and b both disrupted the Z-disc structure of 
cardiomyocytes and diff erentiated C2C12 cells. However, only CHAPb induced stress fi bers, 
similar to the stress fi bers found in CHAPb Tg hearts. In contrast to the CHAPb Tg hearts 
we did not observe a signifi cant upregulation of the actin signaling and reactivation of fetal 
cardiac genes, a hallmark of pathological cardiac hypertrophy. In fact, we observed an opposite 
eff ect on re-expression of fetal cardiac genes, which included a switch in expression of MHC 
isoforms and downregulation of ANF and BNP. Th ese changes were further accompanied by 
translocation of Nuclear Factor of Activated T-cells (NFAT), suggesting that direct eff ects of 
CHAP may be involved in further maturation of muscle cells or even have anti-hypertrophic 
eff ect on striated muscle cells.
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Materials and methods
Animals and cardiomyocyte isolation
Swiss mice were intercrossed for collection of embryos at embryonic day 17.5 (E17.5). Embryos 
were collected and rinsed in PBS. Hearts were removed and rinsed in PBS. Subsequently, 
hearts were rotated over night in 1x trypsin/EDTA (Sigma-Aldrich Chemie). Th e next day 
trypsin/EDTA was removed by transferring hearts over a 70 µm strainer (BD Biosciences). In 
a next step, cardiomyocytes were isolated by shaking the hearts in fractions of collagenase mix 
(0.5 ml 22% BSA (Sigma-Aldrich Chemie) and 15 μl Collagenase type 1A (36.9 u/µl; Sigma-
Aldrich Chemie) in 30 ml 0.9% NaCl for 3 minutes at 37 oC. Aft er each fraction, hearts were 
put over a new 70 µm strainer (BD Biosciences) and fi ltered. Each fraction was collected in 2 
ml fetal calf serum (FCS, Sigma-Aldrich Chemie), followed by rinsing the strainer with 5 ml 
cardiomyocyte medium (Dulbecco’s Modifi ed Eagle Medium F12 [DMEM F12, Invitrogen], 
15% FCS and pen/strep [Invitrogen]). Th e remainder of the hearts was put in a new fraction 
with collagenase mix and the procedure was applied until all hearts were dissolved. All 
fractions were collected, cells were spun down, resuspended in new cardiomyocyte medium 
and fi nally cells were counted and plated on gelatin-coated dishes. Th e amount of cells plated 
was 75,000 per 24-well and 380,000 per 6-well. Th e next day medium was refreshed with 
cardiomyocyte medium without FCS. 
Cell culture
First-generation human adenovirus type 5 (HAdV5) vectors were produced in PER.tTA.
Cre76 cells13. Th ese HAdV5 early region 1 (E1)-transformed human embryonic retinoblasts 
were maintained in DMEM (Invitrogen) containing 10% fetal bovine serum (FBS; Invitrogen) 
and 10 mM MgCl2 and cultured at 37°C in a humidifi ed atmosphere of 90% air and 10% CO2. 
Endpoint titrations of HAdV5 vector preparations were carried out in HeLa cells, which were 
fed DMEM containing 5% FCS (Sigma Aldrich). C2C12 cells were cultured in DMEM with 
10% FCS and pen/strep added. For diff erentiation of C2C12 cells, cells were incubated with 
DMEM with 2% horse serum (Invitrogen) and pen/strep added. Medium was refreshed every 
other day.
Th e latter cell types were cultured at 37°C in a humidifi ed atmosphere of 95% air and 5% CO2.
Generation of  rst-generation HAdV5 vectors encoding murine CHAP  isoforms a and b.
Th e codinq sequences of murine CHAPa and CHAPb were amplifi ed by 
Platinum Taq DNA Polymerase High fi delity (Invitrogen) polymerase chain 
reaction from cDNA templates that were generated earlier7 using the forward 
primers 5’-GCGGCCGCCCACCATGGGTGCTGAGGAGGAGGT-3’ and 
5’-GCGGCCGCCCACCATGGAGACCACCATCCAAGA-3’, respectively, together with 
a single reverse primer (5’-GTCGACACTGGTGCCCTGCCCC-3’), the stopcodon was 
included in a c-terminal fl ag-tag. Th e amplifi cation products were subcloned into pCRII 
(Invitrogen) and subjected to nucleotide sequence analysis. Th e pShuttle-IRES-hrGFP-1 
vector was used for generating adenoviruses of CHAPa (AdCHAPa) and CHAPb (AdCHAPb). 
Th is vector contains a CMV promoter, a multiple cloning site which is followed by internal 
ribosome entry site (IRES), which directs the translation of human recombinant Green 
Fluorescent Protein (hrGFP) as a second open reading frame. Errorless coding sequences 
of murine CHAPa and CHAPb were transferred to pShuttle-IRES-hrGFP-1 (Agilent 
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Technologies) using NotI and SalI to produce pShuttle-mCHAPa-IRES-hrGFP-1 and 
pShuttle-mCHAPb-IRES-hrGFP-1, respectively. Th ese two HAdV5 shuttle constructs were 
linearized with PmeI and used in combination with pAdEasy-1 DNA for the generation by 
in vivo recombineering14 of plasmids pAdEasy-1-mCHAPa-IRES-hrGFP-1 and pAdEasy-1-
mCHAPb-IRES-hrGFP-1 carrying full-length HAdV5 vector genomes. Following treatment 
with PacI to release the HAdV5 vector termini, pAdEasy-1-mCHAPa-IRES-hrGFP-1 and 
pAdEasy-1-mCHAPb-IRES-hrGFP-1 DNA was individually transfected with the aid of 
linear 25-kDa polyethyleneimine (Polysciences) into PER.tTA.Cre76 cells13 to produce seed 
stocks of AdEasy-1-mCHAPa-IRES-hrGFP-1 and AdEasy-1-mCHAPb-IRES-hrGFP-1, 
respectively. Th ese seed stocks were used for large-scale production of both HAdV5 vectors 
in PER.tTA.Cre76 cells essentially as described by Gonçalves et al.13. Th e functional titers 
of the resulting AdEasy-1-mCHAPa-IRES-hrGFP-1 and AdEasy-1-mCHAPb-IRES-hrGFP-1 
vector preparations were determined by limiting dilution assays in HeLa cells using fl ow 
cytometric analysis of hrGFP-1 expression as readout and were expressed in terms of HeLa 
cell-transducing units (HTU)/ml. An adenovirus expressing GFP only was used as control 
and is described in Knaän-Shanzer et al15.
Infection of cells
Cells were infected with multiplicity of infection (MOI) of 10. Aft er 6-12 hours medium was 
refreshed. Th en cells were left  for 24 hours, 48 hours or 7 days.
Immuno uorescence 
Cells were grown on gelatin coated coverslips. Cells were washed with PBS and fi xed 
for 30 minutes in 2% PFA at room temperature, followed by 3 washes in PBS. Cells were 
permeabilized with 0.1% Triton-x-100 in PBS for 8 minutes. Cells were washed 3 times with 
PBS and blocked for 1 hour in 4% normal goat serum (Vector labs) in PBS. First antibody was 
applied over night at 4 oC in PBS/normal goat serum. Antibodies used were anti-CHAP (1:50), 
anti-α-actinin (1:800, Sigma-Aldrich Chemie), myomesin (1:50, kind gift  from E. Ehler), anti-
RhoA (1:100, Santa Cruz), anti-phosphorylated Ezrin/Moesin/Radixin (1:50, Cell Signaling 
Technology) or anti-NFATc2 (1:50, G1 D10, Santa Cruz). Th e next day cells were washed 3 
times with PBS/0.05% Tween-20 (PBS-T) for 10 minutes. Secondary antibodies were dissolved 
in 4% normal goat serum/PBS. Antibodies used were Alexa Fluor® 647 donkey anti-rabbit 
IgG (1:100, Invitrogen), goat anti-mouse/IgG(H+L)/Cy3 (1:250, Jackson Immuno research). 
Cells were 3 times washed in PBS-T for 20 minutes, and then 1 time in PBS. F-actin fi bers 
were stained using Alexa555 conjugated phalloidin (1:100, Invitrogen). Cells were counter 
stained with DAPI for 8 minutes. Coverslips were enclosed with Molviol. Immunofl uorescent 
stainings were analyzed with SP5 confocal microscope (Leica).
Protein isolation and western blot
For protein isolation cells were grown on 6 well plates. Cells were infected and 24 hours, 48 
hours or 7 days later protein was isolated (see previous section). For this cells were washed 
twice with PBS. Th en 250 μl ice-cold RIPA buff er (50 mM Tris-HCl pH8, 150 mM NaCl, 
1% NP-40 (Sigma-Aldrich Chemie), 0.2% sodium deoxycholate and 0.1% SDS) with extra 
added protein inhibitors (protease inhibitor cocktail tablets (10 µg/ml; Roche, Germany), 
0.1 mmol/L dithiothreitol (DTT; Invitrogen) and 1 mmol/L phenylmethanesulfonylfl uoride 
(PMSF; Sigma Aldrich), 5 mmol/L NaF and 1 mmol/L Na3VO4) was added to the cells, which 
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were then left  on ice for 15 minutes. Th en cells were scraped on ice and transferred to an 
eppendorf tube. Lysed cells were spun down (10000 g, 4 oC, 15 minutes) and supernatant 
was transferred to a new tube. Protein concentration was measured with the Bradford assay 
(Bio-rad) using bovine serum albumin (BSA) for a standard curve. Th en 5x sample buff er 
(100 mM Tris-HCl pH 6.8, 10% SDS, 50% glycerol, 25% β-mercaptoethanol and bromphenol 
blue) was added and samples were boiled for 5 minutes at 95 oC. Protein gels were loaded with 
30 μg protein. Gels were blotted (Hybond-P, GE healthcare) for 3 hours at room temperature 
and blocked for one hour with 5% milk/Tris Buff ered Saline-tween (TBS-T: 50mM Tris-HCl 
pH 7.5, 125 mM NaCl, 0.02% Tween-20). First antibody diluted in 5% milk/TBS-T (unless 
stated else) was applied over night at 4 oC. Antibodies used were anti-RhoA (1:200, Santa 
Cruz), anti-actin (1:1000, Millipor), anti-α-actinin (1:1000, Sigma-Aldrich Chemie), anti-
Ezrin/moesin/radixin (1:1000 in 5% BSA/TBS-T, Cell Signaling Technology), anti-Flag 
(1:5000, Sigma-Aldrich Chemie) and anti-GAPDH (1:10000, Millipor). Secondary antibody 
was applied for 1 hour at room temperature. Secondary antibodies used were anti-mouse 
IgG HRP (1:1000, Cell Signaling Technology) or anti-rabbit IgG HRP (1:2000, Cell Signaling 
Technology) dissolved in 5% milk/TBS-T. Blots were visualized by using SuperSignal West 
Pico Chemiluminescent Substrate (Pierce).
RNA isolation and cDNA synthesis
Infected cells were grown in 6 well plates, washed twice with PBS and dissolved in Trizol 
(Invitrogen). Th en RNA was isolated according to the manufactures protocol. RNA was 
treated with DNase (DNA-free, Ambion) and subsequently translated in cDNA (iScript, 
BioRad). qPCR analysis was done using the CFX96 Real-Time PCR detection system (Bio-
Rad). Primers used are listed in table in the Material and Method section of chapter 4, except 
for Myh6: 5’- CTTCATCCATGGCCAATTCT-3’ and 5’- GCGCATTGAGTTCAAGAAGA-3’.




Generation of adenoviral CHAP constructs
To study the eff ects of overexpression of CHAPa- and b in vitro, we generated adenoviruses 
encoding fl ag-tagged CHAPa or –b cDNA (AdCHAPa and AdCHAPb, with additional IRES-
GFP expression). An adenovirus expressing GFP (AdGFP) only was used as control. We fi rst 
investigated the expression of the CHAP adenoviruses in mouse E17.5 cardiomyocytes. For 
this, cells were infected with AdGFP, AdCHAPa, AdCHAPb and non-infected cells were 
used as control. Aft er 2 days RNA and protein samples were obtained and expression levels 
were analyzed with qPCR and western blot. We found a robust overexpression by qPCR for 
both ChapA (Figure 1A) and ChapB (Figure 1B) when compared to control virus and the 
non-infected endogenous CHAP isoforms. Also at the protein level the products of CHAPa 
and CHAPb could be detected with a fl ag antibody (Figure 1C), whereas no bands could be 
detected in the control samples. Th ese results show a specifi c, robust and stable overexpression 
of both CHAPa and CHAPb isoforms.
Figure 1: Generation of AdCHAPa and AdCHAPb viruses. Mouse cardiomyocytes were infected with AdCHAPa or Ad-
CHAPb. A+B) Expression of ChapA (A) or ChapB (B) was analyzed by qPCR, Gapdh, H2A and Pgk were used as internal 
controls. C) Western blot stained with fl ag antibody shows overexpression of CHAPa and CHAPb at the protein level.
Overexpression of CHAP a ects Z-disc organization in both skeletal muscle cells and 
cardiomyocytes
Next, we studied the role of CHAP in skeletal and heart muscle cells in vitro. In chapter 3 
we have seen that CHAP is expressed in developing and adult skeletal muscle cells of mouse 
and chick embryos (see chapter 3). To investigate the role of CHAPa and CHAPb in skeletal 
muscle diff erentiation we used a mouse myoblast cell line, C2C12, which can be diff erentiated 
to skeletal muscle cells by culturing cells in media containing 2% horse serum. Th is results in 
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the formation of multinucleated twitching myotubes in which striations can be detected by 
α-actinin-2 staining. C2C12 cells were infected with AdGFP, AdCHAPa or AdCHAPb, aft er 
the infection medium was replaced for diff erentiation medium and cells were diff erentiated 
for 6 days. Th en cells were stained for CHAP and α-actinin-2. Th e control AdGFP-infected 
cells formed multinucleated myotubes and striations could be detected in these myotubes with 
α-actinin-2 staining (Figure 2, upper panels, arrows). However, formation of multinucleated 
myotubes was disrupted in both AdCHAPa and AdCHAPb infected cells (Figure 2, middle 
and lower panels). Whereas in AdCHAPa infected cells only the sarcomere structure was 
disrupted (arrows in middle panel, Figure 2), in AdCHAPb cells additional stress fi bers were 
formed (arrows in lower panel, Figure 2). In undiff erentiated C2C12 cells overexpression of 
CHAPb also induced stress fi bers (data not shown). 
Figure 2: Overexpression of CHAPa and CHAPb aff ects skeletal muscle diff erentiation. C2C12 cells were infected with 
AdGFP, AdCHAPa or AdCHAPb, diff erentiated and stained for α-actinin-2 (red) and CHAP (cyan). Infected cells can 
be identifi ed by GFP signal (green), nuclei are stained gray, merge images are shown. In AdGFP infected cells (upper 
panels) multinucleated myotubes were formed, in which striations could be detected by α-actinin-2 staining (arrows). 
In AdCHAPa infected cells no multinucleated myotubes were formed and Z-disc was disrupted, which was shown by 
α-actinin-2 staining (middle panels, arrows). In AdCHAPb infected cells no myotubes were formed, instead, stress fi bers 
were formed, that stained for α-actinin-2 and CHAP (lower panel, arrow).
Next, we investigated overexpression of AdCHAPa and AdCHAPb in E17.5 cardiomyocytes. 
In CHAPb Tg mice overexpression of CHAPb induces stress fi bers, which co-stained for 
α-actinin-2 and not for myomesin. In AdGFP infected cells CHAP co-localized in the Z-disc 
with α-actinin-2 (Figure 3A, upper panels) and not with myomesin (Figure 3B, upper panels), 
which is in agreement with our previous fi ndings7. Infection of E17.5 cardiomyocytes with 
AdCHAPa resulted in disruption of Z-disc structure, which was apparent by both CHAP 
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Figure 3: Overexpression of CHAPa and CHAPb results in distinct phenotypes in E17.5 mouse cardiomyocytes. Mouse 
cardiomyocytes were infected with AdGFP, AdCHAPa or AdCHAPb and stained for α-actinin-2 (red)/CHAP (cyan, A) or 
Myomesin (red)/CHAP (cyan, B). Infected cells can be identifi ed by GFP signal (green), nuclei are stained gray, merge 
images are shown. In AdGFP infected cardiomyocytes CHAP localizes at the Z-disc with α-actinin (A, upper panels) and 
not with myomesin (B, upper panels). In AdCHAPa infected cardiomyocytes the Z-disc is disrupted (A, middle panels, 
α-actinin), while the m-band is not aff ected (B, middle panels, myomesin). In AdCHAPb infected cells stress fi bers are 
formed that stain for α-actinin-2 (A, lower panels), while myomesin is not aff ected (B, lower panels).
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and α-actinin-2 staining (Figure 3A, middle panels). Occasionally, infection of AdCHAPa in 
E17.5 mouse cardiomyocytes resulted in nuclear localization of CHAP (Figure 3A, middle 
panel, arrows). Infection of E17.5 cardiomyocytes with AdCHAPb resulted in the formation 
of stress, which stained for CHAP and α-actinin-2 (Figure 3A, lower panels). Staining for 
myomesin showed that in both AdCHAPa and AdCHAPb infected cells the M-band structure 
was not aff ected (Figure 3B, middle and lower panels). Th us formation of stress fi bers in 
AdCHAPb infected cells led to a subsequent loss of Z-disc integrity, whereas the M-band 
was unaff ected. In summary, both CHAP isoforms led to sarcomeric disruption, whereas 
formation of stress fi bers was only evident in AdCHAPb infected cardiomyocytes.
CHAP does not directly a ect actin signaling in is not a ected in muscle cells 
To investigate if the fi bers in cells with CHAPb were F-actin fi bers, we stained the cells for 
F-actin (phalloidin) and co-stained for α-actinin-2. In AdGFP infected E17.5 cardiomyocytes 
phalloidin had a sarcomeric staining pattern (Figure 4, upper panel, arrows). In AdCHAPa 
infected cells a disrupted pattern for F-actin was observed (Figure 4, middle panel, arrows) 
and in AdCHAPb infected cells phalloidin indeed stained the fi bers, which co-stained for 
α-actinin-2. Th ese results show that CHAPb induces actin stress fi bers.
Figure 4: CHAPb, but not CHAPa, overexpression induces F-actin fi bers. Mouse cardiomyocytes were infected with 
AdGFP, AdCHAPa or AdCHAPb and stained for phalloidin (F-actin, red)/CHAP (cyan). Infected cells can be identifi ed 
by GFP signal (green), nuclei are stained blue, merge images are shown. In AdGFP infected cardiomyocytes (upper pan-
els) phalloidin has a sarcomeric staining pattern.  In AdCHAPa infected cardiomyocytes (middle panels) the sarcomeric 
phalloidin staining is disrupted, while in AdCHAPb infected cardiomyocytes (lower panels) phalloidin stains the fi bers.
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Figure 5: Actin signaling in AdCHAPb infected cells. Mouse cardiomyocytes were infected with AdGFP or AdCHAPb and 
stained for CHAP (cyan)/ RhoA (red, A) or pERM (cyan)/myomesin (red, B). A) Infected cells can be identifi ed by GFP 
signal (green), nuclei are stained blue, merge images are shown.  In AdGFP infected cardiomyocytes RhoA has a sarco-
meric staining pattern (upper panels, arrows), while in AdCHAPb infected cardiomyocytes RhoA sarcomeric expression 
pattern is lost (lower panels). B) In AdGFP infected cardiomyocytes pERM expression is diff use (upper panels), whereas 
in AdCHAPb infected cells pERM localizes at the cell membrane (lower panel, arrows). C) Western blot showing expres-
sion of actin, RhoA, pERM, ERM, p-cofi lin, cofi lin, SRF and MEF2 in mouse cardiomyocytes aft er infection with AdGFP 
(n=3), AdCHAPa (n=3) or AdCHAPb (n=3). GAPDH was used as loading control.
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Since we previously observed activation of actin-dependent signaling in CHAPb Tg mice 
(Chapter 4), indicated by upregulated levels of RhoA, actin, α-actinin-2, Ezrin/Moesin/
Radixin (ERM), and SRF) at 6 months of age, we investigated whether cellular changes seen 
in AdCHAPa- or b infected cells were also mediated trough the actin signaling pathway. 
In AdGFP infected E17.5 cardiomyocytes RhoA was expressed at high levels in the nucleus in 
a dotted pattern combined with a sarcomeric expression (Figure 5A, upper panels, arrows). 
In AdCHAPb infected cells the sarcomeric expression of RhoA was lost, whereas the nuclear 
expression was not aff ected (Figure 5A, lower panels).  Expression of pERM in AdGFP infected 
cells was diff use (Figure 5B, upper panels), whereas expression in AdCHAPb infected cells 
pERM was expressed at the membrane of the cells (Figure 5B, lower panels, arrows). Next, we 
investigated the protein expression levels of other components of the actin signaling pathway, 
actin, RhoA, pERM, ERM, p-cofi lin, cofi lin, Serum Response Factor (SRF) and Myocyte 
Enhancer Factor 2 (MEF2) in AdGFP, AdCHAPa and AdCHAPb infected cells. No diff erence 
in expression levels were found between the diff erent conditions (Figure 5C). Although, in 
one experiment, we observed a slight upregulation in p-cofi lin in AdCHAPa infected cells 
and pERM and SRF in AdCHAPb infected cells, these results could not be repeated in other 
experiments using a diff erent batch of cardiomyocytes. Furthermore, shorter exposure (24 
hours) and analysis at a later time point aft er infection (7 days) did not display any diff erences 
between the various conditions (data not shown). Th ese results show that the actin signaling 
pathway is not directly activated.  Although, expression patterns for both RhoA and pERM 
were aff ected in AdCHAPb infected cells, compared to the AdGFP control cells, the expression 
levels of the actin signaling pathway are not aff ected.
CHAP causes downregulation of hypertrophic markers and translocation of NFAT
In the previous chapter we have seen that CHAPb Tg mice displayed cardiac hypertrophy 
which was combined with activation of genetic markers of cardiac hypertrophy. In order to 
study whether CHAP isoforms have a direct eff ect on the activation of hypertrophic markers 
we studied hypertrophic markers following adenoviral overexpression. Surprisingly, we 
observed a clear downregulation of hypertrophy markers. Both ANF (Figure 6A, Nppa) and 
BNP (Figure 6B, Nppb) were downregulated to the same extent in AdCHAPa and AdCHAPb 
cells when compared to AdGFP cells. β-MHC (Figure 6D, Myh7) displayed a stronger 
downregulation in AdCHAPa than in AdCHAPb infected cardiomyocytes. Moreover, α-MHC 
gene expression (Figure 6C, Myh6), which is usually downregulated in cardiac hypertrophy, 
was increased in AdCHAPa and AdCHAPb infected cells. In addition we also investigated the 
expression levels of SERCA2A, endogenous ChapB, Connexin40, 43 and CollagenI and III, 
but no diff erences were detected (data not shown).
Th e calcineurin-Nuclear Factor of Activated T-cells (NFAT) pathway has been described 
in many studies as a crucial pathway in the onset and progression of cardiac hypertrophy. 
Th erefore, we investigated the expression of NFAT2c isoform in infected E17.5 cardiomyocytes. 
Whereas in AdGFP infected cells NFAT2c was localized in the nucleus (Figure 7, upper 
panels, arrows), in AdCHAPa and AdCHAPb infected cells NFAT2c was translocated to the 
cytoplasm, suggesting that overexpression of CHAP is able to inhibited calcineurin-NFAT 
dependent pathway (Figure 7, middle and lower panels, arrow heads).
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Figure 6: qPCR analysis of hypertrophy markers. Mouse cardiomyocytes were infected with AdGFP (dark grey bars), 
AdCHAPa (light grey bars) or AdCHAPb (white bars) and expression of Nppa (A), Nppb (B), Myh6 (C) or Myh7 (D) was 
analyzed. Gapdh, Pgk and H2A were used as internal controls.
Figure 7: NFATc2 localization is aff ected by CHAPa and CHAPb. Mouse cardiomyocytes were infected with AdGFP, Ad-
CHAPa or AdCHAPb and stained for NFATc2 (cyan)/CHAP (red). Infected cells can be identifi ed by GFP signal (green), 
nuclei are stained gray, merge images are shown. In AdGFP infected cells NFATc2 is localized in the nucleus (arrows). 
In AdCHAPa and AdCHAPb infected cells a cytoplasmic localization for NFATc2 is observed (arrow heads). In some 
AdCHAPa infected cells both CHAP and NFATc2 were localized in the nucleus and co-staining of these proteins was 
observed (middle panels).
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Discussion 
Previously we generated transgenic (Tg) mice that overexpress one of both isoforms of CHAP 
specifi cally in the heart. Whereas the CHAPa Tg mice did not develop a phenotype, CHAPb 
Tg mice developed features of cardiomyopathy, which includes cardiac hypertrophy with 
diastolic dysfunction. Furthermore, regionalized suppression of connexin 40, formation of 
stress fi bers, increased collagen production and activation of the actin signaling pathway were 
observed. In order to understand the direct eff ects of CHAP we have analyzed the in vitro 
function of CHAPa and CHAPb by overexpressing these proteins in mouse cardiomyocytes 
and skeletal muscle cells (C2C12). To study the eff ects of CHAP overexpression we developed 
CHAPa and CHAPb adenoviruses.
CHAPa regulates Z-disc integrity
We have shown in a previous study that CHAPa is co-localized with actin and localizes to 
the Z-disc as shown by overexpression in rat neonatal cardiomyocytes, suggesting a putative 
interaction of CHAPa with α-actinin-2, a Z-disc marker7. Besides that CHAPa is expressed in 
adult heart and skeletal muscle (see chapter 2). Th erefore, we expect CHAPa to be essential for 
adult cardiac and skeletal muscle function. Here we generated CHAPa adenovirus to investigate 
the function of CHAPa in vitro. Infection of mouse cardiomyocytes with AdCHAPa resulted 
in a robust overexpression. Overexpression of CHAPa in E17.5 cardiomyocytes, as wells as 
skeletal muscle cells (C2C12) resulted in Z-disc disruption. Both, CHAPa and α-actinin-2 
were ectopically expressed, while myomesin, a m-band marker, is not aff ected. Several 
mouse models have shown that disruption of the Z-disc results in development of dilated 
cardiomyopathy (DCM). Cypher (Oracle/ZASP) is a PDZ-LIM protein that is expressed in 
the heart16, 17 and interacts with α-actinin-2 at the Z-disc17. Disruption of Cypher expression 
leads to the development to DCM in humans, mice and zebrafi sh18-22. Enigma homologue 
protein (ENH) is another PDZ-LIM protein which interacts with α-actinin-2, Cypher and 
calsarcin-123, and disruption of its expression results in loss of Cypher and calsarcin-1 
expression, which leads to development of a DCM phenotype24. Cypher and ENH interact 
with Z-disc protein α-actinin-2 through their PDZ-domains17, 23. Given the fact that CHAPa 
localizes at the Z-disc and bares a PDZ-domain as well, makes it tempting to speculate that the 
PDZ-domain in CHAPa is responsible for interaction with α-actinin-2. However, CHAPb, the 
isoform lacking the PDZ-domain, can interact with α-actinin-2 as well7, therefore it would also 
possible that the PDZ-domain in CHAPa is not responsible for interaction with α-actinin-2, 
but interacts with a diff erent subset of cytoskeletal proteins. Th erefore, it would be of interest 
to investigate interaction partners of the CHAPa PDZ-domain by immunoprecipitation 
experiments. In addition, investigating the function of CHAPa in the cypher/ENH complex 
would be possible by deleting it conditionally from the heart. 
CHAPb induces actin stress  bers
Activation of RhoA promotes both the inhibition of actin depolymerization via the Rho-
associated kinase (ROCK)-LIM-kinase-cofi lin pathway and the polymerization of actin via 
profi lin, leading to a shift  from G-actin to F-actin25, 26. Synaptopodin and myopodin are 
involved in actin bundling via α-actinin 8, 11and RhoA12.  Myocardin-related transcription 
factors (MRTFs) are inhibited by G-actin and depletion of the G-actin pool leads to nuclear 
localization of the MRTFs. In the nucleus they can act as transcriptional cofactors for SRF26. 
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Striated muscle activator of Rho Signaling (STARS) is a novel muscle specifi c activator of 
RhoA and regulates thereby the activity of SRF in muscle cells27, 28. Th e transcription of STARS 
in turn is regulated by MEF229. Cardiac-specifi c overexpression of MEF2A and MEF2C results 
in development of DCM30, whereas knockout models of MEF2A and MEF2D have shown 
that these factors are involved in the expression of genes regulating contractility and energy 
metabolism and genes involved in stress-dependent remodeling of the heart, respectively31, 32. 
We have shown the formation of stress fi bers by staining for α-actinin-2 by CHAPb in vivo 
(chapter 4). In CHAPb Tg mice the formation of stress fi bers was correlated with the induction 
of actin signaling, demonstrated by the increased expression of RhoA, actin, ERM, cofi lin, SRF 
and MEF2. Furthermore, in hearts of CHAPb Tg mice we showed etopic expression of pERM 
and RhoA. Here we show, that overexpression of CHAPb in vitro, in E17.5 cardiomyocytes as 
well as skeletal muscle cells, results in similar F-actin. Although we obtained similar results for 
RhoA and pERM localization, there is no increased expression of the actin signaling pathway. 
Th is could imply that the induction of actin signaling is a secondary eff ect in CHAPb Tg 
mice. Another explanation could be that members of the actin signaling pathway are already 
high expressed in embryonic cardiomyocytes. RhoA, for example, is high expressed during 
development and down regulated in adult heart33. Furthermore, the F-actin to G-actin balance 
might diff er between embryonic and adult cardiomyocytes. In addition it maybe possible that 
stress fi ber formation in this model is regulated via a diff erent mechanism, for example via 
calcineurin-NFAT signaling (see next section).
Role of CHAPa and CHAPb in cardiomyocyte hypertrophy and the calcineurin-NFAT signaling 
pathway
Th e calcineurin-NFAT signaling pathway is an essential pathway in the development of 
hypertrophy. In this pathway the phosphatase calcineurin dephosphorylates NFAT, which 
leads to its nuclear localization and induction of hypertrophy marker genes like ANF, BNP and 
β-MHC3. Transgenic mice expressing a constitutively active form of the calcineurin catalytic 
subunit in the heart developed hypertrophy34, which was mediated by NFATc2 and NFATc335, 
36. Th e nuclear localization of myopodin is regulated by calcineurin as well; phosphorylation 
dependent binding of 14-3-3 protein to myopodin and subsequent nuclear localization is 
regulated by PKA and CaMKII, which phosphorylate myopodin and calcineurin, involved 
in dephosphorylating myopodin10. Furthermore, the stability of synaptopodin and its actin-
bundling activity is regulated through a similar mechanism in kidney podocytes, in this way 
linking actin dynamics and calcineurin signaling37. It would be of interest to investigate if 
CHAP stability can be regulated via similar phosphorylation processes. Overexpression of 
CHAPa or CHAPb in E17.5 cardiomyocytes resulted in translocation of NFATc2 from the 
nucleus to the cytoplasm. In line with this, the expression levels of the hypertrophy markers 
were decreased aft er overexpression of CHAPa or CHAPb. Interestingly, whereas β-MHC was 
decreased, α-MHC expression on the other hand was increased. Changes in the ratio of both 
MHC proteins is not only indicative for cardiac hypertrophy, but as well for the maturation 
phase of cardiac cells, with high levels of α-MHC and low levels of β-MHC. Th erefore, decrease 
in the above mentioned markers may indicate that CHAP either has an anti-hypertrophic 
activity or a maturation-promoting eff ect in striated muscle cells. However, these results are 
in contrast to the observed increase of hypertrophy markers in CHAPb Tg mice (chapter 
4), which might indicate an indirect upregulation of these markers in the CHAPb Tg mice. 
Furthermore, we have to take into account that the cardiomyocytes used for these experiments 
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are fetal and will have a fetal expression pattern of genes. Th erefore, expression of ANF, BNP 
and β-MHC is expected to be high, whereas α-MHC expression is low. In the adult CHAPb 
Tg mice however, expression of these markers are low and increase with age. Th erefore, the 
decrease of these factors in AdCHAPa and AdCHAPb infected cardiomyocytes might refl ect a 
morphological change, partially to a more mature or adult phenotype. To investigate the eff ect 
of CHAPa and CHAPb on gene expression the use of reporter genes would be an alternative. 
Conclusion
Here we show that by in vitro overexpressing of CHAPa and CHAPb these two proteins have 
distinct functions. Whereas CHAPa is involved in Z-disc integrity, CHAPb induces F-actin 
fi bers. It would be interesting to investigate the roles of CHAPa and CHAPb in vivo by 
conditionally deleting one of both isoforms. For example, we generated fl oxed CHAPf/+ mouse 
embryonic stem cells (chapter 3) and mouse lines generated from this line can be intercrossed 
with specifi c Cre transgenic mice. A CHAPb knock out can be obtained by making use of a 
α-MHC-Cre or Nkx2.5-Cre, whereas CHAPa can be conditionally deleted by crossing with 
a tamoxifen inducible mouse line. Furthermore, using a CHAP knock out approach, the role 
of CHAP in calcineurin-induced hypertrophy can also be investigated in vivo, by crossing 
CHAP knock out mice to calcineurin Tg mice.
In addition, investigating the role of PKA, CaMKII and calcineurin in the stability of CHAP 
by in vitro phosphorylation and inhibition experiments, could clarify the role of calcineurin 
signaling in CHAP mediated stress fi ber formation.
Th us in contrast to what was found in CHAPb Tg mice, overexpression of both CHAPa and 
CHAPb in vitro leads to downregulation of the hypertrophy markers ANF, BNP and β-MHC, 
which might be caused by a translocation of NFATc2 from the nucleus to the cytosol upon 
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Expression of CHAP in adult mouse tissues is correlated with 
fi lamentous actin expression
Chapter 6
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Robert Passier
Abstract
Previously, we have shown that CHAP is expressed in striated muscles during developmental 
stages and in adult tissues. Here, we analyzed CHAP expression in multiple mouse adult 
tissues and show that besides expression in striated and smooth muscle, CHAP is expressed in 
small intestine, kidney and brain in an isoform specifi c manner. Expression of CHAP in small 
intestine and kidney was co-localized with expression of fi lamentous actin. Th ese results 





Actin is the major component of the cytoskeleton of eukaryotic cells. Many cellular processes, 
such as division, cell migration, vesicle transport, contractile force generation, cell polarity 
and cell shape changes are regulated by changes in actin dynamics1-3. In mammals and 
birds there are six diff erent actin isoforms, which are encoded by six diff erent genes. Four 
of these actin isoforms are muscle specifi c: α-skeletal actin, α-cardiac actin, α-smooth actin 
and γ2-smooth actin. Th e γ1-actin and β-actin are non-muscle isoforms and function in the 
assembly of the cytoskeleton of non-muscle cells1, 3. Monomeric actin (globular or G-actin) 
can assemble in fi lamentous actin (F-actin), and this balance is regulated by several actin 
binding proteins. Cofi lin enhances actin fi lament turnover by severing actin fi laments and 
promoting dissociation of actin monomers from the pointed ends of actin fi laments. Profi lin 
on the other hand, promotes assembly of F-actin fi bers. Myosin binding to F-actin is essential 
for contraction in muscle cells. Th e myosin-actin interaction is also in important for other 
cellular processes, such as cytokinesis and cell migration1, 3.
In the previous chapters we have described a novel Z-disc protein, which we named 
Cytoskeletal Heart-enriched Actin-associated Protein (CHAP)7. Two isoforms of CHAP exist: 
a longer isoform CHAPa and a shorter isoform CHAPb. Whereas CHAPb is expressed in the 
heart and somites during embryonic development CHAPa is expressed in adult heart and 
skeletal muscle8. We have previously shown that overexpression of CHAP resulted in actin 
stress fi ber formation in vivo and in vitro (see chapter 4 and 5), suggesting a possible role in 
actin signaling.  Th is is further corroborated by the fact that CHAP belongs to synaptopodin 
protein family, of which its other members have also been shown to be involved in actin 
bundling4, 5. Synaptopodin, the fi rst described protein of this family, regulates formation of 
actin stress fi bers, via RhoA signaling6 and is expressed in brain and kidney4. Furthermore, 
myopodin, a second member of this family, is expressed in muscle cells and is also involved in 
actin signaling as well. It contains an actin binding site, binds directly to actin and has actin 
bundling activity5. 
In this chapter we analyzed the expression of CHAP in multiple adult tissues. We confi rmed 
predominant expression of CHAPa and CHAPb isoforms in skeletal muscle by western blot 
analysis. However, low levels of CHAPb could also be detected in adult kidney, brain, small 
intestine and large intestine. Th is was confi rmed by specifi c CHAP immunofl uorescent 
staining on adult mouse tissue sections of kidney and intestine, which strongly co-localized 
with fi lamentous actin.   




Adult Swiss mice were sacrifi ced for the collection of organs. For RNA and protein isolation 
organs were rinsed in PBS, snap frozen in liquid nitrogen and stored at -80 oC until further 
use. 
Organs for cryosections were perfused, collected and rinsed in PBS. Subsequently, organs 
were processed as described in Bajanca et al9. Briefl y, organs were fi xed in 0.2% PFA solution 
containing 4% sucrose, 0.12mM CaCl2.2H2O, 0.2M Na2HPO4.2H2O, 0.2M NaH2PO4.H2O 
over night at 4 oC. Th en, organs were washed in the same solution without PFA during the 
day at 4 oC, followed by 0.24M phosphate buff er and 30% sucrose over night at 4 oC. Th e next 
day embryos were embedded in Tissue-Tek (Sakura Finetek) on dry ice and stored at -20 oC 
until sectioning.
RNA isolation and cDNA synthesis
Organs were homogenized in Trizol (Invitrogen) using the Ultra Turrax tissue separator 
(IKA, Germany). Th en RNA was isolated according to the manufacturers protocol. RNA 
was treated with DNase (DNA-free, Ambion) and cDNA was synthesized (iScript BioRad). 
qPCR was performed using the CFX96 Real-Time PCR detection system (Bio-Rad). Th e 
following primers were used: ChapA (sense: 5’-GAGGAGGTGCAGGTCACATT-3’; 
antisense: 5’-CTGAAGAGCCTGGGAAACAG-3’), ChapB (sense: 
5’-CCGCCGCTTCTTAAACATAA-3 antisense: 5’-GGCTTTAAAGGGCCTTGG-3’) 
and as reference gene Gapdh (sense: 5’-GTTTGTGATGGGTGTGAACCAC-3’, antisense: 
5’-CTGGTCCTCAGTGTAGCCCAA-3’). Data were analyzed with Bio-Rad CFX Manager 
and presented as mean +/- standard error.
Protein isolation and western blot
For protein isolation organs were crushed on liquid nitrogen and dissolved in T-PER tissue 
protein extraction reagent (Pierce) with extra added protein inhibitors (protease inhibitor 
cocktail tablets (10 µg/ml; Roche, Germany), 0.1 mmol/L dithiothreitol (DTT; Invitrogen) 
and 1 mmol/L phenylmethanesulfonylfl uoride (PMSF; Sigma Aldrich), 5 mmol/L NaF 
and 1 mmol/L Na3VO4). Samples were incubated on ice for 15 minutes and centrifuged at 
10.000 RPM at 4 oC for 10 mi nutes and supernatants were transferred to new tubes. Protein 
concentration was measured with the Bradford assay (Bio-rad) using bovine serum albumin 
(BSA) for a standard curve. Th en 5x sample buff er (100 mM Tris-HCl pH 6.8, 10% SDS, 
50% glycerol, 25% β-mercaptoethanol and bromphenol blue) was added and samples were 
boiled for 5 minutes at 95 oC. Protein gels were loaded with 50 μg protein. Gels were blotted 
(Hybond-P, GE healthcare) for 3 hours at room temperature and blocked for one hour with 
5% milk/Tris Buff ered Saline-tween (TBS-T: 50mM Tris-HCl pH 7.5, 125 mM NaCl, 0.02% 
Tween-20). First antibody diluted in 5% milk/TBS-T was applied over night at 4 oC. Antibodies 
used were CHAP (1:200, custom made by Eurogentec) and GAPDH (1:10000, Millipore). 
Secondary antibody was applied for 1 hour at room temperature. Secondary antibodies 
used were anti-mouse IgG HRP (1:1000, Cell Signaling Technology) or anti-rabbit IgG HRP 
(1:2000, Cell Signaling Technology) dissolved in 5% milk/TBS-T. Blots were visualized by 




Organs were sectioned (5 μM) and mounted on starfrost slides (Knittel). Antibody stainings 
were performed as described by van Laake et al10. Antibodies used were CHAP (1:50, 
custom made by Eurogentec), α-smooth muscle actin (1:500, 1A4, Sigma-Aldrich Chemie), 
RhoA (1:100, Santa Cruz). Secondary antibodies were as follows: Cy-3 conjugated anti-
rabbit (1:250, Jackson Immunoresearch Laboratories) and Alexa488 conjugated anti-mouse 
(1:200, Invitrogen). F-actin fi bers were stained with phalloidin conjugated Alexa488 (1:100, 
Invitogen) in PBS for 20 minutes. Cell nuclei were stained with TO-PRO (Invitrogen) and 
slides were enclosed with Prolong Gold (Invitrogen). Stainings were analyzed with SL confocal 
microscope. 
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Results
We have previously demonstrated that CHAP is expressed embryonic and adult heart and 
skeletal muscle and also in smooth muscle cells. To analyze CHAP expression in other adult 
organs we fi rst isolated RNA from diff erent mouse organs, followed by quantitative analysis 
of ChapA and ChapB expression levels (Figure 1A). Expression levels for ChapA and ChapB 
were, as expected, highest in skeletal muscle. Nevertheless, expression levels for particularly 
ChapB could also be observed in the other tissues: kidney, brain, stomach, intestine, spleen 
and lung. ChapA was expressed at lower levels but still detectable in kidney small intestine and 
lung. In order to determine whether CHAPa and b proteins were expressed in these tissues 
we performed western blot analysis (Figure 1B). Whilst in skeletal muscle both CHAPa (140 
kDa) and CHAPb (110 kDa) could be clearly detected, in the other tissues examined we only 
could detect expression at the height, which corresponds to the size of CHAPb, in kidney, 
brain, small intestine and large intestine, confi rming qPCR results the mRNA expression 
levels. Although there was a slight diff erence in the height of the bands between the organs, 
this may be explained by posttranslational modifi cations.
Figure 1: Expression analysis of CHAP in adult tissues . A) qPCR expression analysis of ChapA (dark gray bars) and 
ChapB (light gray bars) in skeletal muscle, kidney, brain, stomach, small intestine, lung and spleen. Gapdh was used 
as internal control. B) Western blot showing expression of CHAP in kidney, brain, small intestine and large intestine. 
GAPDH was used as loading control.
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Next we analyzed expression of CHAP by immunohistochemistry on cryosections of these 
organs. Since we have recently described that CHAP is expressed in smooth muscle cells we co-
stained sections of the intestine with α-smooth muscle actin (ASMA). However, no signifi cant 
CHAP staining was observed in the smooth muscle layer of the small intestine (Figure 2A). 
Instead, we found CHAP to be expressed in the villus of the small intestine. CHAP expression 
was not detected in the bottom of the crypt, but was found in diff erentiated endothelial cells 
in a dotted pattern and expression was lost at the tip of the villus. Th us expression of CHAP 
was restricted to the central part of the villus, which contains diff erentiated endothelial cells. 
Besides this expression of CHAP, expression was also found in the center of the villus (Figure 
2B). Th e homolog of CHAP, Synaptopodin, is involved in actin polymerization via RhoA and 
found that RhoA was upregulated and ectopically expressed in CHAPb Tg mice (see chapter 
4). Th erefore, we co-stained the small intestine for RhoA. Similar to the localization of CHAP, 
RhoA was expressed in the center of the villus. However, no co-immunostaining of CHAP 
and RhoA was found (Figure 2C), indicating that CHAP and RhoA were not expressed in the 
similar cells. 
Figure 2: CHAP expression in the small intestine. A) Staining of the smooth muscle layer for CHAP (red; A) and 
α-smooth muscle actin  (green, A’), merge images are shown (A’’). B) CHAP is expressed in the villi of the small intestine 
in a dotted pattern (arrows). C) Staining of the villus for CHAP (red; C) and RhoA (green; C’), merge images are shown 
(C’’). D) Staining of the villus for CHAP (red; D) and phalloidin (green, D’), merge images are shown (D’’). Scale bars 20 
μm in A, C and D and 100 μm in B.
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In the hearts of CHAPb Tg mice we observed actin stress fi bers and upregulation of the actin 
pathway (see chapter 4). To investigate if CHAP localization correlated with fi lamentous 
actin (F-actin) localization, we co-stained with phalloidin. F-actin stained the microvilli of a 
villus. No co-localization of CHAP with F-actin was observed. Instead, CHAP was expressed 
adjacent to the F-actin stained microvilli (Figure 2D), showing that expression of CHAP was 
restricted to the roots of the microvilli. 
Next we analyzed expression of CHAP in the kidney. Synaptopodin is expressed in kidney 
podocytes of the glomerulus. Staining of the kidney for CHAP showed that CHAP was 
expressed in the kidney tubules but not in the glomerulus (Figure 3A and B). Similar as in the 
small intestine, no co-staining was found of CHAP with RhoA, which was expressed in the 
glomerulus (Figure 3A). However, co-staining of CHAP with F-actin, which stains the tubule 
microvilli, showed that as in the small intestine, CHAP localization was adjacent to that of 
F-actin in the kidney tubules (Figure 3B and C). Th us, CHAP expression was restricted to the 
roots of the kidney tubule microvilli, suggesting a similar staining pattern as observed in the 
small intestine.
We also analyzed the expression of CHAP in the brain, however no specifi c CHAP 
immunostaining could be detected, although we cannot exclude CHAP expression in specifi c 
locations in the brain, that we may have missed in the current analysis.
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Figure 3: CHAP expression in the kidney. A) CHAP (red) is expressed in the kidney tubules and not in the glomeruli, 
where RhoA (green) is expressed. Merge images are shown (A’’). B and C) Staining of kidney tubules  for CHAP (red; B 
and C) and phalloidin (green; B’ and C’). Merge images are shown (B’’ and C’’). Scale bars 50 μm in A, 20 μm in B and C.
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Discussion
In this chapter we analyzed the expression of CHAP in a variety of adult organs Previously we 
have shown that CHAP is expressed in striated muscles (heart and skeletal muscle) and also 
in smooth muscle cells. Here, we show that CHAP is also expressed in brain, small intestine 
and kidney. Based on western blot analysis, we conclude that in these organs only CHAPb 
is expressed. From previous chapters (chapter 4 and 5), we have observed that CHAPb is 
involved in actin bundling activity (chapter 4 and 5). Immunofl uorescence stainings show 
that CHAP is expressed in the roots of the microvilli of the small intestine and kidney tubules. 
Microvilli are cylindrical membrane protrusions and have been identifi ed in the small intestine, 
kidney proximal tubules, and brain. Functions of the villi are increasing the surface area, 
vesicle releasement, fl uid fl ow sensing and mechano-transduction. Microvilli are composed 
of actin bundels, which are oriented with the barbed end at the villus tip and the pointed 
end at the bottom of the bundle. Th e actin bundles are cross-linked by several cross-linking 
and membrane-linking proteins, such as myosins. At the bottom of the villus proteins are 
found that prevent the depolymerization of the actin fi laments11. For example, tropomyosin 
is a rootlet protein in microvilli of the small intestine12 and kidney13, and has been shown 
to prevent actin depolymerization by competing with binding to actin with cofi lin13, 14. Like 
tropomyosin, CHAP could be involved in preventing actin depolymerization as well. 
It would be interesting to investigate expression of CHAP in relation to actin. For example, 
stereocillia are specialized microvilli on the sensory hair cells of the cochlea and vestibular 
apparatus11, where CHAP could be expressed as well. In addition, fi lopodia are single 
actin membrane protrusion, involved in cell movement11, where CHAP expression can be 
investigated as well. Finally, in cancer cells, actin is necessary for cell movement and in these 
cells CHAP could function as a tumor suppressor by preventing actin polymerization. Indeed, 
myopodin has been identifi ed as a tumor suppressor in prostate cancer, as it is (partially) 
deleted in invasive prostate cancers15, 16 and inhibits tumor growth in vitro and in vivo16. 
Th e results of this chapter show that CHAPb is expressed in a pattern, which is closely related 
to the presence of fi lamentous actin and is expressed in diff erent tissue besides heart and 
skeletal muscle.  On the other hand, CHAPa seems to be more restricted to the striated 
muscles, although we cannot exclude that western blot analysis was not sensitive enough to 
detect CHAPa protein levels. Furthermore, these results show that CHAPa is muscle-specifi c 
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In this thesis the function of a novel Z-disc protein Cytoskeletal Heart-enriched Actin-
associated Protein (CHAP) is described, CHAP was identifi ed previously from a genome-wide 
transcriptome study in human embryonic stem cells diff erentiating to cardiomyocytes1. In 
mouse and human genomes two isoforms of CHAP were identifi ed; a longer isoform CHAPa 
containing a N-terminal PDZ-domain and nuclear localization signal (NLS) and a shorter 
isoform CHAPb, which lacks the PDZ-domain. Interestingly, mouse CHAP isoforms have a 
distinct expression pattern; whereas CHAPb is predominantly expressed in heart and skeletal 
muscle during embryonic development, CHAPa is clearly higher expressed in adult heart and 
skeletal muscle. We have recently demonstrated that zebrafi sh chap is essential for skeletal 
muscle and heart development2. In this thesis I further explored the function of CHAP by 
several in vivo and in vitro approaches. And discuss here the potential role(s) of CHAP during 
development, adult stages and disease. 
Function of CHAP during heart and skeletal muscle development
Th e fi rst clues on CHAP function came from its expression pattern during embryonic 
development. CHAP is expressed in the developing heart and somites (that give rise to skeletal 
muscle), and this is conserved between species (zebrafi sh, mouse and chick; previously studied2 
and chapter 2). We showed in chapter 2 that in chick embryos CHAP is expressed in the linear 
heart tube from Hamburger and Hamilton (HH) stage 8 onwards and at older stages, found 
expression in somites as well as the heart. As mentioned before, CHAPb is the predominant 
isoform during mouse embryonic development. However, both in chick and zebrafi sh only 
one isoform of CHAP exists, containing the CHAPa characteristic PDZ domain, suggesting 
that during embryonic development in chick and zebrafi sh, CHAP may have a similar role 
as CHAPb. Alternatively, other proteins that resemble CHAP may substitute for the lack of 
embryonic CHAPb. In this regard, CHAP belongs to a family of actin-bundling proteins, 
with synaptopodin being the fi rst described member and myopodin the second member of 
this family. Whereas synaptopodin is expressed in brain and kidney3, myopodin is expressed 
in heart, skeletal muscle and smooth muscle4 and is thus the most likely candidate protein to 
partially substitute CHAP functionality during muscle development in chick and zebrafi sh. 
We have demonstrated previously that morpholino-mediated knockdown of chap in zebrafi sh 
led to impaired heart looping and disturbed muscle development5, indicating the importance 
of chap during muscle development. However, the role of CHAP in heart and skeletal muscle 
in higher vertebrates still needed to be investigated, especially with respect to the functions 
of the diff erent CHAP isoforms. To investigate the role of CHAP in higher vertebrates, we 
used CHAP specifi c morpholino’s to knockdown CHAP in developing chick embryos and 
followed diff erent to strategies generate CHAP knockout mice (conditional and LacZ knock-
in; chapter 3). Although knockdown of CHAP in chick embryos led to abnormalities during 
cardiac development, such as cardiac looping, these results were variable and not statistically 
signifi cant. Th erefore, to study the role of CHAP during heart development it is essential to 
generate CHAP (conditional) knockout mice. However, in fi rst attempts we were unable to 
achieve germline transmission for CHAP mutant embryonic stem cells, which resulted in the 
study of CHAP in alternative animal models as a fi rst priority: overexpression of CHAP in 
mice or in cells/cardiomyocytes in vitro. 
 e role of CHAP in actin signaling 
What could be the mechanism by which CHAP aff ects cardiac development, or more 
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specifi cally, cardiomyocyte function? One possible role of CHAP involves interference with 
the actin cytoskeleton. Th is has been evidenced by previous studies on other family members 
of CHAP. Synaptopodin has been shown to regulate the actin-bundling activity of α-actinin3 
and also regulates actin-bundling via RhoA6. In line with these fi ndings, myopodin also has 
been shown to have actin-bundling activity and binds directly to actin5. Furthermore, we 
observed co-localization of CHAP and actin, suggesting a role for CHAP in actin signaling5.  
Th e actin cytoskeleton plays an important role in formation of sarcomeres in muscle cells. It 
has been postulated that formation of actin bundles may serve as a scaff old for the formation 
of I-Z-I complexes (referring to the I-bands and Z-discs in sarcomeres). Th ese complexes are 
composed of Z-bodies containing α-actinin and titin which are linked to the actin bundles 
and are associated with the membrane. In the next stage, myosin thick fi laments are organized 
with the I-Z-I complexes and dissociate from the membrane, forming immature sarcomeres 
that already show contraction. In the last stage thin fi laments form and sarcomeres mature7. 
RhoA and its down-stream eff ector Rho-associated kinase (ROCK) have been shown to be 
involved in the formation of actin fi bers and in this way play an important role sarcomere 
formation8, 9. We have shown in chapter 3 that CHAP knockdown and deletion of one allele 
did not aff ect sarcomere formation in vitro. However, this did not result in a complete loss of 
CHAP and therefore remaining levels of CHAP may be suffi  cient for sarcomere formation. 
Knockdown of chap in zebrafi sh resulted in sarcomeric disorganization5, suggesting that chap 
knockdown was more effi  cient in zebrafi sh or that the timing of interference is crucial. In the 
future, complete removal of CHAP in vivo and in vitro will tell us more about the possible 
function of CHAP in sarcomere formation. 
In chapter 4 we showed that cardiac-specifi c overexpression of CHAPb in mice (CHAPb 
transgenic [Tg]) induced cardiomyopathy which was accompanied by activation of actin 
signaling, indicated by the formation of stress fi bers. Th ese stained for α-actinin and CHAP, 
and increased expression of actin, the small GTPase molecule RhoA, Ezrin/Radixin/Moesin 
(ERM) and actin binding protein cofi lin was observed. Furthermore, we showed that 
sarcomeric expression of RhoA was reduced, whereas expression of RhoA at the membrane 
was increased. To investigate if these observed eff ects in the Tg mice were a direct eff ect of 
CHAPb we generated CHAPa- and b adenoviruses to express CHAP in embryonic day 17.5 
(E17.5) cardiomyocytes in culture and in C2C12 cells, a mouse skeletal myoblast cell line. 
Overexpression of CHAP in these cells did not result in increased expression of actin, RhoA, 
cofi lin or ERM (chapter 5), suggesting that CHAP does not directly regulate expression of 
members of the actin-signaling pathway and that secondary eff ects, timing, or additional 
factors, that are not present in vitro cultures, must be involved in vivo. 
CHAP and transcriptional regulation
Another possible role for CHAP could be on transcriptional regulation. Th e fi rst indication 
is provided by the localization of CHAP in the nucleus of undiff erentiated myoblast cells, 
where it co-localizes with RhoA. Both proteins are translocated to the cytoplasm upon muscle 
diff erentiation (fi gure 1). It has been suggested that RhoA is directly involved in maintaining 
skeletal myoblast cells in an undiff erentiated state by activating SRF and suppressing 
transcription factor MyoD, a key factor for skeletal muscle diff erentiation10, 11. Furthermore, 
RhoA inhibits M-cadherin mediated muscle cell fusion, suggesting that RhoA activity needs 
to be suppressed for muscle diff erentiation12. On the other hand, RhoA may regulate Serum 
Response Factor (SRF), a transcription factor, which plays an important role in skeletal 
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muscle growth and maturation13. Th us, the role of RhoA/SRF in skeletal muscle development 
is rather complex. CHAP expression levels increase during muscle diff erentiation. However, 
exogenous expression of CHAPa or CHAPb in C2C12 myoblasts cells prevent muscle fusion 
(chapter 5), similar to overexpression of a dominant positive isoform of RhoA12. Whether 
CHAP plays a role in muscle diff erentiation by aff ecting subcellular localization and/or 
expression levels of RhoA and SRF or any other mechanism needs to be determined. In 
CHAPb Tg mice we showed an increase in the expression of transcription factors SRF and 
Myocyte Enhancer Factor 2 (MEF2). However, adenoviral overexpression of CHAPa and 
CHAPb in fetal cardiomyocytes did not lead to an upregulation of these transcription factors, 
suggesting that CHAP may not directly infl uence transcriptional regulation.  
In addition to the RhoA-SRF pathway, CHAP might also infl uence transcription via the 
calcineurin-NFAT (nuclear factor of activated T-cells) pathway, a key pathway in cardiac 
hypertrophy and disease (see below). In CHAP transfected cells the cardiac fetal genes and 
hypertrophic markers ANF, BNP and beta-MHC were downregulated, which was correlated 
with translocation of NFATc2 from the nucleus to the cytosol. Furthermore, we recently 
found that CHAP interacts with the phosphatase calcineurin and with calcineurin-interacting 
Figure 1: Localization of CHAP (green) and RhoA (red) in undiff erentiated, 3 days diff erentiated and 6 days diff erenti-
ated C2C12 cells. Merge images are shown.
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proteins, such as calsarcins (Beqqali personal communication), suggesting a function for 
CHAP in calcineurin-mediated hypertrophy. Th erefore, it would be interesting to investigate 
the function of CHAP in this pathway by generating CHAPa- and b knockout models and 
by analyzing CHAP in diff erent hypertrophy models, such as calcineurin Tg and calsarcin 
and cypher knockout mice. Furthermore, CHAP might have a direct eff ect on transcription, 
because we have observed nuclear localization of CHAP in cardiomyocytes (chapter 5 and 
unpublished data of A. Beqqali). However, in vivo we never observed nuclear localization of 
CHAP. 
Role of CHAP in sarcomere integrity, cardiac hypertrophy and disease
We have shown previously that CHAP is expressed at the Z-disc of adult hearts and that it 
interacts with α-actinin-22. Several Z-disc components have been identifi ed that interact with 
α-actinin-2 and act as a stretch-sensor. Th e phosphatase calcineurin is a well-described key 
regulator of hypertrophy. During cardiac hypertrophy, which occurs in response to various 
pathophysiological conditions or events, such as myocardial infarction, increased levels of 
Ca2+ lead to activation of calcineurin. Subsequently, activated calcineurin dephosphorylates 
nuclear factor of activated T-cells (NFAT), leading to nuclear translocation of NFAT and 
activation of a fetal gene expression program14, 15. Calsarcins represent a new family of 
calcineurin-interacting proteins, bind to other sarcomeric proteins such as α-actinin-2, are 
expressed in heart and skeletal muscle16 and protect the heart against calcineurin-induced 
hypertrophy17, 18. Cypher (Oracle) is another α-actinin-2-interacting protein and is expressed 
in the heart and skeletal muscle19, 20 and cypher knockout mice displayed decreased calsarcin 
expression21 and development of a dilated cardiomyopathy phenotype in mice21 and zebrafi sh22. 
Both deletion of calsarcin and cypher leads to disruption of the Z-disc17, 21. In addition to 
calsarcin and cypher, CHAP might regulate sarcomeric integrity and cardiac hypertrophy 
via calcineurin-NFAT and/or SRF. SRF, which was upregulated in CHAPb Tg hearts (chapter 
4), is also involved in maintaining Z-disc integrity in adult skeletal muscle by regulation of 
transcription of sarcomeric proteins23. 
In order to investigate the role of CHAP in vivo, we generated transgenic mice by heart-
specifi c overexpression of both isoforms of CHAP. We did not observe any abnormalities in 
hearts of CHAPa Tg mice. Although, we found upregulation of ChapA mRNA expression by 
qPCR experiments and CHAP protein by western analysis in CHAPa Tg mice, we could not 
detect the transgenic protein with a specifi c FLAG antibody (chapter 4) and therefore cannot 
exclude the possibility that CHAPa protein was partially degraded and functionally inactive.
In CHAPb Tg mice both mRNA and protein levels of CHAPb were stably expressed. We 
observed mild hypertrophy and interstitial fi brosis in hearts of CHAPb Tg mice at three 
months of age. Th is was more severe at six months of age and was associated with activation 
of the hypertrophic gene program and expression of collagens. Furthermore, we observed 
conduction disturbances in CHAPb Tg mice, which coincided with a remarkable suppression 
of atrial connexins (Cx40 and Cx43), crucial for electrical coupling of cardiomyocytes. 
Besides electrical dysfunction, CHAPb Tg mice showed diastolic dysfunction in vivo and in 
isolated cardiomyocytes in vitro. Th ese features are comparable to the cardiac abnormalities 
seen in patients with hypertrophic cardiomyopathy (HCM), i.e. cardiac hypertrophy, diastolic 
dysfunction and increased occurrence of arrhythmia (in particular atrial fi brillation). In order 
to identify a possible working mechanism for the observed phenotype, we further studied 
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CHAPb Tg hearts at the cellular level. We observed stress fi ber-like structures in the hearts of 
CHAPb Tg mice, that stained for both CHAP and α-actinin. In addition, we showed that the 
actin signaling pathway was upregulated in CHAPb Tg hearts, as discussed previously. Th ese 
observations led us to conclude that the fetal isoform CHAPb can be involved in the onset 
and progression of cardiac disease, strongly resembling characteristics of cardiac hypertrophy 
and HCM. Th is is further corroborated by recent fi ndings, in which we found that expression 
of CHAPb is upregulated in several models of hypertrophy (personal communication A. 
Beqqali). Th ese data suggest a role for CHAPb during hypertrophic events and it would 
be interesting to investigate the possible working mechanisms further. It would also be 
interesting to analyze the function of CHAP in human disease by sequence analysis of CHAP 
in HCM and in dilated cardiomyopathy (DCM). In HCM and DCM sarcomeric proteins are 
mutated and most mutated proteins are beta-MHC, myosin-binding protein C and troponin 
T24, 25. However, several mutations in other Z-disc components were also identifi ed and these 
mutations interfered with interaction between Z-disc components. For example, a mutation 
found in cypher (D626N) in DCM patients increased the interaction with protein kinase 
C, a key regulator of contractility and growth of cardiomyocytes26. Mutations in Tcap result 
in HCM (T137I and R153H) or DCM (E132Q) and resulted in increased interaction with 
titin and calsarcin-1 or decreased interaction with muscle LIM protein, calsarcin-1 and titin, 
respectively27. Mutations in Z-disc protein nexilin (G650del, Y652C and P611T) leads to 
disruption of the Z-disc, although the exact mechanism was not identifi ed28. 
Th us, in vivo experiments in mice and sequence analysis in HCM and DCM patients may 
reveal more information about the putative function of CHAP in Z-disc integrity and cardiac 
disease.
CHAP in skeletal muscle
In skeletal muscle we found expression of both CHAPa and CHAPb (chapter 2 and 
chapter 6), with expression of CHAPa approximately 10 fold higher than CHAPb. CHAPa 
overexpression in skeletal muscle cells (C2C12) resulted in disruption of the Z-disc, whereas 
CHAPb overexpression induces stress fi bers (chapter 5). As in cardiomyocytes, CHAPa could 
function in maintaining Z-disc intergrity in skeletal muscle cells. Mutations in cypher have 
been described in muscular dystrophy and these resulted in disintegration of the Z-disc29. 
Th erefore, it would be interesting to search for CHAPa mutations in muscular dystrophy 
patients. We also found low expression of CHAPb in skeletal muscle cells. In contrast 
to cardiomyocytes, skeletal muscle cells have the ability to regenerate in adult mice30. Th e 
function of CHAPb here could be, as suggested by its role in cardiac development, to induce 
actin polymerization and serve as a scaff old for new Z-disc formation.
In addition to Z-disc integrity CHAP could also be involved in determining the slow muscle 
fi ber phenotype in adult animals. We fi nd highest CHAPa expression in soleus muscle, 
which is predominantly composed of slow muscle fi bers. Calcineurin, NFAT and MEF2 are 
important regulators of the slow muscle fi bers. In slow muscle fi bers there is a tonic motor 
nerve activity that leads keeps Ca2+ levels constant and calcineurin-NFAT signaling active. In 
fast muscle fi bers, on the other hand, there is phasic fi ring of the motor nerve, leading to high 
amplitude Ca2+ transients that are insuffi  cient to activate the calcineurin-NFAT pathway31, 
32. All NFAT isoforms are important for determining the slow/fast muscle switch. A specifi c 
combination of NFAT isoforms determines the slow or fast muscle gene expression33. MEF2 
is also regulated by calcineurin to induce slow muscle gene expression and the combined 
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binding of MEF2 and NFAT to slow muscle fi ber gene promoters leads to the subsequent 
gene expression34. Calsarcins have been implicated in determining the fast skeletal muscle 
phenotype. Both calsarcin-2 and -3 are expressed specifi cally in fast skeletal muscle35, 36 
and knockdown of calsarcin-2 leads to a switch to slow skeletal muscle fi bers phenotype by 
activation of the calcineurin-NFAT pathway36. Our results suggest that CHAPb regulates 
MEF2 levels in vivo (chapter 4) and both CHAPa and –b are involved in calcineurin-NFAT 
signaling (chapter 5 and unpublished results). Th erefore, it would be interesting to investigate 
the function of the CHAP isoforms in determination of skeletal muscle fi ber phenotype. Th is 
could be achieved by generating tissue-specifi c (inducible) knockout mice for both isoforms 
or by overexpression or knockdown of CHAP isoforms in vitro in muscle progenitor cells.
Possible role of CHAP in smooth muscle cells
Besides expression in adult heart and skeletal muscle, we also found CHAP to be expressed 
in smooth muscle cells (chapter 2). Additional western blot analysis showed that CHAPa 
was expressed in these cells (data not shown). During embryonic development we showed 
expression of CHAP in cardiomyocytes adjacent to the vascular smooth muscle cells (VSMCs) 
of the vena cava at embryonic day 17.5 (chapter 2). Although CHAPb is the predominant 
form in striated muscle cells during embryonic development, we cannot exclude CHAPa 
being expressed in these cells. However, CHAP expression was not detected in smooth muscle 
cells during development, suggesting that CHAP has no role during VSMC development. 
In smooth muscle cells contraction is regulated by so-called dense bodies, co-staining with 
α-actinin will indicate whether CHAP is expressed in dense bodies. 
During pathophysiological events it is possible that CHAPb, like in hypertrophic 
cardiomyocytes, is upregulated. VSMCs respond to hypertension or other stimuli by a 
phenotypic transition from a contractile state to a synthetic state, leading to increased synthesis 
of extracellular matrix and migration of VSMCs to the subendothelial layer, where they 
proliferate to form an artherosclerotic lesion37. Cytoskeletal proteins have been implicated in 
the migration of VSMCs. Phosphorylation of RhoA by cyclic AMP dependent protein kinase 
leads to migration of VSMCs in vitro38. In addition, interleukin-19 inhibits platelet derived 
growth factor induced VSMC migration by decreasing myosin light chain, RhoA activation 
and cofi lin dephosphorylation39. Also CHAPa could function the pathophysiology of VSMCs 
since contractile proteins have indeed been implicated. For example, SM22α restricts plaque 
growth by inhibiting the contractile/synthetic phenotypical switch40. Furthermore, a role for 
contractile proteins has also been implicated in determining the vascular stiff ness41. Both 
CHAPa and CHAPb could be involved here. Additional experiments in mouse models for 
atherosclerosis (e.g. ApoE knock out mice) could address this issue.
In summary CHAPa is expressed in adult heart, skeletal and smooth muscle cells, but 
CHAPb is expressed in embryonic muscle cells only (previous section) and upregulated in 
pathophysiological circumstances (A. Beqqali, personal communication).
Additional functions of CHAPb
Besides expression during heart and skeletal muscle development, we showed that CHAPb is 
expressed in the small intestine and kidney. In these organs, CHAPb expression is adjacent to 
microvilli that can be recognized by staining with phalloidin for fi lamentous actin (chapter 
6). Actin dynamics is involved in many cellular processes like cell movement, cell division 
and cell shape changes42, 43. Th erefore, CHAPb could also be involved in several other cellular 
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processes. In chapter 4 we showed that CHAPb is involved in signaling via RhoA-SRF. SRF 
and RhoA are implicated in several other cellular processes, such as cell polarity, adhesion, 
cell movement, that are important during development and in pathophysiological situations 
as cancer44-46. Moreover, the CHAP homolog myopodin has been implicated as a tumor 
suppressor in prostate cancer47, 48. Th erefore, it would be interesting to investigate the role of 
CHAPb in these cellular processes by in vitro and in vivo experiments.
Conclusions and future directions
In this thesis, the distribution and function of a novel Z-disc protein CHAP was described. We 
showed that CHAPa is expressed in adult muscles and has a function in integrity of the Z-disc 
in vitro. CHAPb, on the other hand, is predominantly expressed during development and 
has a putative function in cardiac and skeletal muscle development. We showed that CHAPb 
is involved in actin signaling by overexpression in vivo and in vitro. Moreover, CHAPb is 
expressed in adult organs and has a putative actin-bundling function. To further explore 
the function of CHAPa and CHAPb in vivo it will be necessary to generate (conditional) 
CHAP knockout models in mice. Furthermore, investigating the function of CHAP in other 
transgenic/knockout cardiac development and disease models should reveal more about the 
putative function of CHAP. Th e role of CHAP in human development and disease can be 
unraveled by making use of DNA databases of congenital heart disease patients or HCM/
DCM patients, such as the CONCOR database, established ten years ago at the Amsterdam 
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In this thesis we investigated the role of a previously described Z-disc protein CHAP, which 
we identifi ed by whole-genome wide transcriptome analysis in diff erentiating cardiomyocytes 
derived from human embryonic stem cells (hESC). Two isoforms of CHAP exist; a longer 
isoform CHAPa with a PDZ-domain and nuclear localization signal (NLS) and a shorter 
isoform CHAPb, which lacks the PDZ-domain. Furthermore, these isoforms diff er in their 
expression; CHAPb is predominantly expressed during embryonic development, whereas 
CHAPa is expressed in adult stages. We have shown that during mouse embryonic development 
CHAP is expressed in early cardiac progenitors tissue as indicated by its expression in the 
cardiac crescent stage which is still maintained in adult hearts. Following expression during 
early heart development, CHAP expression can be identifi ed in somites, which give rise to 
skeletal muscle later in life. Furthermore, CHAP co-localizes and interacts  with α-actinin-2, 
a major component of the Z-disc. In recent years, it has become clear that besides its role in 
contraction, Z-disc proteins may also have additional roles in various signaling pathways, 
such as sensing changes in stretch or stress on cardiomyocytes. In this thesis we performed 
experiments in order to study the role of CHAPa and b during embryonic development in 
chick and mouse and in the adult hearts of mice.
In chapter 2 we sequenced the CHAP isoform in chick (Gallus gallus) and we show that this 
isoform is homologous to the CHAPa isoform in mouse and human. In addition, we show that 
the genomic organization of the CHAP gene in the chick is comparable to the organization 
of the CHAP gene in the mouse. We analyzed the expression of CHAP during embryonic 
development of chick embryos in detail and demonstrated that CHAP is expressed from the 
cardiac crescent stage onwards and in later stages in the somites as well, which is comparable 
to CHAP expression in mouse embryos. Furthermore, we show that CHAP is expressed in 
several muscle groups, such as jaw, eye, tongue and limb muscles in both mouse and chick 
embryos. Finally, we analyzed the expression of CHAP in adult mice and show that CHAP 
expression, in addition to cardiomyocytes, can be identifi ed in vascular smooth muscle cells 
and skeletal muscle cells as well.
From a previous study we know that CHAP plays an important role in the development of 
the heart and skeletal muscle. In order to investigate the specifi c role of CHAP in mice, we 
generated a conventional CHAP knockout (LacZ knockin) and a CHAP conditional knockout 
targeting contruct in order to create diff erent lines of knockout mice. Th is is described in 
chapter 3. For this, we successfully modifi ed mouse embryonic stem cells by gene targeting 
(via homologous recombination), followed by injection in host mouse blastocysts in order to 
generate chimeric mice. Subsequently, chimeric mice mice were crossbred in order to obtain 
heterozygous knockout mice (by germline transmission). Although high-percentage chimeras 
were generated, unfortunately we did not achieve germline transmission for both lines. To 
investigate the eff ect of CHAP heterozygosity in cardiomyocytes in vitro, we diff erentiated 
the CHAP LacZ+/- mouse embryonic stem cells to cardiomyocytes and showed that there 
was no eff ect on sarcomeric structure or functional properties (beating frequency) of these 
cardiomyocytes. Furthermore, we describe the eff ects of CHAP knockdown in chick embryos 
by injection of CHAP-specifi c morpholino antisense oligonucleotides. Although we could 




In chapter 4 we analyzed the role of CHAPa and CHAPb in vivo by generating heart-specifi c 
CHAP transgenic (Tg) mice. Although we found robust overexpression of CHAPa at the 
mRNA-level, we did not fi nd an increase of  CHAPa Tg protein expression. On the other hand, 
CHAPb Tg mice displayed both an increase at the mRNA as well as the protein level. Although 
at one month of age no obvious change in cardiac phenotype was detected, at three month 
of age the left  atria were enlarged and cardiomyocytes of the left  ventricle were hypertrophic 
which coincided with interstitial fi brosis. Th is phenotype was more severe at 6 months of 
age. Th e observed cardiac hypertrophy and interstitial fi brosis was correlated with activation 
of the fetal gene expression program (ANF, BNP and β-MHC) and collagens, respectively. 
Furthermore, we showed that expression of both connexin40 and -43 was downregulated in 
the left  atrium of CHAPb Tg mice, which was correlated with prolongation of the conduction 
from atria to ventricles (PR interval). MRI and single sarcomere measurements showed 
that the cardiomyocytes of CHAPb Tg hearts were dysfunctional in both contraction and 
relaxation. Finally, we showed that in CHAPb Tg hearts the presence of actin stress fi bers 
which correlated with activation of the actin signaling pathway.
To investigate the function of CHAPa and CHAPb in vitro, we generated CHAPa and CHAPb 
adenoviruses (AdCHAPa and AdCHAPb). In chapter 5 we used these viruses to overexpress 
either isoform in embryonic day 17.5 mouse cardiomyocytes or in a skeletal myoblast cell 
line (C2C12), which can be diff erentiated to skeletal muscle cells. As expected, we found 
that following transduction of these cells with AdCHAPa or AdCHAPb and increase of both 
CHAP isoform proteins could be detected. We show that overexpression of CHAPa results in 
disruption of the Z-disc, while the M-band is not aff ected. In vitro overexpression of CHAPb 
leads to the induction of actin stress fi bers, as observed in CHAPb Tg mice. In contrast to our 
fi ndings in CHAPb Tg mice, we did not observe activation of the actin signaling pathway and 
the hypertrophic genetic program, following overexpression of CHAPb. In fact, we showed 
a downregulation of the hypertrophic genes ANF, BNP and β-MHC and a translocation of 
NFATc2, a key player in cardiac hypertrophy, from the nucleus to the cytoplasm, suggesting 
that CHAP does not lead to direct activation of hypertrophy in vitro.
In chapter 6 we analyzed the expression of CHAP in adult organs in more detail and show that 
CHAP is expressed in the brain, kidney and small intestine. Furthermore, we demonstrate 
that CHAPb is expressed in the villus of the small intestine and kidney tubules, adjacent to 
actin fi lament containing micro-villi. 
In chapter 7 we discuss the results of this thesis and give suggestions for future research. For 
example, it would be interesting to perform genetic studies for mutations in CHAP in patient 
databases for diff erent cardiac diseases. Furthermore, a possible role of CHAP in the other 
disease, such as atherosclerosis and cancer could be of interest.
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In dit proefschrift  beschrijven we de functie van een nieuw gen, genaamd Cytoskeletal 
Heart-enriched Actin-associated Protein (CHAP). CHAP is ontdekt na analyse met 
behulp van “whole-genome transcriptome arrays” van humane embryonale stamcellen, die 
gediff erentieerd werden naar hartspiercellen. Er zijn twee varianten van CHAP, CHAPa en 
CHAPb, waarvan CHAPa het langste eiwit is. Tijdens de ontwikkeling van de muis komt 
CHAP tot expressie vanaf het vroegste ontwikkelingsstadium van het hart. In een later 
stadium komt CHAP ook tot expressie in de voorlopercellen van spieren, de somieten. Ook 
in volwassen muizen komt CHAP tot expressie in het hart. Het hart en skeletspieren zijn 
zogenaamde dwarsgestreepte spierweefsels. De contractie in deze weefsels wordt gereguleerd 
door sarcomeren, de kleinste functionele eenheden van dwarsgestreepte spieren. De 
sarcomeren kunnen ook weer worden opgedeeld in compartimenten, de uiteinden van de 
sarcomeren worden gemarkeerd door de zogenaamde Z-lijn. Het eiwit α-actinine-2 is een 
van de meest voorkomende eiwitten in de Z-lijn en bindt allerlei andere eiwitten in de Z-lijn. 
Waar aanvankelijk werd gedacht dat sarcomeereiwitten alleen betrokken zijn bij de contractie 
van spiercellen, is het inmiddels duidelijk dat deze eiwitten ook een belangrijke rol kunnen 
spelen in meerdere biologische processen, zoals het signaleren en overbrengen van stress en 
stretch. Uit eerdere experimenten weten we dat CHAP gelokaliseerd is in de Z-lijn en dat het 
een interactie kan aangaan met α-actinine-2. In dit proefschrift  hebben we experimenten 
verricht met het doel om de rol van CHAPa en CHAPb te bestuderen tijdens de embryonale 
ontwikkeling van de muis en de kip, maar ook in het hart van volwassen muizen.
In hoofdstuk 2 analyseren we de DNA en eiwit sequentie van CHAP in de kip en laten we 
zien dat deze het meest overeenkomt met het CHAPa eiwit, zoals dat bekend is in de muis, 
mens en zebravis. Verder laten we ook zien dat de organisatie van het CHAP gen van de 
kip vergelijkbaar is met de organisatie van het CHAP gen in de muis. In een volgende stap 
analyseren we ook de genexpressie van CHAP tijdens de ontwikkeling van de kip in detail en 
laten we zien dat dit een vergelijkbaar expressie patroon geeft  met dat van de muis, namelijk 
een sterke expressie van CHAP in het hart en somieten. Verder laten we zien dat CHAP in 
de kip en de muis tot expressie komt in skelet spieren van de ledematen, kaak, tong en oog. 
In adulte muizen laten we tot slot zien dat CHAP tot expressie komt in skelet spieren en 
vasculaire gladde spiercellen.
Uit eerdere studies in zebravissen weten we dat CHAP een belangrijke rol speelt in de 
ontwikkeling van het hart en skeletspieren. Om vervolgens de specifi eke functie van CHAP 
in vivo te kunnen bestuderen in muizen, maken we gebruik van de zogenaamde ‘knockout’ 
technologie, waarin het gen wordt uitgeschakeld. Dit wordt beschreven in hoofdstuk 3. Om 
knockout muizen te genereren wordt een allel van het CHAP gen verwijderd in embryonale 
stam (ES) cellen met behulp van genetische modifi catie (homologe recombinatie). Deze 
gemodifi ceerde ES cellen worden vervolgens teruggebracht in een muizenembryo, zodat 
er een mix van gemodifi ceerde en ongemodifi ceerde ES cellen ontstaat, resulterend in de 
geboorte van chimere nakomelingen (muizen afk omstig van beide soorten ES cellen). Deze 
chimere muizen worden vervolgens verder gekruist met het uiteindelijk doel om kiembaan 
transmissie te krijgen, wat wil zeggen dat het uitgeschakelde CHAP gen aan de nakomelingen 




knockout muis en een conditionele knockout muis waarbij we het CHAP gen op een 
gewenste tijd en locatie kunnen uitschakelen. Alhoewel we een hoog percentage chimere 
muizen hebben verkregen, hebben nakomelingen van deze muizen helaas niet geresulteerd 
in kiembaan transmissie. Wel laten we zien dat in vitro hartspiercel diff erentiatie van deze 
gemodifi ceerde ES cellen, waarvan de expressie van CHAP gehalveerd is (heterozygoot, 1 allel 
van CHAP is uitgeschakeld), niet leidt tot waarneembare afwijkingen, zoals veranderingen 
in contractiefrequentie en organisatie van sarcomeren. Tevens beschrijven we in dit 
hoofdstuk wat de eff ecten zijn als we CHAP expressie remmen door gebruik van CHAP-
specifi eke morpholino antisens-oligonucleotiden in kippen embryos. Alhoewel eff ecten op de 
ontwikkeling van het hart waarneembaar waren in meerdere embryos, bleken deze eff ecten 
niet signifi cant
In hoofdstuk 4 bestuderen we de rol van CHAP in vivo door CHAPa en CHAPb specifi ek tot 
overexpressie te brengen in het hart van de muis. In beide CHAP transgene muizenlijnen zien 
we zoals verwachten een verhoogde gen expressie (transcriptie) van CHAP. Echter, in het geval 
van CHAPa transgene muizen leidt dit niet tot een verhoogd eiwit niveau van CHAPa en een 
veranderd fenotype. Aangezien CHAPb transgene muizen laten wel een verhoogd en stabiel 
eiwit niveau van CHAPb in het hart laten zien, hebben we deze verder geanalyseerd. We laten 
zien dat CHAPb transgene muizen een hartaandoening ontwikkelen (cardiomyopathie met 
diastole dysfunctie), die ook sterke overeenkomsten vertoont zoals deze bij de mens voorkomt. 
In CHAPb transgene muizen van 3 maanden zien we dat de harten verdikte kamers en een 
vergroot linker boezem hebben. Verder kunnen we ook zien dat de individuele hartcellen 
vergroot (hypertroof) zijn en dat er fi brose (verhoogde afzetting van collageen) tussen de 
hartcellen aanwezig is. De hypertrofi e en fi brose kunnen we bevestigen door te laten zien dat 
de expressie van genen, specifi ek voor hypertrofi e en fi bose, is verhoogd. In het linker boezem 
van de CHAPb transgene muizen zien we ook dat de eiwitten die noodzakelijk zijn voor 
koppeling en communicatie van hartspiercellen, verlaagd zijn in expressie. Ook kunnen we 
zien dat daardoor de elektrische geleiding van de boezem naar de kamer vertraagd is. Verder 
laten we zien dat de contractie in deze harten en in individuele hartspiercellen verminderd is. 
Tot slot laten we zien dat in CHAPb transgene harten er actine bundels worden gevormd en 
dat de actine signaleringsroute is verhoogd. 
In hoofdstuk 5 bestuderen we de rol van CHAPa en CHAPb door deze tot overexpressie te 
brengen in cellen. We gebruiken hiervoor skelet spiercellen en hartcellen die we isoleren uit 
embryonale muizenharten. In deze experimenten is het CHAPa eiwitproduct wel stabiel. Als 
we CHAPa tot overexpressie brengen in deze cellen dan zien we dat de sarcomeer structuur 
wordt beïnvloedt: de Z-lijn is niet meer herkenbaar.  Overexpressie van CHAPb heeft  de 
vorming van actine bundels tot resultaat, zoals we ook in CHAPb transgene muizen zien. In 
deze experimenten kunnen we geen eff ect op de actine signaleringsroute zien. Verder zien 
we dat de genen die specifi ek zijn voor hypertrofi e, en verhoogd waren in CHAPb transgene 
harten, in deze experimenten juist verlaagd zijn. Tenslotte laten we zien dat het eiwit NFAT, 
dat een belangrijke rol speelt in de activatie van hypertrofi e genen, van de celkern naar het 
cytoplasma van de cel is verplaats. Dit duidt erop dat in vitro CHAPa en CHAPb niet leidt tot 
directe activatie van hypertrofi e in hartspiercellen
In hoofdstuk 6 bestuderen we de expressie van CHAP in andere volwassen muizen organen. 
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We kunnen zien dat CHAPb ook tot expressie komt in de nieren, hersenen, dunne darm en 
dikke darm. Met behulp van immunohistochemische technieken kunnen we bijvoorbeeld zien 
dat in de dunne darm CHAP niet lokaliseert in de gladde spierlaag, maar op een specifi eke 
wijze in de darmvlokken.  We laten verder zien dat het grenst aan de expressie van actine 
fi lamenten. In de nier komt CHAP tot expressie in de nierbuisjes en ook hier zien we dat 
CHAP expressie grenst aan die van actine fi lamenten. 
In hoofdstuk 7 tot slot, bespreken we de resultaten van dit onderzoek en geven we suggesties 
voor vervolg onderzoeken. Zo zou er de mogelijkheid zijn om CHAP te bestuderen in 
hartaandoeningen bij mensen door gebruik te maken van een DNA database en het opsoren 
van mogelijke mutaties in CHAP. Verder zou het interessant zijn om de mogelijk rol van 
CHAP te bestuderen  in andere ziektes zoals artheroslerose (aderverkalking) en kanker.
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